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Background: The Cystic Fibrosis (CF) Registry collects clinical data on all patients attending specialist CF
centres in the UK. These data have been used to make comparisons between centres on key outcomes
such as forced expiratory volume in 1 second (FEV1) using simple rankings, which promote the assumption
that those with the highest measures provide ‘better’ care.
Objectives: To explore whether or not using statistical ‘process control’ charts that move away from
league tables and adjusting for case mix (age, where appropriate; sex; CF genotype; pancreatic sufficiency;
and socioeconomic status) could identify exceptional CF care services in terms of clinically meaningful
outcomes. Then, using insight from patients and clinicians on what structures, processes and policies
are necessary for delivering good CF care, to explore whether or not care is associated with observed
differences in outcomes.
Design: Cross-sectional analyses.
Setting: Specialist CF centres in the UK.
Participants: Patients aged ≥ 6 years attending specialist CF centres and clinicians at these centres.
Main outcome measures: FEV1% predicted.
Data sources: Annual reviews taken from the UK CF Registry (2007–15).
Results: We studied FEV1 in many different ways and in different periods. In our analyses of both adult
and paediatric centres, we observed that some centres showed repeated evidence of ‘special-cause
variation’, with mean FEV1 being greater than the mean in some cases and lower than the mean in others.
Some of these differences were explained by statistical adjustment for different measures of case mix, such
as age, socioeconomic status, genotype and pancreatic sufficiency. After adjustment, there was some
remaining evidence of special-cause variation for some centres. Our data at these centres suggest that
there may be an association with the use of intravenous antibiotics. Workshops and focus groups with
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clinicians at paediatric and adult centres identified a number of structures, processes and policies that were
felt to be associated with good care. From these, questionnaires for CF centre directors were developed
and disseminated. However, the response rate was low, limiting the questionnaires’ use. Focus groups with
patients to gain their insights into what is necessary for the delivery of good care identified themes similar
to those identified by clinicians, and a patient questionnaire was developed based on these insights.
Limitations: Our data analyses suggest that differences in intravenous antibiotic usage may be associated
with centre-level outcomes; this needs to be explored further in partnership with the centres. Our survey
of centre directors yielded a low response, making it difficult to gain useful knowledge to inform further
discussions with sites.
Conclusions: Our findings confirm that the CF Registry can be used to identify differences in clinical
outcomes between centres and that case mix might explain some of these differences. As such, adjustment
for case mix is essential when trying to understand how and why centres differ from the mean.
Future work: Future work will involve exploring with clinicians how care is delivered so that we can
understand associations between care and outcomes. Patients will also be asked for their perspectives on
the care they receive.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Plain English summary
Cystic fibrosis (CF) affects approximately 9000 people in the UK. People with CF are treated at specialistcentres; the national CF Registry contains data on patients attending these centres. Until 2015, annual
reports based on these data included comparisons between centres using rankings. These comparisons,
however, do not tell us whether or not the differences between the ‘best’- and ‘worst’-performing centres
are clinically or statistically meaningful. We explored whether or not adopting a different approach, based on
statistical modelling that accounted for important patient characteristics (such as sex, CF disease severity and
socioeconomic deprivation), and displaying the results in easy-to-interpret graphs, may identify exceptional
CF centres. Outcomes will never be the same everywhere and, owing to the size of centre, variability is
expected. Our approach helps to identify differences that are within the scope of what would be expected
and differences that are exceptional.
We used data from patients who were attending adult and paediatric CF centres. We focused on predicted
lung function, studying it in different age groups, using different reference equations and considering
single-year measures as well as changes over time. It was found that in some centres, both adult and
paediatric, lung function results were repeatedly statistically meaningfully different from the overall average –
either better or worse. Some differences were explained by patient characteristics. In other cases, the results
indicate an association of lung function with the use of intravenous antibiotics, although the evidence is
mixed and needs further exploration.
We spoke to clinicians and patients to understand what they perceived to be important for good CF care.
Clinicians highlighted, among other things, the importance of leadership, education, monitoring and
treatment policies. From these factors, we developed questionnaires for all patients and clinicians. Response
rates to the clinician questionnaire were poor and we did not have sufficient time to disseminate the patient
questionnaire, although we still plan to do so. Future work is needed to link how care is delivered with our
centre comparisons, to understand how differences in outcomes arise.
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Scientific summary
Background
Cystic fibrosis (CF) is a common genetic disease affecting approximately 9000 people in the UK. People
with CF are treated at specialist centres that offer dedicated paediatric or adult care.
The CF Trust – the national UK charity for CF – maintains a national registry database (UK CF Registry) of
detailed clinical data on all patients attending these specialist centres. Patients are invited to attend annual
reviews at their specialist centre and, based on these data, the Trust produces annual reports describing
the health of patients.
Since 2008, the annual reports published by the CF Trust have included comparisons between centres in
terms of key clinical outcomes, using simple rankings. Although these comparisons give a sense of the
distribution of outcomes between centres, they encourage the reader to assume, for example, that centres
with the highest values of lung function measure are ‘better’ than those with lower values. This is misleading
because the rankings make no allowances for differences in patient case mix and there are no formal tests
comparing centres.
An alternative – and increasingly common – approach is to use statistical process control (SPC) charts. These
charts were developed as a means of studying the variability of ‘processes’ over time and have been shown to
be useful when comparing health-care providers, as well as the outcomes of single providers, over time. For
the charts, summary outcome measures for individual units are plotted against time or the size of the unit,
with control limits [at either 2 or 3 standard deviations (SDs)]. They are designed to highlight any variability
caused by factors outside the process, referred to as ‘special-cause variation’. Centres whose summary
measures are outside the control limits (either higher or lower) are said to exhibit special-cause variation.
Aims and objectives
The aim of this project was to determine whether or not there are statistically meaningful differences in
key health outcomes between CF centres in the UK and to determine the processes of care driving
such differences.
Our objectives were to:
1. establish a framework to allow future comparisons of key measures of quality in terms of care
structures and processes
2. develop statistical models using data from the national CF Registry that allow us to adjust clinical
outcomes for the patient case mix at centres
3. compare centres using SPC charts to determine whether or not important differences exist between
centres on key clinical outcomes
4. consult with experts in CF care to turn existing care guidelines into maps of the structures, processes
and policies (SPPs) required to deliver good outcomes and to identify factors that could facilitate or
hinder these from being successful
5. consult with CF patients to ascertain what patients believe are the factors that could facilitate or hinder
these SPPs from being successful
6. collect data from individual centres and describe the structures and processes of care at these centres
based on the SPP mapping exercise
7. explore how the SPPs of care differ between centres with exceptional outcomes and the remaining centres.
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Methods
There were a number of components to this work, each of which is described below.
Centre comparisons
We used annual review data (2007–15, inclusive) from the CF Registry to study the following outcomes.
For paediatric centres:
l forced expiratory volume in 1 second (FEV1) at age 12 years (2007–15)
l FEV1 at age 15 years (2007–15)
l FEV1 change from ages 13 to 15 years (2007–12)
l body mass index (BMI) percentile at age 15 years (2007–12).
For adult centres:
l FEV1 change from ages 18 to 21 years (2007–12)
l BMI change from 18 to 21 years as described above (2007–12).
To inform the analyses of these age groups and to confirm any trends observed, we also conducted
single-year analyses (2007–15, inclusive) of FEV1 using CF Registry data of patients of all ages.
For each outcome, we first generated a funnel plot (form of SPC chart) for the outcomes unadjusted for
case mix. We used 99.8% (3 SDs) and 95% (2 SDs) control limits to identify special-cause variation but
focused our attention on centres that were outside the 3-SD limits in all of our analyses. We then adjusted
our outcomes for different patient case-mix characteristics. Multilevel models allowing for clustering by
centre were used for this adjustment and, from these case-mix adjusted models, new funnel plots
were generated.
From these analyses, we also explored trends in intravenous (i.v.) antibiotic usage in terms of the
proportion of patients on treatment and the median number of days on treatment.
Consultations to identify factors that would help to understand variability
Clinicians
Focus groups were held with clinicians from adult and paediatric centres so that the key determinants
of quality of care could be understood. The purpose of the workshops was to explore the factors that
contributed to high-quality care with the intention of developing a questionnaire that could be sent to CF
centres to reveal local patterns of care. The questionnaires were disseminated online and centre directors
of all of the specialist paediatric and adult centres were invited to participate. They were also asked to
share the questionnaire with members of their multidisciplinary team (MDT) so that we might receive
responses from a range of clinicians.
Patients
We conducted a focus group with the CF Trust’s team of clinical care patient advisors. The first part
focused on the participants’ own experiences of CF care. In the second part, participants were asked to
consider, from their own experiences, factors that could facilitate or hinder the success of the SPPs that
were identified by clinicians and for their views on the importance of these clinician-defined SPPs.
SCIENTIFIC SUMMARY
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Results
Centre comparisons
The analyses showed that using funnel plots on an important and well-completed clinical outcome such
as FEV1 allows us to identify some trends in special-cause variation. We described our results using
anonymised identification (ID) numbers for the centres; these ID numbers do not correspond to the codes
currently used by the CF Trust in its reports.
Centre comparisons: paediatrics
We observed that centre 39 was frequently an outlier, with FEV1 levels outside the lower 3-SD limit in our
unadjusted analyses of young adults. It also repeatedly showed special-cause variation in our year-by-year
analyses, along with centres 12 and 52 (outside the lower 3-SD limits) and centres 25, 28 and 31 (outside
the upper 3-SD limits).
The first step in the pyramid of investigation model involves checking the data. We noted that data were
relatively complete for the case-mix variables considered, but some centres (39 and 43) had lower than
average rates of complete FEV1 data among those patients having annual review encounters.
Following the pyramid of investigation approach, we found that a check of the case mix revealed some
differences in the patient populations at these sites. Adjustment for age, for example, brought centre 28
within the 3-SD control limits, despite patients at this centre being only slightly younger than the mean.
Centres 12 and 31 were brought within the control limits after adjustment for other case-mix factors.
We observed that centre 12 had more female patients and more patients who had a G551D mutation, as
well as having fewer patients with the most deprived socioeconomic status. Centre 31 had fewer patients
who were homozygous for the DF508 mutation and more who were pancreatic sufficient than the overall
paediatric patient population.
After case-mix adjustment, three of the original six centres showed patterns of special-cause variation in
FEV1: centres 39 and 52 (lower than average FEV1 values) and centre 25 (higher than average FEV1 values).
We next considered care; an objective and routinely collected measure of CF care is the use of i.v. antibiotics,
which has been shown to be related to better clinical outcomes. We noted that there was a tendency for
centre 25 – which had better FEV1 outcomes – to be near or outside the lower control limits for the
proportion of patients on i.v. antibiotics. Conversely, centres 39 and 52, which had poorer FEV1 outcomes,
tended to have higher than average proportions of patients on i.v. antibiotics. This, however, tells us about
receiving treatment, not about needing treatment.
Centre comparisons: adults
As performed in the paediatric analysis, we studied FEV1 in many different manners from decline in early
adulthood to studying all adults in repeated single-year analyses. In analyses unadjusted for case mix, we
observed that centres 9, 7 and 34 were frequently outside the 3-SD limits and centre 40 appeared outside
the limits in 2007.
Following the pyramid of investigation, we found that adjustment for case mix is essential to avoid
misattributing differences in outcomes to care or missing important differences. Adjustment for age, for
example, brought centre 40 from within the 3-SD control limits to outside these limits from 2009 to 2015
(except in 2012).
We then considered other patient case-mix characteristics. In models adjusted for a wider range of case-mix
variables, the adjustment substantially affected centre 40 only, which was brought within the 3-SD limits.
This centre differed from the average in many ways: the centre had fewer patients who were homozygous
for DF508, more with the milder G551D mutation and more who were pancreatic sufficient. Our findings at
the other centres (9, 7 and 34) could not be attributed to case mix. To gauge whether or not the patterns
observed were related to the use of multilevel modelling for our case-mix adjustment, we tried a fixed-effects
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modelling approach, which suggested that case mix alone might not explain the outlying results at
centre 40.
We then compared the centres in terms of the proportion of patients receiving i.v. antibiotics. Surprisingly,
centres 9 and 40 frequently exhibited special-cause variation in this variable but in different ‘directions’,
and not entirely consistently with our hypothesis. For example, both centres had fewer patients on i.v.
antibiotics but one had better FEV1 outcomes than the average and the other had poorer FEV1 outcomes
than the average. Exploring the number of days on i.v. antibiotics proved challenging as patterns were not
consistent and the high level of skewness of this variable means that standard funnel plots – and the
associated control limits – would not provide reliable estimates.
Consultation with clinicians
Focus groups with clinicians from adult and paediatric centres were conducted to identify what they
felt were the important SPPs for delivering good CF care. There was a focus on adequate staffing and
sufficient time with different members of the MDT; monitoring and measuring of clinical outcomes and
treatment adherence; communication within the MDT and with patients; patient education and support;
and standard policies on how to deal with infection control and eradication, as well as changes in lung
function and BMI. From this work, questionnaires for the directors of adult and paediatric CF centres
were developed and disseminated nationally. It was hoped that the results from these questionnaires
could help to inform conversations with CF centres that had outcomes that were better or worse than
the average. The response rate, however, was relatively poor; this made it difficult to draw inferences or
to use the responses to start a dialogue with centres.
Consultation with patients
A focus group with the CF Trust’s team of expert patient advisors was conducted to identify what patients
thought was necessary for good CF care. Based on this, we devised a questionnaire to be disseminated to
patients nationally. The focus group concentrated on the characteristics of three areas: (1) good inpatient
stays, (2) good outpatient visits and (3) well-functioning CF units. In relation to inpatient stays, the group
highlighted a number of issues, including the importance of patient involvement in devising a clear
action plan and self-management of medication during the stay. Access to an appropriate and sufficient
number of members of the MDT and consistent quality of care over the course of a 1-week stay were also
identified as important. In the outpatient setting, patients felt that it was important to have sufficient time
to see all members of the MDT, to have access to an outpatient pharmacy and to speak to an experienced
consultant who has detailed knowledge of the patient. It was felt that a well-functioning CF unit will
educate patients about CF, develop a constructive dialogue between patients and CF unit staff, have
patients involved in the measurement and management of key aspects of CF and provide consistent access
to the unit’s MDT. Owing to time constraints, we were unable to conduct the patient survey within the
time frame of this study, but it will take place subsequently.
Conclusions
These findings confirm that the annual review data can be used to identify differences in clinical outcomes
between centres and that case-mix characteristics might explain some of these differences. However, this
adjustment does not account for all differences; therefore, further work is needed to explore the results
that were obtained.
Strengths and limitations
This study’s greatest strength is the completeness and coverage of the data source. Close to 100%
of CF patients consent to their data being included in the CF Registry and, in later years of analysis, the
proportion of registered patients having an annual review recorded in a given year approached 90%. We
also consulted with the CF clinical community and patients in order to understand what outcomes should
be studied for our work to be relevant.
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We tried different strategies in our data analysis – from considering different ways of adjusting for age to
using different reference equations for FEV1 – and we have largely drawn the same conclusions. However,
despite the large number of data collected, we were not always able to adjust for all relevant case-mix
characteristics as a result of data not being available (such as characteristics at transition to adult care
among older adults). In addition, although the CF Registry is very complete, some centres are much smaller
than others and we cannot exclude the possibility that we have failed to detect special-cause variation in
these very small centres.
The low response rates to our centre director surveys meant that we were unable to get a clear sense of
the structures and processes of care at all centres. We did get supplemental information from the CF
Registry – such as days on i.v. antibiotics – but this does not cover the full picture of how care is structured
and delivered at a centre.
Future work
This work has raised questions that could be addressed in future work, for example ‘How does the antibiotic
treatment affect outcomes?’. This would be helpful if explored in discussions with sites at which we could
discuss the approaches to treatment of CF patients in different scenarios.
Another key question is ‘How do patients feel about the care that they receive?’. We developed a detailed
questionnaire for patients that we did not have the time to disseminate and analyse within the context of
this grant.
Implications for practice
The learning from this work regarding the importance of case-mix adjustment, the limitations of such plots
of detecting special-cause variation in small centres, the usefulness of making comparisons across years
rather than using single-year analyses and the potential usefulness of incorporating available process
measures can all be incorporated into future practice at the CF Registry.
Our approach provides a framework for future centre comparisons in CF or other disease areas for which
routine clinical data are available on well-defined patient populations. These can usefully form the basis of
discussions with sites about outcomes – subject to the limitations described here – when following the
pyramid of investigation approach.
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
Background and rationale
Cystic fibrosis
Cystic fibrosis (CF) is a common genetic disease, affecting approximately 9000 people in the UK.1 The genetic
mutation leads to mucus obstruction and infection in the lungs.2 Other organs, such as the liver, intestines
and pancreas, are also affected, which, in turn, leads to poor nutrient absorption and malnutrition.3 The
prognosis for patients with CF has improved dramatically over the years, and it was recently shown that there
has been a clear increase in the median age at death since the early 1970s.4 In 2009, the median predicted
survival for UK patients was 38 years.1
People with CF are treated at specialist centres that offer dedicated paediatric or adult care; transition to
adult care usually occurs after a person’s 16th birthday. Care involves daily treatments that can include drugs
to clear mucus and prevent lung infections, pancreatic enzymes to aid digestion, and physiotherapy.
The CF Trust – the national UK charity for CF – maintains a national registry database (the UK CF Registry)
of detailed clinical and demographic information on all patients attending these specialist centres. Patients
are invited to attend annual reviews at their specialist centre and, based on these review data, the Trust
produces annual reports describing the health of patients. The reports are available on the CF Trust
website to be accessed by patients and clinicians alike [www.cysticfibrosis.org.uk/uk-cf-registry/reporting-
and-resources (accessed 6 July 2018)].
Centre comparisons
From 2008 to 2014, the annual reports published by the CF Trust included comparisons between centres
in terms of key clinical outcomes using simple rankings. Although these comparisons give a sense of
the distribution of outcomes between centres, they encourage the reader to assume, for example, that
centres with the highest values of lung function measure are ‘better’ than those with lower values. This is
misleading on two grounds:
1. The rankings make no allowances for the differences in patient intakes. It could be argued, for example,
that centres with younger patients would have higher age- and sex-adjusted lung function measures
than centres with older patients, because lung function declines with age in people with CF. As such,
between-centre comparisons that do not account for the age of patients risk not detecting good
outcomes in centres where patients are older. Similarly, poor outcomes in centres with younger patients
may not be detected.
2. The rankings include no formal tests comparing centres. Without formal comparisons, we cannot say
that there is evidence that outcomes are better at one centre than another, let alone conclude that any
observed differences are related to the processes of care.
Such shortcomings are important if the reader interprets the CF Trust graphs as league tables. Marshall and
Spiegelhalter5 showed that league tables – even after adjustment for patient intake – are unreliable in
identifying poor performance. Furthermore, Lilford et al.6 suggest that league tables – in which a centre’s
position could be caused by a host of reasons, such as differences in definitions and data quality between
providers, chance or inadequate case-mix adjustment to differences in institutional management – can
generate undue tension as blame is attributed without identification of the reason. After all, the very nature
of a league table is that one provider is ranked bottom, whether or not care is poor, and ranking may simply
be due to chance.7 Without providing any explanation for observed differences, we are no further forward in
knowing how to improve care, which should be the ultimate aim of any institutional comparisons.
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Quality improvement in cystic fibrosis
Quality improvement programmes of varying sorts are not new in CF: there is a long history of such
programmes in the USA8,9 and they have been described in Germany.10 In the USA, the national CF Patient
Registry performs centre comparisons in its routine reporting and this has also encouraged local units to
undertake their own within-centre quality improvement work, making use of the national registry data.11,12
However, in the UK there has been no work testing the hypothesis that there are key differences in
the delivery of care that affect outcomes. We therefore adopted a ‘quality improvement’ approach to
understanding whether or not differences between centres are related to the processes of care, which
builds upon and improves on existing methodologies in CF centre comparisons. In this study, we
considered all centres in our analyses and used statistical process control (SPC) charts to determine
whether or not there are statistically meaningful differences. These charts were developed as a means of
studying the variability of ‘processes’ over time13 and have been shown to be useful when comparing
health-care providers (whether hospitals, clinics or primary care practices) as well as the outcomes of single
providers (e.g. Harold Shipman) over time.14
For the SPC charts, summary outcome measures for individual units were plotted against time or the size
of the unit, with control limits [either at 2 or 3 standard deviations (SDs)]. It is anticipated that there will be
some variability between units, which is intrinsic to the process itself and referred to as ‘common-cause
variation’.13 SPC charts are designed to highlight variability caused by factors outside the process, referred
to as ‘special-cause variation’. Centres that have summary measures outside the control limits (either
higher or lower) are said to exhibit special-cause variation.
An example of a SPC chart is presented in Figure 1. Each dot represents a different CF unit and these CF
units are being compared in terms of the mean forced expiratory volume in 1 second (FEV1) in children
aged 15 years, with the size of the unit on the x-axis, given by the number of 15 year olds with FEV1 data.
The dashed lines represent the control limits. Units located between the limits show ‘common-cause
variation’ and those outside the limits show ‘special-cause variation’. Limits of 95% are equivalent to 2 SDs
and limits of 99.8% are equivalent to 3 SDs.
Use of clinical audits in improving care
The vast wealth of health information collected from patients in both primary and secondary care is
increasingly seen as a valuable resource, with the potential to help understand health outcomes as well
as how care is delivered. By understanding how care is delivered and how care relates to autcomes,
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FIGURE 1 Example of funnel plot. FEV1, forced expiratory volume in 1 second.
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it is hoped that patient outcomes can be improved. The nature of registries and clinical audits varies: some,
like the UK CF Registry, require centres to manually input specified data onto secure systems, whereas
others, like the UK Renal Registry, take regular, automatic downloads from centre information technology
systems. Both of these registries are run by national charities. NHS Digital has been commissioned to run a
range of clinical audits for organisations such as NHS England and the Healthcare Quality Improvement
Partnership (HQIP). These audits are designed to allow for performance to be compared with defined
standards, and HQIP has published guidance on how to detect and manage outliers in such audits, which
includes reference to the importance of case-mix adjustment.15
The importance of adjustment in centre comparisons is reflected in recent National Institute for Health
Research (NIHR)-funded work by Pagel et al.16 They sought to improve their risk adjustment model for
30-day mortality after heart surgery and to improve how information was communicated back to patients.
Given that the impact of identifying outliers can be dramatic for centres – surgery at one paediatric centre
was halted under the original risk model – appropriate risk modelling was identified as important. Careful
attention was given to developing the model, which involved an iterative process of clinical discussions to
identify risk factors, statistical modelling and assessments of model performance of cross-validation.
Aims and objectives
The aims of this project were to determine whether or not there are statistically meaningful differences
in key health outcomes between CF centres in the UK and to determine the processes of care driving
such differences.
Our objectives were to:
1. establish a framework to allow future comparisons of key measures of quality in terms of care
structures and processes
2. develop statistical models using data from the national CF Registry database that allow us to adjust
clinical outcomes at centres for the patient case mix
3. compare centres using SPC charts to determine whether or not important differences in key clinical
outcomes exist between centres
4. consult with experts in CF care to turn existing care guidelines17 into maps of the structures, policies
and processes (SPPs) required to deliver good outcomes and to identify factors that could facilitate or
hinder such SPPs being successful
5. consult with people with CF to ascertain what they believe are the factors that could facilitate or hinder
these SPPs from being successful
6. collect data from individual centres and describe the structures and processes of care at these centres
based on the SPP-mapping exercise
7. explore how the SPPs of care differ between centres with exceptional outcomes and the
remaining centres.
Structure of this report
Chapter 2 outlines our methodologies for all components of the study. Our statistical analysis of the CF
Registry data is described in Chapter 3. The workshops and focus groups with clinicians and people with
CF to understand the SPPs that can help or hinder good care are described in Chapter 4. In Chapter 5
we describe the results of our questionnaire to clinicians across all centres. In Chapter 6 we discuss and
summarise our results.
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Chapter 2 Methodology
Introduction
In order to address our research objectives, we structured our work around centre comparisons and
consultations with clinicians and patients to identify factors that would help to understand variability,
describe care structures and identify differing processes.
Centre comparisons
We used data from the CF Registry to compare CF centres in the UK in terms of key clinical outcomes.
Data source
Annual review data (2007–15 inclusively) from the CF Registry database were used for all analyses. Centres
are allocated an identification (ID) number by the CF Trust, which is used in the CF Trust’s reporting. We
generated new, anonymised, IDs to ensure that, while conducting our analyses, we were blind to the
identity of centres. This means that the IDs used in this report will not match those used by the CF Trust.
Outcomes
Consultation with members of the CF Registry steering committee and with centre directors identified a
number of respiratory and nutrition outcomes deemed clinically meaningful for measuring the performance
of both paediatric and adult centres. For paediatric centres we considered:
l FEV1 at 12 years of age
l FEV1 at 15 years of age
l FEV1 change from 13 to 15 years of age
l body mass index (BMI) percentile at 15 years of age.
For adult centres we considered:
l FEV1 change from 18 to 21 years of age
l BMI change from 18 to 21 years of age as described above.
In the first instance, we performed our analyses using data from 2007–12, as stated in our original
protocol. We subsequently amended the protocol to use data from 2013–15, when the data became
available. With these additional data, we repeated the analyses of FEV1 at 12 and 15 years of age.
To inform our analyses of these age groups and confirm any trends observed, we also conducted single-year
analyses (for 2007–15 inclusive) using the CF Registry data of patients of all ages. The outcome considered
for these was FEV1% predicted. We also considered trends in intravenous (i.v.) antibiotic treatment.
The CF Registry provides FEV1% predicted, calculated using the Knudson reference equations18 based on a
patient’s age, and these values were used for our analyses. We also studied our outcomes using the more
recently developed Global Lung Function Initiative (GLI) reference equations,19 which have been shown
to be superior in modelling FEV1 during the adolescent period. Researchers found that transitioning from
one set of reference equations to another when moving into adulthood can lead to disproportionate step
changes in FEV1% predicted, which GLI eliminates.20 Predictions of FEV1 using the GLI reference equations
require more detailed information on ethnicity; therefore, there were some missing data using this method
compared with the other method. From 2016 onwards, the UK CF Registry adopted the GLI reference
equations for their reporting, although they continue to record absolute FEV1 in litres so that any changes
to the GLI reference equations can be accommodated.
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Candidate variables for case-mix adjustment
Case-mix adjustment involved adjusting outcomes for non-modifiable factors that are known to be
associated with health-care outcomes and to differ between centres. By adjusting outcomes for the patient
case mix, we eliminated factors that the centre has no control over from our between-centre comparison.
In the case of this study, candidate variables were the patient’s CF genotype, sex, whether or not they
have sufficient pancreatic function to digest food without supplements, socioeconomic status [(SES)
based on Townsend deprivation scores)21], age (measured in months) and age at diagnosis (measured
in months).
Inclusion criteria
We considered all centres and all patients with annual review data during the relevant time periods. At the
individual level, all patients who were within the age ranges stated above (see Chapter 2, Outcomes) at
the time of their annual review were considered eligible for the analysis. For outcomes relating to changes
in FEV1 and BMI over time, we required that patients have at least two annual reviews at the same centre.
Data analysis
For each outcome we analysed, we began by identifying the patient population in terms of their demographic
characteristics and the completeness of the data they provided. As the case-mix variables were not expected
to change over time, we made use of a patient’s full history of annual reviews, when possible, to estimate
missing values in any given year. For example, if a patient’s genotype was not available in the 2007 annual
review data, we carried it over from later years when it was available. Minimising missing case-mix data is
important, as only those patients without missing data were included in our case-mix adjustment models,
and rates and patterns of ‘missingness’ have the potential to bias our results. Centre variation in rates of
‘missingness’ for these variables was described using descriptive statistics and funnel plots.
Following these explorations of data completeness and case mix, the means of the observed (i.e. not
case-mix adjusted) outcomes for each outcome were analysed using funnel plots, which allowed us to
look at the differences in outcomes between centres. For outcomes relating to change in FEV1 or BMI, we
performed linear regression analyses for each patient, calculating the annual decline in the outcome during
the period of interest. These individual changes in FEV1 or BMI were then pooled by centre to generate
funnel plots of mean change in FEV1 or BMI by centre.
As the control limits were influenced by the rare occurrence of extremely small centres, which made
interpretation of the plots illegible, we restricted many of our plots to centres providing data on at least
five patients.
Next, to understand the impact of case mix, we adjusted our outcomes for case mix using multilevel linear
regression models, fitting centres as a random effect. The random intercept model allowed the outcome
to vary between centres and the unstructured covariance option was used to allow all variance–covariance
parameters to vary. Having fitted a random intercept model, we used the likelihood ratio test to check
for cluster-level variation. We generated funnel plots of the level 2 residuals of our case-mix adjustment
models using the funnelcompar command in Stata® version 14 (StataCorp LP, College Station, TX, USA).
If a centre was outside the upper 3-SD limits of these plots, it indicated that the mean of the outcome for
that centre was greater than the overall mean; similarly, a centre outside the lower limits had a mean
smaller than the overall mean.
In single-year analyses that considered wide age ranges and in which it was unlikely that there would be a
linear association between age and FEV1, we considered different methods for the adjustment of age in
children and in adults.
l Children (aged 6–15 years): in each year of analysis, we ran a generalised linear model (GLM) of FEV1%
predicted across age as a categorical variable (with 6 years as the referent group) and from this model we
obtained predicted values. Our age-adjusted FEV1% predicted values were then calculated using the ratio
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of the original FEV1% predicted to the values predicted by the regression model multiplied by 100.
Centre-level means of this age-adjusted FEV1% predicted were generated and funnel plots produced to
assess how this adjustment affected centre comparisons. These age-adjusted outcomes were then used
as outcomes in multilevel models that further adjusted for other case-mix variables.
To contrast with the above approach, we also considered age adjustment by fitting a single linear term
for age in our multilevel models. The results for both approaches are presented.
l Adults (aged ≥ 16 years): in each year of analysis, we ran a GLM of FEV1% predicted across age deciles
and from this model obtained predicted values. Our age-adjusted FEV1% predicted was then calculated
using the ratio of the original FEV1% predicted to the values predicted by the regression model multiplied
by 100. Centre-level means of this age-adjusted FEV1% predicted was generated and funnel plots produced
to assess how this adjustment affected centre comparisons. These age-adjusted outcomes were then used
as outcomes in multilevel models that further adjusted for other case-mix variables.
Another approach to dealing with potential non-linearity is to use beta-splines, as has been done in other
studies of FEV1 in CF.22 Knots were placed at 18, 28 and 40 years for each year’s analysis. The splines
were incorporated into multilevel models and from these we used the random intercept predictions in
our funnel plots.
To complement these analyses, we described our case-mix variables using means or medians for
continuous measures and frequencies and proportions for categorical variables. We also generated funnel
plots of the proportion of patients taking i.v. antibiotics, assuming a binomial distribution.
A number of sensitivity analyses were performed to assess the robustness of our results. These included
the following:
1. We compared the FEV1 results that we obtained using the Knudson reference equations18 with those
obtained when using the GLI reference equations.19
2. In our year-by-year analysis of FEV1, we re-ran our models for 2013–15, this time excluding patients
with the milder G551D mutation, as a large proportion of these patients would have been taking a
new CF treatment, called Ivacaftor (Kalydeco ©, Vertex), that has been shown to be highly successful.
3. In our year-by-year analysis of paediatric centres, we re-ran our models, this time excluding those
patients receiving shared care. We were interested to see if the outcomes of the main centre changed
when these patients – who can have varying levels of contact with the main centre – are excluded.
There has been some evidence that the model of care can affect clinical outcomes.23
4. In some cases in which multilevel models are used for case-mix adjustment, the resulting centre-level
means are drawn towards the overall mean, thus potentially masking true differences.15 This is referred
to as ‘shrinkage’. We explored whether or not the interpretation of our case-mix adjusted funnel plots
would differ if we used fixed-effect GLMs rather than multilevel models to adjust for case mix. From our
GLMs, we compared the predicted outcome with the observed outcome to obtain a measure of what
‘proportion’ of the outcome is explained by case mix. The centre-level mean ‘proportions’ were then
presented in funnel plots.
All funnel plots were generated using the funnelcompar command in Stata® and all analyses were
conducted in Stata®.
Consultations to identify factors that would help to understand variability
Consultation with clinicians
Focus groups to understand key determinants of quality of CF care were held in October 2013. Clinicians
from adult centres attended on day 1 and clinicians from paediatric centres attended on day 2. The
meeting started with an introduction that highlighted the purpose of the day, which was to explore the
factors that contributed to high-quality care, with the intention of developing a questionnaire that could
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be sent to CF centres so the researchers could understand local patterns of care. Determinants of care
were explored in three general categories:
1. Structures – clinicians were asked to explore the resources that they considered to be important in
delivering high-quality care in terms of buildings, staff and equipment.
2. Policies – clinicians were asked to explore the policies that they considered to be important in delivering
high-quality care in terms of approaches to care, for example the approach taken to detecting new
isolates of Pseudomonas.
3. Processes – clinicians were asked to explore the processes that they considered to be important in
delivering high-quality care, for example the processes employed within clinics to monitor adherence or
carry out quality improvement.
The analysis of the focus group data was guided by the principles of interpretative thematic analysis,
whereby the transcripts were thoroughly read by the researcher and codes and categories were assigned
to sections of the text to highlight key thematic areas with regard to factors that hinder or facilitate SPPs.24
In addition, a form of content analysis – an assertions analysis25 – was undertaken of each transcript to
examine the frequency with which particular barriers or facilitators are characterised in a particular way.
Following the workshops, the outcomes of each workshop were shared with participants to provide the
opportunity to comment on the synthesis of the data collected and to suggest any final refinements.
Questionnaire
The topics discussed in the focus groups were used to develop a questionnaire for paediatric centre teams
and a questionnaire for adult centre teams. The development of the questionnaire is described in more
detail in Chapter 5.
Consultation with patients
In consulting with patients we aimed to develop a questionnaire to be issued to patients.
The process also allowed us to investigate the patients’ views on the key SPPs that were identified in the
consultation with clinicians (described in Consultation with clinicians) to assess if these were important to
them as well as to clinicians. To do this, we conducted a focus group with the team of seven clinical care
patient advisors who are tasked by the CF Trust with promoting high-quality care. The focus group was
conducted by teleconference and comprised two components. The first focused on participants’ own
experiences of CF care. The second asked participants to consider, from their own experiences, factors that
could facilitate or hinder the SPPs identified in the consultation with clinicians as being successful and their
views on the importance of these clinician-defined SPPs.
The focus group schedule of questions was developed with input from the study management group as
well as patient clinical care advisor Dominic Kavanagh, who was involved in the development of this project.
The results of the patient focus groups will be analysed using the same techniques of thematic analysis
and assertions analysis as described in Consultation with clinicians.
Describing care structures
We administered the online questionnaires developed from our consultation with clinicians (Consultation
with clinicians) to centre directors of all specialist CF centres in the UK – who cascaded the questionnaire
to their multidisciplinary teams (MDTs). The results of the survey were tabulated and presented using
descriptive statistics.
Patient and public involvement
A patient and a CF Trust representative were members of the study management group that developed
and refined the research approach adopted as the study progressed.
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Chapter 3 Centre comparisons
This chapter considers the centre comparisons performed using different clinical outcomes as part ofwork package 1. This work is presented separately for paediatric and adult centres.
Owing to the large number of figures and tables referred to in these analyses, many are presented in
Appendix 2 (figures) and Appendix 3 (tables).
Paediatric analyses
Analyses of children attending paediatric centres focus first on young adolescents whose outcomes, we
hypothesised, would be most strongly affected by specialist clinical care. Based on our original project plan,
we considered data from 2007–12 (see Analyses in young adolescents: 2007–12) and pooled data across
the study period to maximise our sample size. We then updated some of these analyses using more
recently available data from 2013–15 (see Analyses in young adolescents: 2007–15).
This work is complemented by single-year analyses of data from 2007 to 2015 inclusive for all children
between the ages of 6 and 15 years [see Analyses in all children aged 6–15 years by year (2007–15)].
The aim of this separate analysis was to explore whether or not there were patterns in outcomes over
multiple years.
Analyses in young adolescents: 2007–12
Between 2007 and 2012, 9914 unique patients had at least one annual review recorded on the UK CF
Registry. This includes 2112 patients aged 12–15 years who attended paediatric centres; 31 paediatric
centres contributed data to the CF Registry during this period.
Our prespecified outcomes in children each relate to different age groups:
l 12 years – FEV1
l 15 years – FEV1 and BMI percentile
l 13–15 years – FEV1 change from ages 13 to 15 years.
Given that these outcomes differ in nature (some focus on an outcome at a single age and others focus on
changes in outcomes over time), different eligibility criteria are applied to each, as described in Chapter 2.
For each outcome, we described the identified patient population in terms of their demographic
characteristics and the completeness of the outcome and case-mix data that they provided (Table 1).
In the analysis of each outcome, there was an approximately equal split of boys and girls and most of the
patients were taking pancreatic enzyme supplements for pancreatic insufficiency. Just over half of patients
were homozygous DF508, whereas < 10% of genotyped patients had no DF508 mutations. Using home
postcode data to determine area-level SES, we note that those in the most deprived quintile were under-
represented for each outcome analysis.
As these variables were to be used in case-mix adjustment, and only those patients with non-missing data
for these variables would be included in case-mix adjustment models, rates and patterns of ‘missingness’
had the potential to bias our results. We therefore sought to quantify and explore variations between
centres in rates of ‘missingness’ for these variables. For the variables considered, there were few missing
data (< 5%) in any of the analysis populations (inclusion in an analysis population depended in part on
having non-missing outcome data).
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Outcome: FEV1 in children aged 12 years
Data were available for a total of 1193 12-year-olds across the 31 paediatric centres. Estimates of the
predicted FEV1 can be obtained using the Knudson reference equations,18 but, more recently, it has
become common to use the GLI reference equations.19 We considered both methods and analysed the
data first using the Knudson reference equations.18
Of the 1193 12-year-olds studied, 87 did not have FEV1% predicted data available. A funnel plot illustrated
the proportion of patients at each centre with non-missing data and showed that, although the vast
majority of centres had good levels of non-missingness (≥ 85%), centres 39 and 43 exhibited low levels of
non-missingness and were outside the lower 3-SD limits (see Appendix 2, Figure 18a).
The means of the observed (i.e. not case-mix adjusted) FEV1% predicted of 12-year-olds at each of
the 31 CF paediatric centres were plotted into a funnel plot (Figure 2a). This allowed us to look at the
differentiation between the centres in terms of their observed FEV1% predicted. The plot shows eight
centres outside the 2-SD control limits, although only four were outside the 3-SD limits. The results suggest
that some centres have higher mean FEV1 values than the average, whereas others have lower mean FEV1
TABLE 1 Characteristics of patients for each outcome
Characteristic
Outcomes, n (%)
12 years of age
(patients eligible for
analysis, N= 1193)
15 years of age
(patients eligible for
analysis, N= 1151)
13–15 years of age
(patients eligible for
analysis, N= 1180)
Sex
Male 614 (54.5) 566 (49.2) 578 (49.0)
Female 579 (48.5) 585 (50.8) 602 (51.0)
Number of missing observations
(% based on those eligible)
0 (0) 0 (0) 0 (0)
Pancreatic enzyme
Yes 1067 (91.7) 1054 (92.1) 1105 (93.9)
No 97 (8.3) 91 (8.0) 72 (6.1)
Number of missing observations
(% based on those eligible)
29 (2.4) 6 (0.5) 3 (0.3)
SES
1 (least deprived) 254 (21.8) 237 (21.2) 258 (22.6)
2 242 (20.7) 225 (20.1) 216 (19.0)
3 233 (20.0) 218 (19.5) 239 (21.0)
4 240 (20.6) 254 (22.7) 244 (21.4)
5 (most deprived) 198 (17.0) 185 (16.5) 183 (16.1)
Number of missing observations
(% based on those eligible)
26 (2.2) 32 (2.8) 40 (3.4)
Genotype
Homozygous 653 (55.4) 632 (55.5) 635 (54.3)
Heterozygous 434 (36.8) 413 (36.3) 437 (37.4)
No DF508 92 (7.8) 94 (8.3) 98 (8.4)
Number of missing observations
(% based on those eligible)
14 (1.2) 12 (1.0) 10 (0.1)
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FIGURE 2 FEV1 at 12 years of age. (a) Mean of the unadjusted FEV1% predicted (Knudson18); (b) predicted random
intercepts of FEV1% predicted (Knudson
18); (c) mean of the unadjusted FEV1% predicted (GLI
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random intercepts of FEV1% predicted (GLI19). (continued )
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values than the average. Centres with fewer patients tended to have slightly lower than average FEV1
values and the two largest centres had slightly higher mean FEV1 values. The same pattern was observed
when we calculated the FEV1% predicted using the GLI reference equations (Figure 2c).
We explored whether or not there were between-centre differences in the case-mix variables (see
Appendix 2, Figure 19) using funnel plots. Although there was some variability between centres, this rarely
exceeded the 3-SD control limits. The exception to this is centre 43, which had a larger proportion of
patients in the most deprived quintile than the other centres (see Appendix 2, Figure 19c).
To assess whether or not the observed between-centre variation was attributable to differences in the
distribution of case-mix variables, we generated multilevel models of our outcome adjusted for these
factors (see Appendix 3, Table 17). The results of our model suggest, as expected, that males have higher
FEV1 values than females and that patients taking pancreatic enzyme supplements have lower FEV1 than
those not requiring this treatment. There was also some evidence that patients in more socioeconomically
deprived areas had lower FEV1 values than those in the most affluent quintiles. A funnel plot of the
random effect variation (see Figure 2b) after case-mix adjustment reveals that, although many of the same
centres remain outside the 2-SD control limits as in the unadjusted analysis, centre 39 remains outside the
3-SD limits. These results suggest that differences in case mix between centres may be responsible for
some – although not all – of the differences in FEV1. Similar results were obtained when FEV1% predicted
was calculated using the GLI reference equations (see Figure 2d).
Outcome: FEV1 in children aged 15 years
Data were available for a total of 1151 15-year-olds across the 31 paediatric centres. Of these, only 85 did
not have FEV1% predicted values.
Funnel plots illustrated the proportion of patients at each centre with non-missing FEV1% predicted and it
was observed that, although the vast majority of centres had good levels of non-missingness (≥ 85%), as
was observed with 12-year-olds, centres 43 and 39 exhibited low levels of non-missingness (see Appendix 2,
Figure 20a).
The means of the observed FEV1 of 15-year-olds at each of the 31 paediatric centres were plotted into a
funnel plot (Figure 3a). Eight centres were outside the 2-SD limits and many (centres 12, 26, 31, 39 and 59)
were also outside these limits in the analysis of 12-year-olds. In contrast to the plots of 12-year-olds,
however, none of the centres was outside the 3-SD limits.
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As was observed in 12-year-olds, case-mix factors differed between centres (see Appendix 2, Figure 21);
none of the centres was outside the 3-SD limits.
Our case-mix adjustment model (see Appendix 3, Table 18) showed similar patterns of association for
15-year-olds as was observed for 12-year-olds, in that FEV1 was lower among females, lower for those with a
more deprived SES and lower for those taking pancreatic enzyme supplements. The SD of the between-centre
variation of the random effect is comparable between the two models. Inspection of the funnel plots of the
predicted random intercepts showed no centres outside the 3-SD control limits and showed that larger
centres tended to have FEV1 values that were slightly greater than the mean (see Figure 3b).
Analyses were repeated using the GLI reference equations19 and the results were very much the same for
the unadjusted funnel plot (see Figure 3c) and the funnel plot adjusted for case mix (see Figure 3d).
Outcome: body mass index percentile in children aged 15 years
In total, BMI percentile data were available for 1117 15-year-olds across the 31 paediatric centres.
Funnel plots illustrated the proportion of patients at each centre with non-missing BMI (percentile) and it
was observed that, although the vast majority of centres had good levels of non-missingness (≥ 85%)
(see Appendix 2, Figure 22), one centre (39) had a lower proportion of missingness than the average.
The means of the observed BMI of 15-year-olds at each of the 31 paediatric centres were plotted into a
funnel plot (Figure 4a). No centres were outside the 3-SD control limits, but a few were outside the 2-SD
limits: centres 31, 52 and 54 had a higher than average BMI percentile and centres 12, 53 and 59 had a
lower than average BMI percentile.
We considered the same case-mix variables as with our FEV1 analyses and, in case-mix adjusted models,
we showed that gender, pancreatic enzyme use and living in the most deprived quintile had a significant
effect on lowering a patient’s BMI percentile (see Appendix 3, Table 19).
Inspection of the funnel plots of the predicted random intercepts from the case-mix adjusted model
showed no centres outside the 3-SD control limits and only centre 52 near the upper 2-SD limit
(Figure 4b).
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Outcome: change in FEV1 in children aged 13–15 years
As one of the aims of CF care is to maintain good lung function, we sought to assess whether or not
there were statistically meaningful differences between centres in the rate of change of FEV1 during the
early teenage years (age 13–15). We identified 1180 patients who had had at least two annual reviews
with FEV1% predicted recorded between the ages of 13 and 15 years during the study period. Although
most centres contributed data for the vast majority of their patients (see Appendix 2, Figure 23a), centres
39 and 43 had sufficient FEV1 data to calculate decline for < 60% of their eligible patients. These same
centres also had poor completeness of FEV1 data for 12- and 15-year-olds, as described in earlier sections.
We performed linear regression analyses for each patient, calculating the annual decline in FEV1 in those
aged between 13 and 15 years. These individual changes in FEV1 were then pooled by centre to generate
funnel plots of mean change in FEV1 by centre. The mean FEV1 decline across centres was a decline of
1.2% predicted per year (SD = 11.1) and there was equal variability between centres above and below
this mean. Although three centres were outside the 2-SD control limits, none was outside the 3-SD limits
(Figure 5a).
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A multilevel model, using the estimated change in FEV1 as the outcome, was generated to explore the
impact of case-mix variables (see Appendix 3, Table 20). Unlike earlier models for FEV1 at ages 12 and
15 years, none of the case-mix variables was statistically significant. Furthermore, the between-centre SD
was 0.58, suggesting minimal difference between centres. This was confirmed in a funnel plot of the
predicted random intercepts (Figure 5b), in which all centres were very close to the mean.
As described in Chapter 2, when using multilevel modelling for case-mix adjustment it is possible that the
model draws centre estimates to the overall mean in a process known as ‘shrinkage’. This can give the
false impression that it is the case-mix variables that are responsible for differences between centres.
To explore the potential role of shrinkage in our case-mix adjusted analysis, we re-ran the adjustment
using fixed-effects GLMs. This analysis showed one centre to be outside the 3-SD limits (centre 54; see
Appendix 2, Figure 24). The fixed-effects case-mix adjustment model explained very little of the variability
in the outcome (R2 = 0.0071), however, making it difficult to infer what the centre-level estimate means.
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Analyses in young adolescents: 2007–15
Our analyses of children aged 12 and 15 years – described in the previous three sections – were repeated
with the addition of annual review data from 2013 to 2015. When these data became available to
researchers, we used them to see if our previous findings were altered by the inclusion of the new data.
We did not explore lung function decline between 13 and 15 years of age as there was no evidence of
special-cause variation in the case-mix adjusted results using multilevel modelling; we felt that it was highly
unlikely that this would change with the addition of further data.
Outcome: FEV1 in children aged 12 years (2007–15)
With the addition of the 2013–15 data, we had annual review data on 1853 12-year-olds attending
paediatric CF centres. Of these, 1737 (93.7%) had non-missing FEV1% predicted data. These patients
came from the same centres as studied previously, but now each centre contributed the data of more
patients to the analysis.
The means of the observed (i.e. not case-mix adjusted) FEV1% predicted were plotted into a funnel plot
(Figure 6a). As with the analysis of the 2007–12 data, the plots showed eight centres to be outside the
2-SD control limits, although these were not the same centres as before (see Figure 2a). Only two of the
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FIGURE 6 FEV1 at 12 years of age using data from 2007–15. (a) Mean of the unadjusted FEV1% predicted
(Knudson18); and (b) predicted random intercepts of FEV1% predicted (Knudson
18).
DOI: 10.3310/hsdr07060 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 6
© Queen’s Printer and Controller of HMSO 2019. This work was produced by MacNeill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
centres (12 and 39) were outside the 3-SD limits, and these remained outside after case-mix adjustment
(Figure 6b). In our original analysis, centre 25 was on the upper 3-SD control limit after case-mix
adjustment (see Figure 2b), but, when the later data were added, this centre was drawn closer to the
overall mean.
As in the analysis of change in FEV1, we explored the role of shrinkage by generating a funnel plot of
the ‘percentage predicted’; the outcome is presented in Appendix 2, Figure 25. This model shows some
consistency with Figure 6b, in which, after case-mix adjustment, centres 12 and 39 remained outside the
3-SD control limits. Interestingly, smaller centres such as 23 and 26 – which, when using multilevel models
for case-mix adjustment, moved from between the lower 2- and 3-SD control limits to well within the 2-SD
limits – remained outside the 2-SD limits when the role of shrinkage was explored, but they were never
outside the 3-SD control limits. Our results suggest, however, that case mix was not necessarily the driver
in moving these centres closer to the overall mean.
Outcome: FEV1 in children aged 15 years (2007–15)
With the addition of the 2013–15 data, we had annual review data on 1844 15-year-olds attending
paediatric CF centres. Of these, 1736 (94.1%) had non-missing FEV1% predicted data.
The means of the observed FEV1 of 15-year-olds at each of the 31 paediatric centres were plotted into a
funnel plot (Figure 7a). Eleven centres were outside the 2-SD limits, including all of those identified in the
earlier analysis using data from 2007–12 (see Figure 3a). Using the more recent data, however, moved
three of the centres outside the 3-SD control limits (centres 12, 31 and 39), in addition to bringing three
centres outside the 2-SD limits for the first time (centres 18, 25 and 61). After case-mix adjustment, many
of these centres were brought within the 2-SD limits, but centres 12 and 39 remained outside the lower
3-SD limit.
We explored the effect of shrinkage on our results (see Appendix 2, Figure 26). As seen in the earlier
case-mix adjusted analysis in Figure 7, centres 12 and 39 had FEV1 values outside the lower 3-SD control
limit. Centre 31, however, shifted slightly to within the 3-SD limits.
Outcome: body mass index percentile in children aged 15 years (2007–15)
Incorporating data from 2013–15 increased the number of 15-year-olds with non-missing BMI percentile
data to 1804. As in the original analysis, there were no centres outside the 3-SD control limits (Figure 8a)
and the same centres tended to be outside the 2-SD limits as in the original analysis (see Figure 4). The
only differences were centre 52, which was no longer outside the upper 2-SD limit, and centre 44, which
moved outside the upper 2-SD limit. Case-mix adjustment largely brought centres closer to the mean and
in the updated analysis only centre 59 was outside the 2-SD control limits after case-mix adjustment.
As seen in Figure 8, when we used fixed-effects modelling to explore the role of shrinkage, we found that
none of the centres was outside the 3-SD control limits (see Appendix 2, Figure 27).
Analyses in all children aged 6–15 years, by year (2007–15)
To complement the analyses of outcomes in targeted age groups that were carried out by pooling data
across multiple years, we conducted all-age analyses by year. By exploring outcomes in all ages year by
year, we can see whether or not there are trends in clinical outcomes.
For the analyses of paediatric centres we focused on FEV1% predicted in all patients aged 6–15 years,
excluding those patients who had previously had a lung transplant as these patients are likely to have
much better lung function. First, we used FEV1, measured using the Knudson reference equations18 as
reported in the UK CF Registry, and, second, sensitivity analyses were performed (see Global Lung Function
Initiative reference equations) using the GLI reference equations.19
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We considered data from 2007 to 2015 inclusive; the number of patients having annual reviews, and
those providing FEV1 data at these reviews, had changed over that period, reflecting overall improvements
in the completeness of the UK CF Registry, as highlighted in Table 2.
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FIGURE 7 FEV1 at 15 years of age using data from 2007–15. (a) Mean of the unadjusted FEV1% predicted
(Knudson18); and (b) predicted random intercepts of FEV1% predicted (Knudson
18).
TABLE 2 Number of annual reviews and FEV1 recordings at paediatric CF centres by year from 2007 to 2015
Contributing data 2007 2008 2009 2010 2011 2012 2013 2014 2015
Number of centres 28 30 31 31 31 31 31 31 31
Total number of annual reviews 1315 1742 2111 2201 2290 2271 2339 2321 2376
Total number of FEV1% predicted measures 1230 1586 1834 1958 2104 2121 2074 2078 2149
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Unadjusted analyses
Centre-level analyses unadjusted for any case-mix factors illustrated that centres varied widely in size and
that outcomes varied between centres (Figure 9a and b).
Each year’s plot was investigated to see whether or not centres appeared inside or outside the 2- or 3-SD
control limits. We also took note of centres that ‘hovered’ near control limits without being outside those
limits, so that we could monitor whether or not they had crossed the control limits previously or in
subsequent years. These results are summarised in Table 3.
We note that a large number of centres appear between the 2- and 3-SD limits and few appear to be
outside the upper 3-SD limit, which indicates higher than average FEV1 values. The patterns in the data
suggest that some centres appear outside (or near) the 3-SD control limits repeatedly, and we focused our
attention on these.
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l Centres with lower than average FEV1 values: the centres appearing outside the lower 3-SD limit
most frequently were centres 12, 39 and 52. Centres 12 and 52 were outside the limits in the early
years (2007–11) but subsequently moved to within the limits and sometimes within the 2-SD limits.
Centre 39, in contrast, was outside the 3-SD limits in the later years (2010, 2012 and 2013) and
similarly moved within the 2-SD limits outside these years.
l Centres with higher than average FEV1 values: the centres appearing outside the upper 2- or 3-SD
limits most frequently are centres 25, 28 and 31. From 2013, however, they were generally between
the 2- and 3-SD limits.
As was done with the earlier age-specific analyses, we conducted a pyramid of investigation approach to
understanding the data.
Pyramid of investigation: data
The UK CF Registry was re-established in 2007 and since then has grown progressively. In 2012, data from
the annual reviews on the CF Registry were used for banding centres for funding. Although funding is
linked to other features in addition to severity of FEV1 impairment, it has encouraged centres to provide
complete data. The growing number of patients providing annual review data therefore reflects, in part,
this push for greater data completeness. To explore whether or not the patterns observed in Figure 9 are
related to the changing centre size, and changing proportions of data completeness for FEV1, we present
the frequencies and proportions by centre and year in Table 4.
For many centres there was an increase in the number of annual reviews at each centre over time, with
lower numbers of annual reviews in 2007 and 2008.
As well as considering the number of annual reviews submitted, we also considered what percentage of
these annual reviews included non-missing FEV1 data. This should be near 100%, as FEV1 constitutes an
important component of annual reviews for CF, and this result was observed for the majority of centres.
Non-missingness was generally > 80%, although of notable exception is centre 39, which had a period
between 2009 and 2011 during which non-missingness ranged from 37% to 68%. The centre was
outside at least the 2-SD limits from 2010 to 2013, covering both this period of poor data completeness
and the period in which rates of non-missingness improved.
TABLE 3 Centres showing evidence of special-cause variation and ‘borderline’ centres, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside lower 3-SD limit Outside lower 2-SD limit Outside upper 2-SD limit
Outside upper
3-SD limit
2007 12, 52 and 59 11, 16,a 23 and 53a 14, 31, 36, 37 and 54 25
2008 12 and 52 1, 13, 18 and 26 36 and 44 25 and 28
2009 11, 12 and 52 16, 23, 43 and 59 36, 46 and 60 25 and 31
2010 12 and 39 23, 52 and 59 36, 46a and 54a 31
2011 12 and 23 18 and 39 31a and 61 –
2012 39 23,a 26, 50a and 52a 25, 31,a 43 and 54 28
2013 39 23, 26, 50 and 53 25, 28, 31 and 61 60
2014 53 25, 39, 50 and 52 13, 28, 31, 44, 60 and 61 –
2015 53 25, 26, 39,a 50 and 52a 16, 28, 31, 43, 60a and 61 –
a Centres approaching the 2-SD control limit without being outside it.
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TABLE 4 Number of patients providing annual review data and FEV1 data and the proportion of annual reviews with non-missing FEV1, by year and centre
Centre
2007 2008 2009 2010 2011 2012 2013 2014 2015
AR FEV1 % NM AR FEV1 % NM AR FEV1 % NM AR FEV1 % NM AR FEV1 % NM AR FEV1 % NM AR FEV1 % NM AR FEV1 % NM AR FEV1 % NM
Centres with lower than average FEV1 values
12 41 40 98 49 43 88 92 85 92 98 95 97 94 89 95 102 98 96 104 96 92 103 95 92 98 93 95
39 – – – 1 1 100 126 46 37 169 97 57 179 121 68 178 143 80 170 142 84 168 141 84 157 138 88
52 79 78 99 89 87 98 136 129 95 131 121 92 149 142 95 155 148 95 168 154 92 157 148 94 164 146 89
Centres with higher than average FEV1 values
25 144 126 88 165 153 93 181 167 92 175 162 93 178 167 94 175 166 95 168 152 90 156 140 90 155 138 89
28 42 40 95 45 44 98 43 41 95 50 47 94 51 49 96 51 48 94 68 63 93 76 68 89 74 72 97
31 65 63 97 93 86 92 86 79 92 95 89 94 96 89 93 85 78 92 91 77 85 99 81 82 104 93 89
AR, number of patients providing annual review data; FEV1, number of patients providing FEV1 data; % NM, percentage of annual reviews with non-missing FEV1 data.
–, the centre did not provide data that year.
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Prior to being disseminated, UK CF Registry data undergo quality checks by those preparing the CF
Registry’s annual report, during which time outlier values are queried with the centres that are able to
compare CF Registry data with their own records. Since centre-level summary statistics started to be
published in these annual reports, centre directors have been given the opportunity to query results that
do not seem to align with their own clinical experience. For this reason, we did not explore the quality of
the FEV1 values further in this work.
After considering possible discrepancies in the data, the next step in the pyramid of investigation is to
consider case mix. This is particularly relevant in the year-by-year analyses in which all patients aged
6–15 years are included in the analyses.
Pyramid of investigation: case mix
Age
Earlier analyses of FEV1 in select, narrow age groups did not account for age, but FEV1 declines with age
and – as the mean age of patients varies slightly between centres (see Appendix 3, Table 21) – it is
essential to adjust FEV1 accordingly.
Statistical adjustment should account for the documented non-linear association between FEV1 and age.
To do this, for each year of analysis we ran a GLM of FEV1% predicted across age as a categorical variable
(with 6 years as the referent group) and from this obtained model-predicted values. Our age-adjusted
FEV1% predicted was then calculated using the ratio of the original FEV1% predicted to the values
predicted by the regression model multiplied by 100. The results are described in Appendix 2, Figure 28,
and Appendix 3, Table 22, and show very similar patterns to the unadjusted analysis, with some centres
moving from outside to inside the 3-SD limits. Notably, centre 28, which had previously been outside the
upper 3-SD limits, was now consistently within these limits and, thus, closer to the mean.
We also ran a separate analysis simply incorporating age as a linear term into multilevel models and we
used the random intercept predictions, which estimate the difference between the overall mean and
the centre-level mean, after adjustment for age. As a result, the y-axes for this graph (see Appendix 2,
Figure 29) will be different from those in earlier funnel plots (see Appendix 2, Figure 28). In both cases,
however, we are looking at differences from the mean. The results from this analysis are broadly similar to
those of the other adjustment (for age), but in various years brought some centres outside the 3-SD limits
to either within these or within the 2-SD limits (see Appendix 2, Figure 29, and Appendix 3, Table 23).
The centres affected by this were centres 12, 23, 31, 50, 53, 54 and 60.
Additional case-mix variables
Beyond age, a number of other factors that may influence FEV1, which are not influenced by care and
which are collected on the UK CF Registry, as outlined below.
Sex (see Appendix 3, Table 24) A number of studies have shown that females have poorer CF
outcomes than males. We explored whether or not centres with better outcomes have a lower proportion
of female patients. We observed that approximately 50% of patients were female in most centres.
Genotype: homozygous DF508 (see Appendix 3, Table 25) As CF is a recessive genetic disease,
every effort is made to have all patients genotyped, and this information is recorded on the UK CF Registry.
The most common genotype in the UK is DF508, and it has been shown in many studies that those who
have two of these mutations (i.e. are homozygous for DF508) have poorer outcomes. In those centres with
lower than average FEV1 values, the proportion of patients who have homozygous DF508 was generally
≥ 50%. There appeared to be less variability between the centres with higher than average FEV1 values.
If we look uniquely at 2015, half of the centres had just under 50% homozygous DF508 patients and half
had slightly more.
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Genotype: any G551D mutation (see Appendix 3, Table 26) In 2012, a new CF therapy called
Ivacaftor became available in the UK for patients with a G551D mutation. Clinical trials showed promising
results and uptake of the drug was swift in those patients who were eligible to receive it. There is also
some evidence26 suggesting that patients with at least one G551D mutation have less severe CF than those
who are homozygous DF508. The mutation was not very common in the centres selected for analysis here:
in 2015, the centres with the highest prevalence of the mutation were centre 31 (10.6%) and centre 39
(8.2%). The former had higher FEV1 than the average and the latter had lower FEV1 than the average.
Pancreatic sufficiency (see Appendix 3, Table 27) A marker of CF severity is pancreatic sufficiency
(i.e. pancreatic enzymes are not required to digest food). Here we considered the proportion of patients
who were pancreatic sufficient. We noted that in centres with higher than average FEV1 values, the
proportions of patients who are pancreatic sufficient varied widely. For example, there was a near twofold
difference in the proportion of patients who are pancreatic sufficient between centres 25 and 31, although
both report higher than average FEV1 values. In centres with lower than average FEV1 values, there was
variability between centres, but pancreatic sufficiency was rarely as common as in centre 31.
Socioeconomic status (see Appendix 3, Table 28) As with many conditions, there is evidence that
individuals from more disadvantaged backgrounds have poorer outcomes. Here, SES was summarised in
quintiles: we explored what proportion of patients were in the fifth (most deprived) quintile. All other things
being equal, we would expect that 20% of patients in a given centre would be in any given quintile.
Although this was observed in some centres (such as centres 39 and 52, which had lower than average FEV1
values, and centre 28, which had higher than average FEV1 values), patients in the most deprived quartile
were under-represented in other centres reporting lower than average FEV1 values (centre 12) and higher
than average FEV1 values (centre 31). Contrary to expectation, centre 36, which reported higher than average
FEV1 values, had a consistently high proportion of patients (> 30%) from the most deprived quintile.
All of these results suggest that case-mix factors shown in the literature to be associated with FEV1 differ
between centres, although not in entirely consistent ways. Adjustment for these factors may be helpful in
explaining some of the associations seen in our earlier funnel plot.
Case-mix adjusted analysis All case-mix variables were included in multilevel models and adjustment
for age was undertaken, adopting the approaches described earlier in this section. Both approaches gave
largely similar results, as described in Tables 5 and 6 and Figures 10 and 11. Centre 31 moved from
outside the upper 3-SD limits to within these limits in 2010 and centre 28 moved within the upper 3-SD
limits in 2012. Conversely, centre 25 moved outside the 3-SD limits in 2013, although this was seen only
in the analysis that adjusts for age using a GLM.
As with the other analyses, we ran a sensitivity analysis to assess the role of ‘shrinkage’. Our findings
were broadly similar to those obtained using the multilevel model approach. A summary of contrasting
approaches is presented in Appendix 3, Table 29, and the funnel plots are presented in Appendix 2,
Figure 30. Occasionally, however, centres that had been brought inside the 3-SD limits using the multilevel
modelling approach stayed outside those limits when adopting the GLM approach (centre 28 in 2008,
centres 12 and 23 in 2011, centre 28 in 2012, centre 39 in 2013 and centre 53 in 2015). In these
instances, concluding that case mix was solely responsible for special-cause variation in the unadjusted
models would be inappropriate.
Pyramid of investigation: care
Given that we saw more consistent signals of special-cause variation in these year-by-year analyses, we
explored measures of clinical care to see if these are associated with the trends observed in FEV1. It has
been shown in the USA that centres that use more i.v. antibiotics have better FEV1 outcomes.27 One way
of exploring whether or not that trend exists in the UK is to look at the proportion of patients receiving
i.v. antibiotics and at the total number of days on i.v. antibiotics for those patients receiving any antibiotics
(see Appendix 3, Table 30). There was no consistent trend showing that centres with lower than average
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FEV1 values have systematically different rates and durations of i.v. antibiotic treatment than those centres
with higher FEV1. The most consistent trend among these centres was that centre 31 tended to have a lower
proportion of patients taking i.v. antibiotics (2008–11) and a shorter duration of treatment among those
patients receiving them (2012). This trend of lower than average proportions of patients on i.v. antibiotics at
centre 31 was also in evidence in the funnel plots presented in Figure 12, in which centre 31 frequently
shows special-cause variation, being outside the lower 3-SD limit.
TABLE 5 Centres showing evidence of special-cause variation and ‘borderline’ centres in analyses adjusted for age
(using GLMs), sex, pancreatic sufficiency, genotype (homozygous DF508, heterozygous DF508 or other) and SES
quintile, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 52 and 59 12 and 23 31 and 54a 25
2008 12 and 52 – 28, 44 and 50a 25
2009 12 and 52 1 and 59 31, 36, 46a and 50a 25
2010 12 and 39 23, 52a and 59 25, 31, 36a and 44a –
2011 – 1,a 12, 23a and 39 25a –
2012 39 12 and 52a 14,a 25, 28 and 43a –
2013 39 50 31 25
2014 – 39,a 50 and 52 – –
2015 – 25,a 50a and 52a 31,a 61 and 43 –
a Centres approaching the 2-SD control limit without being outside it.
TABLE 6 Centres showing evidence of special-cause variation and ‘borderline’ centres in analyses adjusted for age
(using a linear term), sex, pancreatic sufficiency, genotype (homozygous DF508, heterozygous DF508 or other) and
SES quintile, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 12, 52 and 59 23 31, 36a and 54a 25
2008 12 and 52 – 28, 44a and 50a 25
2009 12 and 52 1 and 59 31 and 36 25
2010 12 and 39 23, 52 and 59 25, 31, 36a and 44a –
2011 – 12, 23a and 39 25a –
2012 39 12 and 52a 14, 25, 28 and 43a –
2013 – 39 and 50 31 25
2014 – 39,a 50 and 52 44a –
2015 – 25,a 50a and 52a 31, 43 and 61 –
a Centres approaching the 2-SD control limit without being outside it.
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FIGURE 12 Funnel plots of the proportion of patients receiving i.v. antibiotics, by year. (a) 2007; (b) 2008; (c) 2009;
(d) 2010; (e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015.
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Sensitivity analyses
Global Lung Function Initiative reference equations
In recent years there has been a move to adopt the GLI reference equations for calculating FEV1%
predicted, as they more effectively model FEV1 during the teenage years. We replicated the unadjusted
analyses presented in Unadjusted analyses using the new reference equations to explore whether or
not – given differences in case mix – centre-level mean FEV1 may be affected by the change in reference
equations. We noted (see Appendix 2, Figure 31, and Appendix 3, Table 31) that the same general trends
emerged. Occasionally, a centre crossed the 3-SD limit (in either direction) but remained outside the 2-SD
limit. On other occasions, centres crossed the 2-SD limits when they had hovered below the limit previously
(and vice versa). Some centres moved within the 2-SD limits in the GLI analyses, including centre 25, which
no longer showed special-cause variation in 2012 and 2014. Centre 12 was the only centre to show
special-cause variation (2-SD) in the GLI analysis in 2012 when it was within the control limits in the
original analysis.
Excluding patients with a G551D mutation from 2012 onwards
As described in Pyramid of investigation: case mix, in 2012 a new CF treatment was launched, targeting
patients with the G551D mutation. Uptake was swift on the basis that the treatment had been shown to
be very successful in improving lung function. We re-ran the unadjusted analyses for 2012 onwards to
explore whether or not patients with the G551D mutation influenced the centre comparisons in these years,
as it is suggested that the G551D mutation has a milder phenotype and there is effective new treatment
available for patients with this mutation. The results of the original analysis – with sensitivity analysis in
italics – are presented in Table 7. We can see that there is some shifting of single centres between the 2- and
3-SD control limits, but the results do not change drastically. The most consistent shift among centres outside
the control limits (rather than borderline centres) was for centre 31, which had a relatively high proportion of
G551D patients (10%) and no longer showed special-cause variation in 2013 and 2014 at 2SD when these
TABLE 7 Centres showing evidence of special-cause variation and ‘borderline’ centres in unadjusted analyses,
by year. Original analyses presented alongside analyses excluding G551D patients
Year
Centres with lower than average
FEV1 values
Centres with higher than average
FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit
Outside
3-SD limit
2007 12, 52 and 59 11, 16,a 23 and 53a 14, 31, 36, 37 and 54 25
2008 12 and 52 1, 13, 18 and 26 36 and 44 25 and 28
2009 11, 12 and 52 16, 23, 43 and 59 36, 46 and 60 25 and 31
2010 12 and 39 23, 52 and 59 36, 46a and 54 31
2011 12 and 23 18 and 39 31a and 61 –
2012 39 23,a 26, 50a and 52a 25, 31,a 43 and 54 28
2013 All patients 39 23, 26, 50 and 53 25, 28, 31 and 61 60
Excluding G551D 39 23, 26, 50 and 53 25, 28, 31,a 60 and 61 –
2014 All patients 53 25, 39, 50 and 52 13, 28, 31, 44, 60 and 61 –
Excluding G551D 53 25, 39, 50 and 52a 13, 28, 44, 59,a 60a and 61 –
2015 All patients 53 25, 26, 39,a 50 and 52a 16, 28, 31, 43, 60a and 61 –
Excluding G551D 53 25, 26, 50 and 52a 16, 28,a 31, 43 and 61 –
a Centres approaching the 2-SD control limit without being outside it.
Note
Italicisation indicates sensitivity analysis.
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patients were excluded; this suggests that part of the reason for this centre’s high FEV1 levels is its cohort of
these patients.
Excluding identified network clinics from centre analyses
The way in which specialist paediatric care in CF is delivered is different from the way in which adult CF
care is delivered. In paediatrics there is a model of care that involves main centres sharing care with smaller
‘network’ clinics. This model is devised, in part, to allow patients to receive CF care close to home, with
input from a larger centre; how this is delivered differs by network.
Many of these network clinics input their data to the UK CF Registry in such a manner that the patients
attending the network clinics are clearly identified; to ensure sufficiently large centre sizes, we pooled the
network clinics with the main centres in all of our analyses. To assess, however, whether or not a centre’s
outcomes would differ if only those patients attending the main centre were studied, we conducted a
sensitivity analysis removing identified network patients from the centres. As these network clinics are
small, we did not study them separately but rather excluded them from the analysis entirely.
Comparing the results of the original analysis with those excluding the network clinics yields comparable
results, as seen in Table 8. In the analysis unadjusted for case mix, excluding network patients resulted in
largely identical trends to the original analysis. Occasionally, however, centres moved closer to the overall
TABLE 8 Centres showing evidence of special-cause variation and ‘borderline’ centres in unadjusted analyses,
by year. Analysis of all patients presented alongside analysis excluding network patients
Year
Centres with lower than average
FEV1 values
Centres with higher than average
FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit
Outside
3-SD limit
2007 All patients 12, 52 and 59 11, 16,a 23 and 53a 14, 31, 36, 37 and 54 25
Excluding shared care 12, 52 and 59 11, 16a and 23 14, 31, 36, 37 and 54 25
2008 All patients 12 and 52 1, 13, 18 and 26 36 and 44 25 and 28
Excluding shared care 12 and 52 1,a 13, 18 and 26 36, 44a and 46a 25 and 28
2009 All patients 11, 12 and 52 16, 23, 43 and 59 36, 46 and 60 25 and 31
Excluding shared care 11 and 52 12, 16, 23, 43 and 59 36, 46 and 60 25 and 31
2010 All patients 12 and 39 23, 52 and 59 36, 46a and 54a 31
Excluding shared care 12, 23 and 39 3a and 59 36, 50a and 54 31
2011 All patients 12 and 23 18 and 39 31a and 61 –
Excluding shared care 23 12, 18 and 39 31a and 61 –
2012 All patients 39 23,a 26,a 50a and 52a 25, 31,a 43 and 54 28
Excluding shared care 39 12,a 26 and 53a 14, 31,a 43, 54 and 61 28
2013 All patients 39 23, 26, 50 and 53 25, 28, 31 and 61 60
Excluding shared care 39 3, 26, 50 and 53 25, 28, 31, 60 and 61 –
2014 All patients 53 25, 39, 50 and 52 13, 28, 31, 44, 60 and 61 –
Excluding shared care 50 and 53 39a 13, 28,a 31,a 44 and 61 –
2015 All patients 53 25, 26, 39,a 50 and 52a 16, 28, 31, 43, 60a and 61 –
Excluding shared care 53 25,a 26 and 50a 16, 31, 43a and 61 –
a Centres approaching the 2-SD control limit without being outside it.
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mean (excluding network clinics); in some cases, the centre moved further away. For example, centre 12
was outside the lower 3-SD limits in 2009 and 2011, but moved within those limits and, thus, closer to
the overall mean, when its network patients were excluded. Centres 25 and 52 also moved to within
the lower 2-SD limits in 2014 and centre 28 moved within the upper 2-SD limits in 2015. Conversely,
centre 23 moved outside the 3-SD limits when it had previously only been outside the 2-SD limits in 2010,
as did centre 50 in 2014.
Adult analyses
Analyses of patients attending adult centres focus first on young adults in the early years after transitioning
to adult care, whose outcomes we hypothesised would be most strongly affected by specialist clinical
care. Later analyses consider all patients aged ≥ 16 years attending adult centres. Based on our original
project plan, we considered data from 2007–12 (see Analyses in young adults: 2007–12) and pooled data
across the study period to maximise our sample size. Given the trends observed in the analysis of patients
in this age group using 2007–12 data, we did not further expand on these analyses using 2013–15 data.
This work is, however, complemented by single-year analyses of all adults aged ≥ 16 years using data from
2007–15, inclusive (see Analyses of all patients attending adult centres: 2007–15). The aim of these
separate analyses is to explore whether or not there are patterns in outcomes over multiple years in the
wider adult patient population.
Analyses in young adults: 2007–12
There were 1439 unique patients aged 18–21 years attending adult CF centres during the study period
who fulfilled the study inclusion criteria and had non-missing outcome data. There were 28 adult centres
contributing data to the UK CF Registry during this period.
Our two prespecified outcomes in adults were changes in FEV1 and BMI between 18 and 21 years of age.
To be eligible for the analysis, patients required at least two annual review encounters at the same centre
between 2007 and 2012. Table 9 shows the identified patient population in terms of their demographic
characteristics and the completeness of the outcome and case-mix data that they provided. We considered
using measures of patient health at the time of transition to adult care as case-mix variables, as this would
allow us to account, in part, for the care delivered in paediatric centres. However, this information was
infrequently available for older adults, who were less likely to have data from when they were 16 years
old, as UK CF Registry records go back as far as 2007 only.
Outcome: change in FEV1 in adults aged 18–21 years
We identified 1439 patients with non-missing FEV1 data who fulfilled the inclusion criteria for this analysis.
As was carried out in the paediatric analyses, we performed linear regression analyses for each patient,
calculating the annual decline in FEV1 between 18 and 21 years of age. These individual changes in FEV1
were then pooled by centre to generate funnel plots of mean change in FEV1 by centre. The mean decline
across centres was 1.78%. Although two centres were outside the 2-SD control limits, none was outside
the 3-SD limits (Figure 13a).
A multilevel model, using the estimated change in FEV1 as the outcome, was generated to explore the
impact of case-mix variables with the addition of age at the first visit in this analysis (Table 10). Only sex
proved statistically significant in this analysis. A funnel plot adjusted for case mix shows that intercepts
(Figure 13b) for all centres were very close to the mean.
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As with other outcomes, we considered the possible role of shrinkage and used a fixed-effects model
to adjust for case mix. The results are shown in Appendix 2, Figure 32, and no centres are outside the
3-SD limits.
Outcome: change in body mass index in adults aged 18–21 years
We identified 1432 patients with non-missing BMI data who fulfilled the inclusion criteria for this analysis.
As for the earlier adult analyses, we performed linear regression analyses for each patient, calculating the
annual decline in BMI between the ages of 18 and 21 years. These individual changes in BMI were then
pooled by centre to generate funnel plots of mean change in BMI by centre. The mean change across
centres was a 0.17 unit increase. Only one centre was outside the 2-SD control limits; it was within the
3-SD limits, however (Figure 14a).
A multilevel model, using the estimated change in BMI as the outcome, was generated to explore the
impact of case-mix variables (Table 11). None of the case-mix variables proved statistically significant in this
analysis. A funnel plot adjusted for case mix shows that intercepts (Figure 14b) for all centres were very
close to the mean.
TABLE 9 Characteristics of patients for each outcome
Characteristic
Patients aged 18–21 years (patients eligible
for analysis, N= 1439), n (%)
Sex
Male 784 (54.5)
Female 655 (45.5)
Number of missing observations (% of eligible) 0
Pancreatic enzyme
Yes 1337 (92.9)
No 98 (6.8)
Number of missing observations (% of eligible) 4 (0.3)
SES
1 (least deprived) 302 (21.0)
2 273 (19.0)
3 260 (18.1)
4 300 (20.8)
5 (most deprived) 285 (19.8)
Number of missing observations (% of eligible) 19 (1.3)
Genotype
Homozygous 795 (55.2)
Heterozygous 499 (34.7)
No DF508 117 (8.1)
Number of missing observations (% of eligible) 28 (1.9)
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To assess the impact of shrinkage we conducted sensitivity analyses, as we had done for other outcomes.
As observed in the analysis of change in FEV1 in children, we observed some outliers in this analysis that
were not evident in the unadjusted or multilevel model-adjusted analysis (see Appendix 2, Figure 33). As
before, however, the case-mix adjustment model explains very little of the outcome variability (R2 = 0.007)
and it is difficult to interpret what these results mean.
Analyses of all patients attending adult centres: 2007–15
To complement the analyses of outcomes in targeted age groups pooling data across multiple years,
we conducted all-age analyses by year, as was done for the paediatric sample.
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For the analyses of adult centres, we focused on FEV1% predicted in all patients aged ≥ 16 years, excluding
those patients who had previously had a lung transplant. We used FEV1 measured using the Knudson
reference equations,18 as reported in the UK CF Registry, and sensitivity analyses were performed using the
GLI reference equations.19
We considered data from 2007 to 2015 inclusive; the number of patients having annual reviews and those
providing FEV1 data at these reviews changed over that period, reflecting improvements in the completeness
of the UK CF Registry (Table 12).
Unadjusted analyses
Centre-level analyses unadjusted for any case-mix factors illustrated that centres varied widely in size and
that FEV1 varied between centres (Figure 15).
Each year’s plot was investigated to see if centres appeared inside or outside the 2- or 3-SD control limits.
We also took note of centres that ‘hovered’ near control limits without being outside them. These results
are summarised in Table 13.
TABLE 10 Fixed and random components of the multivariable model analysis for factors associated with FEV1%
predicted [n= 1392 (ages 18 to 21 years)]
Fixed effect Estimate (95% CI) p-value
Constant 0.09 (–2.28 to 2.47) 0.939
Sex (male) –1.56 (–2.49 to –0.62) 0.001
Genotype
Homozygous DF508 – 0.643
Heterozygous DF508 0.23 (–0.79 to 1.25)
No DF508 0.87 (–0.98 to 2.72)
Pancreatic enzyme supplement use –0.88 (–2.88 to 1.21) 0.389
SES
1 (least deprived) – 0.764
2 –0.89 (–2.35 to 0.57)
3 –0.59 (–2.07 to 0.90)
4 –0.81 (–2.24 to 0.63)
5 (most deprived) –0.41 (–1.91 to 1.09)
Age at first visit 0.29 (–0.86 to 0.28) 0.325
Random effect
Between-centre SD 0.78 (0.29 to 2.11)
Within-centre SD 8.81 (8.48 to 9.14)
CI, confidence interval.
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There are some patterns in the data that suggest that some centres are outside the control limits consistently.
l Centres with lower than average FEV1 values: centre 9 is outside the 3-SD limits for most years,
although – as the largest centre by a large margin and located where the control limits are at their
narrowest – it is generally close to those limits. Centre 10 was frequently outside the 2-SD limits from
2010 (and outside the 3-SD limits in 2014). In the early years of the study period (2007–11), centre 2
was frequently outside the limits, as was centre 21 from 2011 onwards.
l Centres with higher than average FEV1 values: centres 34 and 40 were frequently outside the control
limits and, between 2009 and 2012, centre 34 was outside the 3-SD limits. In the later years of the
analysis, centre 47 was also frequently outside the 2-SD limits and was outside the 3-SD limits in 2015.
In 2007 and 2008, centre 7 was outside the 3-SD control limits and from 2009 was either borderline
on the 2-SD limits or within the 2-SD limits. Similarly, centre 5 was often outside the 2-SD limits in the
early years, but moved to a borderline position within the control limits after this.
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We will explore the patterns seen at those centres appearing outside the 3-SD limits (centres 7, 9 and 34)
in more detail, adopting the pyramid of investigation approach, and will consider whether or not issues in
the data have led to these trends.
Pyramid of investigation: data
To explore whether or not the patterns observed in Figure 14 are related to the variations in the number of
annual reviews submitted – and to explore variations in the proportion of patients with poor FEV1 (< 40%
predicted) – we stratified patients by FEV1 and we present the frequencies by centre and year in Appendix 3,
Table 32. There was a general increase in the number of annual reviews at each centre over time. As
discussed in relation to the paediatric data, we did no further validation of the adult data, given the data
validation already performed by the CF Trust.
After considering possible discrepancies in the data, the next step in the pyramid of investigation was to
consider case mix. This was particularly relevant in the year-by-year analyses in which all patients aged
≥ 16 years were included.
TABLE 11 Fixed and random components of the multivariable model analysis for factors associated with BMI
(kg/m2) [n= 1387 (ages 18–21 years)]
Fixed effect Estimate (95% CI) p-value
Constant –0.05 (–0.40 to 0.30) 0.778
Sex (male) 0.13 (–0.01 to 0.27) 0.068
Genotype
Homozygous DF508 – 0.7450
Heterozygous DF508 0.04 (–0.11 to 0.19)
No DF508 0.10 (–0.17 to 0.37)
Pancreatic enzyme supplement use 0.05 (–0.25 to 0.34) 0.755
SES
1 (least deprived) – 0.295
2 0.10 (–0.11 to 0.32)
3 0.01 (–0.21 to 0.23)
4 0.10 (–0.11 to 0.31)
5 (most deprived) 0.22 (0.002 to 0.44)
Age at first visit –0.03 (–0.11 to 0.05) 0.485
Random effect
Between-centre SD 0.13 (0.06 to 0.30)
Within-centre SD 1.29 (1.25 to 1.34)
CI, confidence interval.
TABLE 12 Number of annual reviews and FEV1 recordings at adult CF centres by year from 2007 to 2015
Contributing data 2007 2008 2009 2010 2011 2012 2013 2014 2015
Number of centres 26 27 29 29 28 28 27 28 28
Total number of annual reviews 2263 3060 3588 3924 4349 4440 4569 4945 5079
Total number of FEV1% predicted measures 2163 2889 3355 3732 4234 4220 4387 4742 4872
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Pyramid of investigation: case mix
Age
It is known that FEV1 declines with age; therefore, as the mean age of patients varies between centres
(see Appendix 3, Table 33), it is essential to adjust FEV1 accordingly.
Statistical adjustment should account for the documented non-linear association between FEV1 and age.
To do this we adopted two approaches:
1. For each year of analysis we ran a GLM of FEV1% predicted across age deciles and from this obtained
model-predicted values. Our age-adjusted FEV1% predicted was then calculated using the ratio of the
original FEV1% predicted to the values predicted by the regression model multiplied by 100. When
considering those centres identified as exhibiting special-cause variation in the unadjusted analysis,
we saw that adjustment for age resulted in some shifting across the control limits. Centre 9 moved to
within the 3-SD limits in 2008, 2012–15. The results are described in Appendix 2, Figure 34, and
Appendix 3, Table 34.
2. We used beta-splines for age with knots chosen at 18, 28 and 40 years based on visual inspection of
the 2012 data. This was done to accommodate possible non-linear associations between age and FEV1,
as has been seen in a number of studies.22 These splines were incorporated into multilevel models and
we used the random intercept predictions in our funnel plots. With this adjustment, some of the
centres that showed evidence of special-cause variation in unadjusted analyses were now within the
2-SD control limits (centres 2, 5, 7 and 21). Centre 9 continued to show evidence of special-cause
variation, but in 2008, 2010 and 2012 moved to within the 3-SD limits. However, some ‘positions’
remained unchanged, such as that of centre 34, which remained outside the 3-SD limits in 2009–11
and outside the 2-SD limits in 2012–15. The results of these analyses are presented in Appendix 2,
Figure 35, and Appendix 3, Table 35.
3. This analysis was repeated using a simple linear adjustment for age and similar results were obtained
(results not shown).
These results suggest that age may have accounted for some of the differences between centres, but not
in all cases. In addition, regardless of the method used to account for age, consistent signals are detected
in centres exhibiting the greatest difference from the mean.
TABLE 13 Centres showing evidence of special-cause variation and ‘borderline’ centres, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 9 2 and 35 47 7 and 40
2008 9 35a 5 and 48a 7
2009 9 2, 10, 17a and 21 5, 7a and 40 34
2010 9 2, 10 and 17 40 and 51 34
2011 9 2, 21, 35a and 41 5a and 40 34
2012 9 8a and 10 6, 40, 47 and 51a 34
2013 – 9, 10, 20,a 21 and 56 34, 40 and 47 –
2014 9 and 10 20, 21 and 29a 17, 34, 40, 45 and 47 –
2015 – 9, 10, 20, 29 and 56 34, 40, 45 and 48 47
a Centres approaching the 2-SD control limit without being outside it.
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Additional case-mix variables
In addition to age, there are a number of other factors that may influence FEV1, which are not influenced
by care and which are collected on the UK CF Registry.
Sex (see Appendix 3, Table 36) A number of studies have shown that women have poorer CF outcomes
than men. For this reason, we explored whether or not centres with better outcomes have a lower
proportion of female patients. We observed that, except for a few outliers, at most centres and at most
times the proportion of females ranged from 40% to 55%.
Genotype: homozygous DF508 (see Appendix 3, Table 37) As CF is a recessive genetic disease, every
effort is made to have all patients genotyped, and this information is recorded on the UK CF Registry.
The most common genotype in the UK is DF508, and it has been shown in many studies that those who
have two of these mutations (i.e. are homozygous DF508) have poorer outcomes. We considered this and
noted that in most centres approximately 50% of patients are homozygous DF508. It is also of note that
centre 40, which consistently had higher than average FEV1 results, reports < 35% of its patients being
homozygous DF508. This suggests that patients at centre 40 have a different CF genotype profile from
patients at other centres.
Genotype: any G551D (see Appendix 3, Table 38) In 2012, a new CF therapy called Ivacaftor became
available in the UK for patients with a G551D mutation. Clinical trials showed promising results and
uptake of the drug was swift in those patients who were eligible to receive it. We explored what
proportion of patients had at least one G551D mutation and found that the mutation was not very
common, but was more common at centre 34, which showed higher than average FEV1 values, in line
with our hypothesis.
Pancreatic sufficiency (see Appendix 3, Table 39) A marker of CF severity is pancreatic sufficiency
(i.e. pancreatic enzymes are not required to digest food). Here we considered what proportion of patients
were pancreatic sufficient. We noted that there was variability between centres and that the centre
with the highest proportion of pancreatic-sufficient patients was centre 34, which had higher than
average FEV1 values. Centre 7, which had higher than average FEV1 values, had the lowest proportion
of pancreatic-sufficient patients.
Socioeconomic status (see Appendix 3, Table 40) As with many conditions, there is evidence that
individuals from more disadvantaged backgrounds have poorer outcomes. Here, SES was summarised in
quintiles: we explored what proportion of patients were in the fifth (most deprived) quintile. All other
things being equal, we would expect that 20% of patients in a given centre would be in any given
quintile. This was the pattern observed in some of the centres, but we noted that centre 7 (which had
better FEV1 outcomes) had far fewer patients in the fifth quintile. In the later years of the analysis,
centre 40 (better FEV1 outcome) also had fewer patients in this quintile. Contrary to this trend, however,
centre 34 – which consistently had better FEV1 outcomes – had > 25% of its patients in the fifth quintile.
All of these results suggest that some case-mix characteristics may explain some of the FEV1 patterns we
observed and, therefore, adjusting for these in our analyses would be worthwhile. There are, of course,
many other variables unrelated to care at an adult CF centre that could influence clinical outcomes but
we are limited to those available on the UK CF Registry and those that have good data completeness.
Case-mix adjusted analysis Case-mix variables were included in multilevel models and adjustment for
age was carried out using the approaches described earlier. Both approaches gave very similar results, as
described in Tables 14 and 15 and Figures 16 and 17. This additional adjustment generally reduced the
number of centres between the 2-SD and 3-SD limits in the case of centres with lower than average
FEV1 values. In the case of those centres with higher than average FEV1 values, in later years this
adjustment seemed to bring centres that were once outside the 3-SD limits to between the 2- and
3-SD limits.
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Recognising the possible role of shrinkage in moving centres from outside the 3-SD control limits to within
these limits after case-mix adjustment, we conducted sensitivity analyses as described above; in this case,
splines were used to adjust for age. The resulting funnel plots are presented in Appendix 2, Figure 36,
and, to compare this method of case-mix adjustment with that using multilevel modelling and unadjusted
results, a summary of centres outside the 2- and 3-SD control limits using all three methods is presented in
Appendix 3, Table 41. In focusing on the centres outside the 3-SD limits, there were only occasional years
in which the case-mix adjusted results using multilevel modelling drew centres within the control limits,
whereas the method using GLM resulted in them being outside the limits. Often, centre 40 was outside
the 3-SD limits in the fixed model-adjusted analysis but was between the 2- and 3-SD control limits in the
multilevel modelling approach.
TABLE 14 Centres showing evidence of special-cause variation and ‘borderline’ centres in analyses adjusted for age
(using GLMs), sex, pancreatic sufficiency, genotype (homozygous DF508, heterozygous DF508 or other) and SES
quintile, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 9 – 7 and 40 –
2008 9 – – 7
2009 9 10 7,a 29a and 40a 34
2010 9 10 40 34
2011 9 41a – 34
2012 – 9 and 10 34 –
2013 – 9 34 and 40 –
2014 – 9 and 10 34 and 40 –
2015 – 9 and 10a 34, 47a and 48 –
a Centres approaching the 2-SD control limit without being outside it.
TABLE 15 Centres showing evidence of special-cause variation and ‘borderline’ centres in analyses adjusted for age
(using splines), sex, pancreatic sufficiency, genotype (homozygous DF508, heterozygous DF508 or other) and SES
quintile, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 9 – 7 and 40 –
2008 9 – – 7
2009 9 10 7a and 29 34
2010 – 9 and 10 40a 34
2011 9 41a 7a 34
2012 – 9 and 10 34 –
2013 – 9 34 and 40 –
2014 – 9 and 10 34 and 40 –
2015 – – 34, 40,a 47a and 48 –
a Centres approaching the 2-SD control limit without being outside it.
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Pyramid of investigation: care
As was done in our analysis of outcomes in paediatric centres, we explored the use of i.v. antibiotics
(see Appendix 3, Table 42).
Focusing first on those centres that, after case-mix adjustment, showed consistent signs of special-cause
variation (lower than average FEV1 values: centre 9; higher than average FEV1 values: centre 34), the
patterns were not entirely clear or consistent. In some of the years under study, patients at centre 9
seemed to have the lowest number of days on i.v. antibiotics (15.5 days in 2008, compared with
21.5 days and 25 days at sites 40 and 34, respectively, in the same year). In other years, the number
of days on i.v. antibiotics was similar between sites with lower and higher than average FEV1 values, but
the proportion of patients actually receiving i.v. antibiotics differed (in 2009, 50% of patients at centre 9
received i.v. antibiotics, whereas 62% received them at centre 34). Similar tendencies were noted in
analyses restricted to patients with FEV1 < 40% predicted.
To explore graphically whether or not there were differences between centres in the proportion of patients
receiving i.v. antibiotics, we generated funnel plots of these by year (see Appendix 2, Figure 37). Here we
noted that centre 9 consistently had a smaller proportion of its patients on i.v. antibiotics than the average,
as did centre 40, which had better FEV1 outcomes. Centre 10, which had poorer FEV1 outcomes, had more
patients on i.v. antibiotics than the average.
Sensitivity analyses
Global Lung Function Initiative reference equations
We replicated the unadjusted analyses (presented in Unadjusted analyses) using the new GLI reference
equations19 and noted very similar trends (see Appendix 2, Figure 38, and Appendix 3, Table 43).
Excluding patients with a G551D mutation from 2013 onwards
As described earlier, we re-ran the unadjusted analyses for 2013 onwards to explore whether or not
patients with the G551D mutation influenced the centre comparisons in these years, as it is suggested that
the G551D mutation has a milder phenotype and there is effective new treatment available for patients
with this mutation. The results of the original analysis – with sensitivity analysis in italics – are presented in
Appendix 3, Table 44. We can see that there is some shifting of single centres between the 2- and 3-SD
control limits, but the results do not change drastically. The biggest difference is for 2015, in which
centre 48 hovers near the upper 2-SD limit in the full analysis and moves outside the 3-SD limits in the
sensitivity analysis.
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Chapter 4 Consultation with clinicians and people
with cystic fibrosis to identify factors that would help
in understanding variability
Introduction
Cystic fibrosis clinicians and people with CF were consulted to explore the CF issues that are important
to them, which may explain variability in quality of care between CF units. These consultations were
undertaken to inform the development of questionnaires for completion by CF centre staff and patients.
Three focus groups were held to inform questionnaire development: (1) a focus group of CF clinicians from
adult centres, (2) a focus group of CF clinicians from paediatric centres and (3) a focus group of adults with
CF. The focus groups were facilitated by research team member Jonathan Boote; focus groups with clinicians
were supported by research team members Stephanie J MacNeill, Martin Wildman and Steve Harrison, all of
whom took field notes. The focus group discussions were transcribed and a copy of the transcript was made
available to participants to view if they wished, in order to correct any factual inaccuracies.
The analysis of the focus group data was guided by the principles of interpretative thematic analysis. The
transcripts were thoroughly read by the researcher, and codes and categories were assigned to sections of
the text to highlight key thematic areas with regard to factors that hinder or facilitate SPPs.24 In addition,
a form of content analysis – an assertions analysis25 – was undertaken of each transcript to examine the
frequency with which particular barriers to, or facilitators of, the development of SPPs are characterised in
a particular way.
Focus groups with clinicians
The clinician focus groups formed the second part of the 1-day workshops, which were held for the
clinicians from adult and paediatric CF centres as part of this research study. In the first part of the
workshop, the clinicians explored the SPPs that they consider important to enable the best outcomes
for CF patients. In the second part of the workshop, the focus group explored in more detail the
characteristics of a well-performing CF unit, with respect to the SPPs identified as being important.
The focus group of clinicians from adult centres was attended by two consultants, two dietitians,
a psychologist, a social worker and two physiotherapists. The focus group of clinicians from paediatric
centres was attended by a consultant physician (plus a paediatric consultant physician from the research
team), two nurses, a psychologist and a dietitian.
No key differences in the issues raised were found between the two clinician focus groups. A summary of
the focus group discussions is provided below, in terms of key SPPs that participants thought should be
in place within a high-performing CF unit. Illustrative quotations from the focus group transcripts are
provided to support the analysis.
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In terms of structures, focus group participants associated a high-performing CF unit with the following:
1. a well-qualified MDT including dietitians, diabetologists, physiotherapists, pharmacists and
gastroenterologists, as well as administrative support, with sufficient time to spend with the patient –
The CF team moves away from that medical model and is much more holistic and multidisciplinary
than the average medical setting.
Participant 1, adult CF focus group
2. sufficient resources to provide high-quality CF care –
In terms of resources, I think that food is always an issue with patients and I think whenever the CF
Trust do a satisfaction survey, like they do with the peer review, the food always comes out rated
as poor. And I think part of that is that a lot of patients when they are in hospital actually have not
got good appetites, so their enjoyment of food is impaired. But I think we are still, in most units,
not meeting their needs even if their needs are very high. I think we are not meeting them and that
is because we have restrictions of funding.
Participant 3, adult CF focus group
Negative pressure rooms [are often lacking in CF units]. That means that the patients with different
bugs can be in closer geographical proximity and have better use of the facilities because that, to
some extent, enables infection control. And at the moment I think with the new bugs that are
coming in, the worry is that any new facilities or quality facilities that you have got might not be
accessible to all patients because those with unusual bugs have got infection control.
Participant 3, paediatric CF focus group
3. strong clinical leadership –
What helps is leadership, isn’t it? Somebody who is creative about where they are going to go to
get resources and committed in getting them, I think that helps.
Participant 5, paediatric CF focus group
4. provision of education and training for CF centre staff –
As a team you have education once a month, where we are supposed to come up with external
topics. External people come in and deal with relevant MDT topics, I think that means that
sometimes it is more psychosocial. Sometimes it is more medical. The whole team go with the idea
that it [education] is all relevant to everybody.
Participant 6, adult CF focus group
In terms of processes, focus group participants associated a high-performing CF unit with the following:
1. the existence of clear processes for the measurement and monitoring of key outcomes, such as lung
function over time, weight and BMI, and Pseudomonas aeruginosa –
What are the metrics that matter to us? Well, your gold standard is the client’s lung function
absolutely, BMI and weight.
Participant 4, adult CF focus group
A unit should measure its mean adherence rate.
Participant 3, paediatric CF focus group
I think measuring quality of life versus treatment is an increasing issue.
Participant 6, adult CF focus group
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2. strong MDT processes, such as written treatment plans and pre- and post-clinic MDT meetings –
Good team processes as well so that we know what is being said to the patient and that sort of
group, joint team approach, as in a double consultation with, say, a doctor and physio[therapist],
or physio and dietitian saying almost the same thing.
Participant 5, adult CF focus group
If you have a good relationship within your team, good interdisciplinary working, if you know
another member of the team discusses something that is not strictly their area because it has come
up, or the patient has a good rapport with that person and they bring it up, say, like with the
physio and they bring up breastfeeding and then that works well.
Participant 1, adult CF focus group
3. support for the team to engage in process improvement –
I mean we do regular audits and look at our data and look at improving that, whether it be
patients, like for dietitians we do an annual vitamin D audit. And we have changed our practice
with vitamin D supplementation with regard to that. We also do an annual food survey to try and
improve the food service and look at our BMI data.
Participant 4, adult CF focus group
I suppose a team that is supported to reflect on what their needs are. You know, being able to see
if there is a glaring hole on how we manage this, or we are not very good at doing that.
Participant 5, paediatric CF focus group
In terms of policies, focus group participants associated a high-performing CF unit with having the
following policies in place:
1. clear expectations of what patients can expect of the unit, and the expectations that the unit has of
each patient –
A good unit should have high expectations of its patients. But staff should be encouraged to
communicate . . . in a non-judgemental way when patients are struggling.
Participant 6, adult CF focus group
Particularly important that we communicate our expectations effectively where patients should be
on the growth and lung function charts.
Participant 3, paediatric CF focus group
2. patient education about key aspects of their treatment and care –
We produce a lot of information leaflets on, well, for nutrition, on every aspect that we deal with
really. And we have got a website as well which we do and a newsletter which we put in patient
information and hot topics and other bits of information.
Participant 2, adult CF focus group
It is a challenge providing the education without giving them false hope or guarantees. We cannot
give a guarantee, so you want to educate that if you take nebulisers more often, they want a
guarantee that they will live till they are 50 or they will not have IVs [i.v. antibiotics] for another
six months. You always have to build in that guarantee so it then reinforces them.
Participant 5, adult CF focus group
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3. patient-centred care, such as tailored support to those patients struggling to self-medicate, and patient
involvement in decision-making about their care and treatment –
And I think visual tools can really help [to explain issues to patients struggling with their treatment].
Like the BMI chart when you show them where they are and the difference in relation to the
healthy range visually I think is quite powerful.
Participant 1, paediatric CF focus group
I think communication skills of the team are the bottom line with helping [patients consider
treatment options]. I think often real experience, real skills, communicative skills of the teams
because they are so used to adapting to different situations and difficult situations and different
groups. I think that really helps.
Participant 2, adult CF focus group
4. standardisation of key aspects of CF care, such as protocols for newly diagnosed patients, policies for
dealing with declines in lung function and BMI, eradicating Pseudomonas aeruginosa infections, general
infection control and managing diabetes –
Clinic protocol adhesion is what you are expecting from clinic – who are you going to see in clinic
should be standard for everyone. And inpatient admission should be standard.
Participant 6, paediatric CF focus group
I mean we do have standards for our nutrition therapy. So we have standards for interventions,
vitamin targets. What else have we got? Diabetes, yeah we do have written standards for diabetes
and for annual review. So if someone turns up for an annual review, they all have the same
standard annual review and you individualise it, but they are all going to have the same things and
the same tests. That is definitely how it should be.
Participant 7, adult CF focus group
Information obtained from the clinician focus groups was used to guide the development of the questionnaires
for CF centre directors and their teams on the SPPs affecting CF care quality. The questionnaires were reviewed
and refined by the wider research team and the questionnaire was piloted in two centres. The results of the
survey are described in Chapter 5.
Patient focus group
The focus group with CF expert patients considered those factors that, from a patient perspective, may
help a CF unit to perform well. Five expert patients attended the focus group. To minimise the risk of
cross-infection, this focus group was run as a teleconference. As the group consisted of CF expert patients,
participants were invited to reflect on their own personal experiences of care and treatment within their
own CF unit, as well as the care and treatment experiences of other CF patients known to them.
A topic guide was developed to structure the expert patient focus group (see Appendix 1). The focus
group topic guide was based around the key factors that CF unit staff had previously identified as helping
a CF unit to perform well, although the CF expert patients were invited to consider other issues of
importance to them. Issues identified in the expert patient focus group were subsequently used to
construct a patient questionnaire for distribution within both adult and paediatric CF units.
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For the first part of the focus group, participants were asked to describe factors affecting the quality of inpatient
stays in, and outpatient visits to, their CF units. Characteristics of a good-quality inpatient stay included:
1. a clear action plan for the stay and patient input in the content of the action plan –
I suppose a good inpatient stay, obviously you have your initial consultation, work out a plan
of action for your stay. And then you have a plan with the nurses about if you take your own
medication and I suppose it is being informed about what is going to happen during your stay, and
having a little bit of – I want to say control. A bit of a say of what goes on within your treatment as
well. That would be a good place for me is to know what’s going on every day and what plans
there are for me.
Participant 3
2. timely admittance and timely commencement of treatment on admittance –
I would like to say right from the outset, soon after admission, that the treatment was started as
early as possible without unnecessary delays due to very inexperienced ward staff who were unable
to stick cannulas for instance.
Participant 2
3. a clean and tidy inpatient room –
Basically for me it is sensible that there is actually a room and I am not waiting days. And I know a
good experience of mine, I think the longest I’ve waited is maybe 7 hours for my bed. Not weeks
like other patients wait. And that room is actually cleaned to a standard that I want. A bad
experience is that it is not cleaned and it is disgusting. So for me it would be a case that the bed is
actually available and done.
Participant 5
4. access to all appropriate MDT members –
It’s just having that access to and input from all the team, including the physiotherapist.
Participant 1
5. self-management of medication during the inpatient stay –
One of the things that is a really great advantage at my unit is that we are actually able to take our
own medications and manage our own medications on the ward. So that is quite a positive aspect,
which is good because it gives you back that control and that normality.
Participant 3
6. appropriate food and food portion sizes –
The food and the portions of food, and the food’s of good quality, is important to me.
Participant 2
Also obviously food or nutrition is an important part of an inpatient stay, and subsequently nice
food during the stay, albeit it proper meals or snacks from the trolley, that sort of thing.
Participant 4
7. consistent quality of care between that provided at weekends and that provided on working
weekdays –
And I would say it is more the communication and maybe it’s when it’s weekends. Things tend to
go wrong on a weekend, I don’t know why. And as long as your CF team are contactable, then
that’s OK, but if they are not, then that can cause trouble if the ward actually don’t know what
they are doing. And I have had it where we have actually stopped treatment before because
obviously they haven’t known what to do.
Participant 2
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8. sufficient numbers of trained staff on the unit to perform key procedures –
One bad experience would be when the ward staff are under-resourced. And in the evenings when
they are trying to deal with quite a few poorly patients, that means your last dose of IVs don’t start
till the early hours of the morning. You know, as late as two in the morning sometimes. And the
knock-on effects of that. Sometimes where staff haven’t got the competency to be able to perform
certain procedures, which again results in delays of treatments and the knock-on effects of that.
Participant 5
Characteristics of a good-quality outpatient experience included the following:
1. sufficient time to see all the relevant members of the MDT within the allocated appointment time –
I think for me mainly it’s the time factor. And because you obviously spend a long time at
outpatient and regularly you can spend anywhere up to 2 to 3 hours depending on who you see
and obviously you need to take into consideration there may be other CF patients needing longer
or whatever.
Participant 1
2. access to an outpatient pharmacy –
I am really jealous of the clinics that have outpatient pharmacies, separate pharmacies for outpatients.
Participant 2
I think not only do you have the outpatient appointment, but you do have prescriptions to wait for
was well, and it just adds so much time on to the appointment. And obviously you have got the
risk of bumping into other people with CF and quite often risk cross-infection and things like that
as well.
Participant 3
3. seeing an experienced consultant with detailed knowledge of the patient –
For me, a good experience or better experience is having a consultation with a doctor that knows
you well, or one of the more experienced consultants. When things get more complex, it is
important that they are able to make the right decisions and obviously negotiated with myself,
and it is really good to be able to go to a patient appointment and come out with a solution to
something that has been sort of nagging.
Participant 1
4. well-organised segregation of patients –
Good segregation, arriving at the outpatients clinic and being directed straight to a room always
makes me feel better.
Participant 5
5. timely explanations if there are to be delays in seeing any member of the MDT –
I just wanted to add really and going back to the time thing, actually I don’t mind waiting, just as
long as someone tells me why I’m waiting. So if there has been a reason why the CF team has
been held up for any reason. That has happened before and they have just, I have been sat an
hour before I’ve seen anyone. I would actually like to know why, because then I might not be so
cross about it.
Participant 4
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For the second part of the focus group, participants identified and discussed a number of key issues that
are considered important for a CF unit to perform well from a patient perspective. These are outlined
as follows.
1. Education of patients about the condition: participants felt that the CF unit had a very important
educational role to play, from providing information following a patient’s CF diagnosis as a child,
through to further education of the patient in adulthood –
And obviously when you are first diagnosed, the information will be straight from the CF team.
That team is obviously your first port of call . . . some sites will give them the information that
they need.
Participant 5
I think also the importance of educating patients is very important further down the line as well.
And well in advance of when the patients come across more complex aspects of their CF and
more critical aspects, because it often means there is a seriousness of CF. You can pick up that
information beyond our CF centres if we want to and particularly in the subcontext of teenagers
where they often need encouragement and incentivisation to take their CF seriously and take
treatments that are suggested to them for the moment until they can think ahead and encouraging
them to carry on doing the things they want to do in their lives. And linking that to the importance
of their treatment and understanding their CF. I think education could be used in a sort of
encouraging way as well as just a means to an end.
Participant 2
2. Developing a constructive dialogue between patients and CF unit staff – this was seen as particularly
important in providing ongoing motivation to patients to self-care and self-medicate, especially around
their transition from a paediatric to an adult CF unit –
. . . because going back to the sort of teenage years where we were reliant on our parents quite a
bit and reliant on the CF team to make decisions and take the lead. There comes a time in all of
our lives when we are going to become more independent and have to make those decisions
ourselves. Be it if we’ve left home, or if we’ve lost parents. And so to prepare ourselves, I think
it needs the taking of responsibility from early days, and at the right time obviously.
Participant 3
The CF centre highlighting that point in all its literature and some other information platforms
that patients need to take responsibility for their treatment as much as being led by the CF team.
Because it’s a two-way process, isn’t it? It’s not just absorbing everything the CF team says. It’s also
explained about taking your own responsibility as well, as a patient.
Participant 4
However, it was acknowledged that such constructive dialogue will be dependent on the following:
1. The amount of time that units have to develop such dialogue during inpatient and outpatient visits.
2. The attitude of the individual patient. It was thought that a well-performing CF unit would be able to
be creative in the methods/platforms that it uses to develop a constructive dialogue with patients –
I think time is the factor for staff to be able to have those discussions. The importance of taking
responsibilities, those discussions with patients, or the lack of this done during inpatient treatment.
And also the attitude of patients, because not everyone wants to take responsibility. They’re not all
model patients.
Participant 1
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I think a unit that has sufficient resources both in terms of staffing and time, and sufficient funding
and facilities I suppose to be able to provide a variety of platforms for engaging with patients with
constructive engagement. Be it to developing a CF centre website or a newsletter where they
haven’t got a newsletter, and perhaps even offering sort of twilight teleconference sessions. Again
it might be a bit unrealistic given the funding and staff and resources that currently we have to
contend with.
Participant 4
3. Patient involvement in the measurement and management of key aspects of CF. Participants discussed
a range of CF outcomes that they are either actively involved in measuring and managing (such as lung
function) or that they would like to be more involved in measuring and monitoring (such as exercise
tolerance) –
I do think some people get a bit obsessed by what their lung function is, you know. You see them
talking on the internet and chat rooms and stuff. ‘Well mine’s this and last week it was this and
. . .’ I think sometimes it is good to know and have as a benchmark, but some people can sort of
obsess over them a bit, which I think is unhealthy.
Participant 1
I think exercise tolerance should be measured perhaps more routinely, or more frequently. And
then there is annual review. And even at annual review, there isn’t always an exercise tolerance
there; and what about adherence feedback? In terms of the I-neb [I-neb AAD System; Philips,
Amsterdam, the Netherlands], I-neb downloads of how much treatment is being taken. I did a brief
study where I could see it for about a month. And actually I was really shocked because I thought
I was doing it a lot more than I was. So it actually made me realise. So I think seeing that sort of
thing could be useful, because sometimes I think you sort of delude yourself to think you are doing
something. And it’s not until someone actually points out some kind of hard-core data that this is
actually what you are doing. Or not doing, as it turned out, that made me really sort of think.
Participant 4
4. Access to a consistent MDT on the CF unit. Participants felt that it is important for patients to try to see
a consistent MDT during inpatient stays and outpatient visits, although it was acknowledged that this is
not always possible. It was also considered important that teams communicate a consistent message to
patients with regard to key aspects of their care –
I think, at my centre, the communication is very good and the messages consistent. Occasionally, I
think inevitably, there are some differences in opinion on some treatments. One example I can give
you is inducing tamsulosin infusion. Sometimes it’s been down from a high dosage and sometimes
it’s just stopped immediately and there are implications of the latter, complications from the latter.
Participant 5
Patients reported that, during visits to their unit, it was not always possible to see certain members of
the MDT:
I think a common, well, two common people that . . . probably are quite difficult to see across all the
centres, is usually psychologists and social workers. Sometimes even the clinics don’t have access to
them and they don’t have them necessarily on the team. So usually they are not available to see as
generally as most patients would like. And I think, I used to find it hard in paediatrics to get hold of
a dietitian and they weren’t always available during clinic time. And you had to make a separate
appointment when obviously you are going to the hospital for appointments anyway which are
generally quite long, having to come back in for a dietitian appointment is actually not very ideal.
Obviously there’s been change since I’ve been there, but I know they were without a dietitian quite a
while in the centre I went to. But yeah, in general the idea from patients is that psychologists and
social workers which is not great because they are part of a very important part of the team.
Participant 1
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[Participant name] has mentioned about the inconsistency and psychosocial coverage and dietetic
coverage of some centres and I would add to that also physiotherapy, because having spoken to some
of the paediatric teams and parents, and also from my own experience in adults, it is not always
consistent that we get sufficient physiotherapy support, particularly at weekends. Although things
have improved considerably at my centre.
Participant 4
A patient questionnaire was developed, informed by the issues raised at the patient focus group; this was
then discussed and refined by the wider research team and included input from the study’s patient advisor.
The resulting questionnaire included questions relating to:
l whether or not the patient has adequate time with their CF team
l facilities at the unit
l access to support
l how CF is measured and monitored by the CF team
l how treatments are discussed between the CF team and patients
l how changes in lung function are communicated to patients
l communication with the CF team
l CF team expectations of patients
l leadership at the centre.
We aimed to disseminate the questionnaire online via the CF Trust’s social media connections, targeting
adult patients and the parents of paediatric patients. REC and NHS approvals were obtained for the
questionnaire, but we were unable to co-ordinate the dissemination of the questionnaire in time for
analysis and synthesis prior to the end of the study.
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Chapter 5 Understanding the structures,
processes and policies of care
In parallel with the use of CF Registry data to explore whether or not outcome data could identify CFcentres that were high performing and those that were low performing, work was undertaken to
understand whether or not high- and low-performing centres differed in the SPPs that underpinned care.
Four stages to identify structures, processes and policies
Stage 1: understanding structures, processes and policies associated with
high-performing centres
Two 1-day workshops were held with clinicians (1 day for clinicians from adult centres and 1 day for
clinicians from paediatric centres). The aim of these was to understand from clinicians the SPPs that were
considered to be associated with high-quality care. Details of how the focus groups were run and how the
data were analysed are described in Chapter 4.
Stage 2: generating a questionnaire to gather data about structure, process and policy
in cystic fibrosis centres
The data collected in the focus groups, as described in Chapter 4, confirmed that there were
commonalities in the way in which care was delivered, as identified in previous investigations of quality
improvement in US centres.27,28 An important issue in quality improvement is paying attention to important
aspects of care. It was intended that the design of the questionnaires would elicit the extent to which
clinicians in individual centres concentrated on the structures, processes and policies that were thought to
be associated with high-quality care. Two questionnaires were developed – one for use in adult units and
one for use in paediatric units.
Stage 3: collecting and analysing questionnaire data from UK cystic fibrosis centres
The questionnaires were sent out to adult and paediatric centres by e-mail using SurveyMonkey®
(Palo Alto, CA, USA). The initial aim was to analyse the data by centre to understand the SPPs by centre.
However, the response rate was too low to allow this; instead, the responses were aggregated and
analysed in two groups: (1) across all adult units and (2) across all paediatric units.
Stage 4: comparing structures, processes and policies in centres by outcome
The aim of stage 4 was to compare the SPPs in the centres with the best outcomes with those with the
worst outcomes. The within-centre response rates did not allow for the definition of SPPs at centre level,
so this part of the work could not be completed and, hence, this aspect of our work is unable to give a
perspective on SPPs across the centres that might provide an insight into areas in which challenges arise.
Adult questionnaire
Response rate and respondents
The questionnaire was sent by e-mail using SurveyMonkey to the centre directors at all 29 adult centres.
A total of 136 responses from 16 centres were obtained, with a median of six responses per responding
centre [interquartile range (IQR) 4–16 responses]. Appendix 3, Table 45, shows the distribution of
responses by centre and clinical role; it is observed that the majority of responses came from only five adult
centres. Respondents had worked in CF for a median of 7 years (IQR 4–10 years), with nine respondents
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having ≥ 20 years of CF experience. Thirty-three doctors (of whom 25 were consultants), 25 nurses,
24 physiotherapists and 17 dietitians made up the majority of respondents.
To explore how centres that participated in the survey compared with those that did not, we examined
annual review data from all centres in 2015, as this was the year of the survey. We considered the size of
the centre to be the number of annual reviews conducted that year and found that the centres responding
(regardless of the number of responses within the centre) were slightly larger than the centres that did not
respond (median number of annual reviews: 194 vs. 169). The mean FEV1% predicted of all patients at
annual review was also compared, and only minimal differences were observed between participating
and non-participating centres (mean 65.9% predicted vs. 66.2% predicted, respectively). Participating
centres included sites in England and Scotland; non-participating centres included the only adult centre
in Northern Ireland and six of the eight adult centres in Scotland. It is noteworthy that the participating
centres that returned the most questionnaires included the sites of collaborators (King’s College Hospital
and Northern General Hospital, which also helped to pilot the questionnaire). It is impossible to know how
widely the questionnaire was disseminated within teams, as centre directors were asked to cascade the
weblink to the survey to their teams. As such, we are unable to comment on the composition of the MDTs
of non-participating centres.
Facilities, staffing and resources
Respondents were asked about the facilities, staffing and resources in their centres by seeking their
agreement or disagreement with statements describing attributes that were deemed to be desirable by
the focus groups. The responses are shown in Appendix 2, Figure 39, with the proportion on the x-axis
indicating the proportion of respondents agreeing with the statements. Less than half of the respondents
felt that their centre had adequate administrative staffing, access to a gastroenterologist as required,
a dedicated CF-related diabetes clinic or a dedicated diabetologist who has a high level of expertise in
CF-related diabetes. More common than this were responses relating to access to CF outpatient facilities,
allowing the team to meet the CF Trust standards of care and having a strong co-ordinator (> 80%; see
Appendix 2, Figure 39).
Capacity and demand
Respondents were asked about capacity and demand; Appendix 2, Figure 40, shows that, although < 50%
of respondents could provide appropriate home visit support, > 90% could review patients of concern within
48–72 hours.
Leadership
Respondents were asked about the leadership within the hospitals and centres where they worked;
Appendix 2, Figure 41, shows the proportion of respondents agreeing with the statements. Although
< 50% of respondents felt valued by hospital management, > 90% of respondents felt that their teams
had skilled clinical leadership.
Measurement and monitoring
Respondents were asked about the monitoring systems to support CF care that are available within their
centres; Appendix 2, Figure 42, shows the proportion of respondents agreeing with the statements. Less
than one-third of respondents felt that their centre had an excellent system specifically to support CF, but
> 80% felt that they were able to promptly identify patients with new Pseudomonas aeruginosa infections
or declining lung function.
Multidisciplinary team processes
Respondents were asked about the organisational processes that support care delivery (see Appendix 2,
Figure 43). Less than half of respondents reported that they had a ‘fool-proof’ system and never
overlooked results or felt that their centre was known for running efficiently. Encouragingly, > 80%
of respondents felt that all members of the MDT had their voices heard.
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Quality improvement of care delivery processes
Respondents were asked about the quality improvement work occurring in their units (see Appendix 2,
Figure 44). Less than one-third of respondents reported that their centre routinely uses quality
improvement tools, whereas most reported that the team measures and shares outcome, satisfaction,
clinical process and safety data with the MDT in order to make improvements.
Treatment policies
Respondents all showed high rates of agreement with policies regarding the use of i.v. antibiotics that
might be considered to reflect prompt and proactive care (see Appendix 2, Figure 45).
Time lag to starting antibiotics for cough and cold
Appendix 2, Figure 46, shows that almost all respondents would start antibiotics in adults with cough and
cold symptoms if symptoms persisted for 7 days.
Expectations
Respondents were asked about expectations of care to try to understand how determined teams were
in their delivery of care and in not tolerating decline. Appendix 2, Figure 47, shows that > 40% of
respondents have very high expectations of care, insofar as they expect no yearly decline in lung function.
Paediatric questionnaire
The paediatric questionnaire differed from the adult questionnaire because the clinicians from paediatric
centres attending the workshop in which the questionnaire was developed had slightly different concerns
when thinking about the determinants of care.
Response rate and respondents
As with the adult questionnaire, the questionnaire to paediatric centres was sent via e-mail using
SurveyMonkey to the lead clinicians in 33 CF centres. A total of 95 responses were received from 24 (73%)
of the 33 centres, but in half of these there were ≤ 3 individual respondents. Forty (42%) respondents were
doctors, 16 (17%) were physiotherapists, 11 (12%) were nurses and 10 (11%) were dietitians. Respondents
had worked in CF for a median of 12 years (IQR 7–20).
As was the case with the adult centres, we used 2015 annual review data to compare centres that
did and did not respond to the survey, based on the number of patients attending annual review and
the FEV1% predicted at these centres. As was observed for the adult centres, centres that participated
tended to be slightly larger (median number of patients: 124 vs. 106). Mean FEV1% predicted at the
centres participating was slightly higher than at the centres not participating (87.9% predicted vs. 83.8%
predicted), and their patients tended to be slightly older (mean age 8.7 years for participating centres
compared with 8.0 years for non-participating centres). It is noteworthy that some centres contacted the
research team to indicate that the questionnaire could be difficult to complete in the case of network
clinics with different facilities and resources.
Facilities, staffing and resources
Appendix 2, Figure 48, describes the responses to questions investigating resource issues. Only 20% of
respondents felt that they had adequate social worker resources; however, 80% of respondents felt that
they had adequate consultant time for patients.
Capacity and demand
Appendix 2, Figure 49, shows that centres were able to meet capacity and demand requirements with
varying degrees of success. Whereas only 41% of respondents felt able to provide popular food for
inpatients, 97% of respondents felt able to review patients of concern within 48–72 hours.
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Leadership
Appendix 2, Figure 50, shows that participants generally felt more valued by the clinical leaders in their
team (86%) than by hospital management (43%). More than 80% of participants felt that their teams
were well organised and had skilled and experienced CF clinical leadership.
Measurement and monitoring
Appendix 2, Figure 51, shows the range of responses in the paediatric teams’ views about measuring
and monitoring. Whereas only one-third of respondents thought that they had an excellent computerised
system for monitoring patients, > 90% of respondents thought that they identified new Pseudomonas
aeruginosa infections promptly.
Multidisciplinary team processes
Appendix 2, Figure 52, shows that just over 50% of teams thought that they had ‘foolproof’ systems,
which ensured that they never overlooked important results. This means that almost 50% of respondents
did not have such systems. Most respondents (> 80%) felt that their annual review processes were
effective in delivering treatment plans that were followed through, that in their MDT meetings all voices
were heard and that the post-clinic meetings were held with the appropriate people.
Quality improvement of care delivery processes
Appendix 2, Figure 53, shows the respondents’ answers to questions about the processes used to improve
systems within the CF centre. It can be seen that, although < 10% of respondents were using formal tools
for improvement, almost 60% were using data to improve team performance. The lack of use of formal
quality improvement tools in paediatric centres is consistent with what was observed in adult centres.
Treatment policies
Appendix 2, Figure 54, shows that 78% of respondents believed that they could avoid rescue i.v.
antibiotics by using preventative treatment, and 96% of respondents agreed that nutrition is important
and interventions are expected.
Overview of the questionnaire data
The questionnaire was useful, as its preparation provided a cause to work with the focus groups to
understand the factors that clinical teams felt were important in delivering high-quality CF care.
Unfortunately, we were missing information from a number of sites and, because the number of
respondents in any centre was also limited, it was difficult to be confident that the responses gave a
representative description of the care in the centre. Nevertheless, the topics raised by the focus groups
point towards areas of interest that might be explored in the future to understand why centres differ in
their outcomes.
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Chapter 6 Discussion
Summary of results from centre comparison work
The analyses of adult and paediatric CF centres show that using funnel plots on a clinically important and
well-completed clinical outcome such as FEV1 allows us to identify some trends in special-cause variation.
By analysing each year separately, we were able to compare results in any given year with those of other
years, thus allowing us to disregard one-off departures from the mean.
Identifying special-cause variation allows us to engage in a scientific method to explore these differences;29
therefore, we adopted a pyramid of investigation approach.6 Summaries of the main findings from our
analyses are presented separately below for paediatric and adult specialist centres.
Paediatrics
We studied FEV1 in two different ways in children: (1) by pooling data across multiple years for adolescents
and (2) by studying all children aged 6–15 years in repeated single-year analyses. We observed that centre
39 was frequently an outlier, with FEV1 levels outside the lower 3-SD limit in our unadjusted analyses of
young adults. It also repeatedly showed special-cause variation in our year-by-year analyses of the wider
paediatric patient population, along with centres 12 and 52 (outside the lower 3-SD limit) and centres 25,
28 and 31 (outside the upper 3-SD limit).
The first step in the pyramid of investigation model involves checking the data. Members of the study
group had already contributed to annual processes of data validation of CF Registry data – through either
conducting the validation themselves or providing a validation framework for others within the CF Trust
to follow. As a result, the data analysed had already gone through lengthy validation checks involving
querying outlier data with the centres, and so they were not verified again. We did, however, explore
the completeness of the outcome data used in our analyses of young adults. We noted that data were
relatively complete for the case-mix variables considered, but some centres (39 and 43) had lower than
average rates of complete FEV1 data among those patients having annual review encounters. As lung
function measurements form a key part of the annual review process, such data should be available.
Continuing with the pyramid of investigation approach, we explored differences in case mix and
found some differences in the patient populations at those sites showing special-cause variation in FEV1.
Adjustment for age, for example, brought centre 28 within the 3-SD control limits, despite patients
at this centre being only slightly younger than the mean. Centres 12 and 31 were brought within the
control limits after further adjustment for genotype, pancreatic sufficiency, sex and SES. Compared with
the centres overall, centre 12 had more female patients and more patients who had the milder G551D
mutation, in addition to having fewer patients living in the most deprived SES quintile. Centre 31 had
fewer patients who were homozygous DF508 and more who were pancreatic sufficient than the overall
paediatric patient population. For these two centres, we suggest that differences in FEV1 are a result of
the patient case mix.
After adjustment for our case-mix variables, three of the original six centres continued to show patterns
of special-cause variation in FEV1: centres 39 and 52 (lower than average FEV1 values) and centre 25
(higher than average FEV1 values). We next considered care; an objective and routinely collected measure
of CF care is the use of i.v. antibiotics. In the USA, this has been shown to be associated with better
clinical outcomes.27 We reported the median number of days on i.v. antibiotics as well as the proportion
of patients receiving these treatments. We noted that there was a tendency for centre 25 – which had
better FEV1 outcomes – to be near or outside the lower control limits for the proportion of patients on
i.v. antibiotics. Conversely, centres 39 and 52 – which had poorer FEV1 outcomes – tended to have higher
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than average proportions of patients on i.v. antibiotics. This, however, tells us about receiving treatment
and not about needing treatment, as the CF Registry does not explicitly record pulmonary exacerbations
for which i.v. antibiotics would be needed, nor does it record whether the course of antibiotics was
planned or unplanned. A US study showed that there is variation in how pulmonary exacerbations are
treated in paediatric CF care.30
A summary of possible explanations for special-cause variation base on the pyramid of investigation is
presented in Table 16.
Adults
As performed in the paediatric analysis, we studied FEV1 in different manners, from decline in early
adulthood to studying all adults in repeated single-year analyses. In analyses unadjusted for case mix, we
observed that centres 7, 9 and 34 were frequently outside the 3-SD control limits, and centre 40 appeared
outside the limits in 2007. All centres except centre 9 showed evidence in these analyses of having mean
FEV1 values that were higher than the overall average.
Following the pyramid of investigation we found that adjustment for case mix is essential to avoid
misattributing differences in outcomes to care and to avoid missing important differences. Adjustment
for age, for example, brought centre 40 from within the 3-SD control limits to outside these limits for
2009–11 and 2013–15.
We then considered other patient case-mix characteristics to see if these were responsible for our findings.
In considering models adjusted for case mix, this adjustment substantially affected centre 40 only, which
was brought within the 3-SD limits. This centre differed from the average in many ways: the centre had
fewer patients who were DF508 homozygous, more patients with the milder G551D mutation and more
patients who were pancreatic sufficient. Our findings at the other centres – 7, 9 and 34 – could not be
attributed to case mix.
As discussed in our summary of results from paediatric centres, an objective measure of CF care is the use
of i.v. antibiotics, which has been shown to be related to better clinical outcomes.27 For this reason, we
explored how the centres compared in terms of the proportion of patients receiving i.v. antibiotics. Centre
9 frequently exhibited special-cause variation in this variable and had a smaller proportion of patients on
i.v. antibiotics. It is difficult to explore the number of days on i.v. antibiotics using funnel plots because
of the skewed distribution of the data, but we observed that, among patients at this site receiving i.v.
antibiotics, the median number of days on antibiotics in 1 year tended to be fewer than the median across
all sites – a pattern observed both overall and when considering the subgroup of patients with lower lung
function (FEV1 < 40% predicted).
TABLE 16 Possible explanations for special-cause variation at paediatric centres
Centre
Primary
explanation Evidence
12 Case mix There is a higher proportion of female patients and patients with the DF508 mutation at this
centre than in the overall centre patient population. The centre also has a lower proportion
of patients in the most deprived SES quintile. After adjustment for these and other factors,
the centre moved to within the 3-SD control limits
28 Age of patients After adjustment for age, this centre moved to within the 3-SD control limits. The difference
in mean ages, however, was small
31 Case mix This centre had fewer homozygous DF508 patients than the overall centre patient population
and more pancreatic sufficient patients, suggesting less severe disease. After adjustment for
these and other case-mix variables, the centre moved to within the 3-SD control limits
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Summary
These findings confirm that the annual review data from the UK CF Registry can be used to identify
differences in clinical outcomes between centres and that case-mix characteristics might explain some of
these differences. This adjustment does not, however, account for all differences; therefore, further work is
needed to explore the results we obtained.
Summary of consultations with clinicians and patients
Focus groups with clinicians from adult and paediatric centres were conducted to identify what they
felt were the important SPPs for delivering good CF care. There was a focus on adequate staffing and
sufficient time with different members of the MDT, monitoring and measuring of clinical outcomes and
treatment adherence, communication within the MDT and with patients, patient education and support,
and standard policies on how to deal with infection control and eradication as well as changes in lung
function and BMI. From the focus groups, questionnaires for CF centre directors (in both adult and
paediatric centres) were developed and disseminated nationally. It was hoped that the results from these
questionnaires could help to inform conversations with CF centres that had outcomes that were better or
worse than the average. The response rate, however, was relatively poor, making it difficult to draw
inferences or to use the information to start a dialogue with centres.
A focus group with the CF Trust’s team of expert patient advisors was conducted to identify what people
with CF think is necessary for good CF care. Based on the outcomes of this, we devised a questionnaire to
be disseminated to patients nationally. The focus group concentrated on three areas: (1) the characteristics
of good inpatient stays, (2) the characteristics of good outpatient visits and (3) the characteristics of
well-functioning CF centres. In relation to inpatient stays, the group highlighted a number of issues which
included the importance of patient involvement in devising a clear action plan and self-management of
medication during the stay. Access to appropriate and sufficient numbers of members of the MDT and
consistent quality of care over the course of 1 week were also identified as important. In the outpatient
setting, patients felt that it was important to have sufficient time to see all members of the MDT, to have
access to an outpatient pharmacy and to speak to an experienced consultant who has detailed knowledge
of the patient. It was felt that a well-functioning CF unit will educate patients about CF, develop a
constructive dialogue between patients and CF unit staff, have patients involved in the measurement and
management of key aspects of CF and provide consistent access to the unit’s MDT. We were unable to
conduct the patient survey within the time frame of this study, but it will take place subsequently.
Although we cannot compare survey results between the clinician and patient questionnaires, we can
compare the issues that were raised by both groups. Several overlapping themes emerged: the importance
of written treatment plans, involvement of patients in decision-making, sufficient access to relevant
members of the centres’ MDTs, policies regarding infection control and effective communication between
the patient and MDT.
Patient and public involvement
The co-applicants on this study included a person with CF as well as the CF Trust. All co-applicants were
involved in identifying research priorities and were members of the study management group.
The CF Trust helped make links with their team of expert patient advisors to enable us to conduct our
patient focus group. Our patient member participated in the research itself by participating in the study
focus group.
DOI: 10.3310/hsdr07060 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 6
© Queen’s Printer and Controller of HMSO 2019. This work was produced by MacNeill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
Our clinician survey benefited from feedback from our CF Trust member in its development, and the
CF Trust gave us the opportunity to promote the study – and our clinician survey – at a national CF
Registry meeting.
Moving forward, the CF Trust has shown a commitment to supporting us to address some of the outstanding
elements of our work.
Strengths and limitations
Data
This study has many strengths and limitations. Its greatest strengths are the coverage and completeness of
the data source. Virtually all CF patients consent to their annual review data being included in the CF Registry
and data completeness has grown such that, by 2015, 89% of registered patients provided complete data.31
Data from the CF Registry are used for clinical care commissioning and pharmacovigilance work in recent
years, thus encouraging complete returns. When UK ethics approval for the new web-based system was
granted in 2007, there was a big increase in centres being involved and there was a learning curve for
data clerks.
However, despite the large number of data collected and satisfactory patient coverage, we were not always
able to adjust for all relevant case-mix characteristics. For example, when studying adult care it would be
helpful to adjust for clinical characteristics at the time of transition to adult care. Adults who transitioned to
adult care before 2007, or in the early years of the CF Registry in which data completeness was not as good,
will not necessarily have relevant data. We explored using characteristics data at transition in our analyses of
18- to 21-year-olds but did not pursue using these data as it would have meant losing a large proportion of
our patients for centre comparisons because of missing case-mix variables.
The number of data collected is also related to the size of CF centres. Although we observed evidence of
special-cause variation in large and medium-sized centres, we cannot exclude the possibility that in very
small centres, for which the control limits are widest, we were unable to detect statistically meaningful
departures from the mean. Absence of special-cause variation, therefore, does not exclude the possibility
of true differences from the mean. Recent comparisons between adult centres indicate that for small
absolute differences in FEV1 predicted of 5% to be reliably detected at the 95% significance level,
a minimum of 273 patients per centre would be required.32
In terms of the appropriateness of the outcomes under study, we met with CF centre directors and patient
advisors early in the design stage of the study to discuss our intentions and proposals. This was done to
ensure that the outcomes directly related to the issues raised by the clinical community and patients.
There are new variables being collected that were not available at the time we began this study, so these
may form a framework for the future analyses.
Analysis
Conclusions based on Shewhart’s13 SPC approach are subject to two types of error. The first is to treat an
outcome resulting from a common cause as if it were a special cause. The second is to treat an outcome
resulting from a special cause as if it were a common cause. Although we cannot entirely eliminate the
possibility of making these errors, we can minimise it. For this reason, Shewhart13 argued that variation from
stable processes lies within limits that – combining mathematical theory, empirical evidence and pragmatism –
can be usefully set at 3-SD limits from the mean. For this reason, and in keeping with Shewhart’s original
work in this field,13 other centre comparison studies using funnel plots and the pyramid of investigation
approach,33 we focused much of our attention on identifying special-cause variation at 3-SD limits.
Our results were largely robust and replicated in sensitivity analyses, and we obtained very similar results
regardless of whether we used the GLI reference equations19 or Knudson17 reference equations. We cannot
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exclude the possibility, however, that there were unmeasured case-mix variables that might have explained
some of the differences we observed.
Analyses of changes in FEV1 over time failed to show much variability after case-mix adjustment analysis
using multilevel models; this may be because we were not necessarily able to get a good measure of
‘change’, owing to the small number of data points available. The individual year analyses, however,
afforded us the opportunity to explore whether or not centres showed special-cause variation multiple times
over the study period, but this approach also meant that we risked observing regression to the mean.34
As the CF Registry grows, there will be more opportunities for longitudinal analyses considering changes in
lung function over time as well as patient characteristics at the time of transition.
An issue arising from the use of funnel plots for centre comparisons is one of overdispersion.35 This can
occur when there is insufficient risk adjustment and is exhibited by the presence of many outliers in the
plots. Our research team benefited from the expertise of a group of clinicians with a great deal of
knowledge of the outcomes being studied and of the quality of the data on the CF Registry; with them,
we identified those clinically meaningful variables that were well recorded on the CF Registry and could
affect outcomes. Invariably, however, there will be other factors, or better measures of the factors that we
considered, that may be more appropriate. For example, we considered only current area-level measures of
deprivation, but it may be more important to look at early-life exposures to second-hand tobacco smoke.
However, these data were not available. Similarly, we are aware that our analyses of outcomes in adult
centres could be improved with the addition of more information on the health of patients at the time at
which they transitioned to adult care. We are, however, limited by the data available. One recommended
method of dealing with overdispersion is the use of mixed-effects modelling, which is the approach we
used. With this approach, we found few centres exhibiting special-cause variation.
A consequence of the use of multilevel modelling, however, is that ‘shrinkage’ can occur when the adjusted
results are drawn to the overall mean, thus giving the false illusion that case mix explains variability. This can
have the greatest effect for smaller centres. We attempted to address the impact of this in our analyses by
running sensitivity analyses in which we used fixed-effects GLMs that did not account for centre to generate
predicted outcomes. We compared the observed and predicted outcomes by generating the ‘% predicted’
outcomes and generated our funnel plots from these new outcomes. Comparing the results obtained using
this method of analysis with the multilevel modelling approach generally yielded similar results. Occasionally,
a centre that was within the 3-SD limits in the analysis using multilevel modelling stayed outside those limits
when a fixed-effects modelling approach was used. This is of particular relevance to adult centre 40, the
results of which were thought to be driven largely by case mix, but which remained an outlier in our fixed-
effects modelling approach. Nonetheless, our results were generally consistent. When looking at change in
FEV1 in children and change in BMI in adults, however, we observed some large outliers in the fixed-effects
modelling approach that were not present in the multilevel modelling approach. Those centres outside the
control limits were within the control limits in the unadjusted analysis. Predictions from our case-mix adjusted
model were very poor, making interpretation of our modified outcome of ‘% predicted’ difficult.
Consultations with clinicians
We ran two successful workshops with clinicians – from adult and paediatric centres, separately – to gain
insight into the SPPs needed to deliver good CF care. Participants in these discussions came from a variety
of disciplines, thereby ensuring that we had insight covering all aspects of care delivered by MDTs. This
approach uncovered broad areas that clinicians felt were important and from these consultations we devised
questionnaires that were disseminated to all centre directors for them and their teams to complete.
The clinician survey alone would be insufficient to gain insight into the SPPs associated with good care,
but it was designed to help inform the conversation with sites and provide a starting point for discussions
regarding the causes of variations in clinical outcomes. Owing to the low response rate for this questionnaire,
we were unable to get a clear sense of the structures and processes of care at all centres. We can obtain
supplemental information from the CF Registry (such as days on i.v. antibiotics and use of chronic
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preventative therapies, which have been suggested as a reason for better lung function outcomes in the USA
than in the UK36) but this does not cover the full picture of how care is structured and delivered at a centre.
Alternative approaches to understanding how sites deliver care – such as through observation – may have
yielded more information than a questionnaire. Questionnaires about how care is delivered can be prone to
the selective bias of recalling more incidences of desirable behaviours and fewer incidences of undesirable
behaviours. However, we felt that responses to our questions might signpost areas of further inquiry. The
response rate to our questionnaire reflects the intense pressure that clinicians are under. Our choice of a
relatively unsophisticated approach was an attempt to pragmatically sample a population that we knew to
be very busy.
As indicated, it was anticipated that these questionnaires would provide hypotheses of the reasons for the
differences in clinical outcomes observed, which are discussed in Chapter 3. These would then be explored
in site visits at a sample of adult and paediatric centres. Centres were to be chosen in such a way that
some would have average outcomes, some would have below average outcomes and others would have
above average outcomes. Our plan for these site visits was described in the protocol; it involved an
iterative process whereby the centre comparisons on clinical outcomes would be shared with the centre
directors, who would be invited to comment and provide their own hypotheses, which we could then
investigate with the data collected. Based on these analyses, we would have further discussions and
discuss hypotheses generated from the centre director survey. However, it was felt that conducting the site
visits without clear hypotheses driven by the survey would not be helpful or informative, so these were
not conducted.
Consultation with patients
Our consultation with patients yielded insight into what patients feel is important in the delivery of CF
care. It is only because of time restrictions that we were unable to disseminate, analyse and present our
results within the context of this study.
The questionnaire on its own was not designed to enable us to perform statistical hypothesis testing, but it
can be best conceptualised as a qualitative survey tool; as such, we would be looking for data saturation
as an indicator that the important themes had been uncovered. However, understanding differences
between centres would be difficult.
Unanswered questions and future work
Questions raised by this project
There remain questions to be addressed. How does i.v. antibiotic treatment (and, potentially, other
medications) affect outcomes in CF patients? We observed that centre 9 was frequently outside the 3-SD
limits for FEV1, despite adjustment for case mix, and there was some evidence that this centre has a smaller
than average proportion of patients receiving i.v. antibiotics. It has been suggested that CF centres with
better FEV1 give more i.v. antibiotic treatments27
,37 and analyses comparing FEV1 in US and UK CF patients
suggested that the determined use of treatments in the USA may be a driver of differences between US
and UK CF centres.36 Future work could explore the role of antibiotic treatments through more detailed
analysis of CF Registry data and discussions with sites.
Are there other measures that could be used for centre comparisons? The outcomes studied in this project
were those that were felt to be important to clinicians and that have been shown to be associated with
survival. Mant38 suggests, however, that process measures would be more sensitive to change in quality
improvement than clinical outcomes. Therefore, future studies may involve exploring which process
measures would be most reliable and relevant to studying CF care. We, and another research group,37
studied the number of days on i.v. antibiotics as process measures and found interesting results that
encourage further exploration. We studied the number of days on i.v. antibiotics as it was the most reliable
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process measure routinely collected by the CF Registry at the time, but the exploration of other data sets
may suggest other measures that, in future, could be incorporated into national comparisons. There is, for
example, current work funded by the CF Registry that is exploring the potential of linkages between the CF
Registry and other routine data sets such as Hospital Episode Statistics. Such linked data could potentially
yield useful data in this regard.
If we are to concentrate centre comparisons on measures of lung function, are there other measures of
lung function that might prove insightful? In recent years, the UK CF Registry has collected information on
‘best’ FEV1 as well as FEV1 at annual review. Future research could involve comparisons between centres on
this ‘best’ measure and – if data become available in the future – an exploration of the care received by
patients in the period leading up to their ‘best’ FEV1. There is evidence from those sites providing both
measures of FEV1 in 2013 that ‘best’ FEV1 differs from FEV1 values at annual review (when patients are
‘stable’) and that differences are greater for larger and smaller centres (see appendix C37).
Are there better ways of adjusting for patient case mix? The case-mix adjustment models used in the current
analyses were based on clinical feedback on important patient characteristics and the data available. A more
detailed exploration of patient histories, using evolving CF Registry data, may allow for refinement of the
case-mix adjustment models, which could be validated against data from other well-established CF
Registries, such as those in Canada and the USA.
What is the role of SES on observed differences between centres on FEV1? The importance of SES in health
outcomes in CF has been studied extensively.39 There is evidence that disparities exist, at least from the earliest
point (at age 6 years) at which lung function is routinely recorded. It is not obvious what the mediating factors
are, but it has been proposed that exposure to tobacco smoke may play a role. Future work to understand
how centres can address this might, for example, involve exploring more closely the SPPs of those centres that
have good clinical outcomes as well as a mixed patient population in terms of SES.
Beyond the potential role of the use of i.v. antibiotics, we were unable to identify the SPPs related to good
CF care. Our survey of clinicians did not yield sufficient data to inform discussions with the sites. Taking an
ethnographic approach based on observation, however, may yield more useful information.
How do patients feel about the care that they receive? We developed a detailed questionnaire for patients,
which we did not have time to disseminate and analyse within the context of this study. Relevant approvals
for this project have been obtained and we hope to disseminate the questionnaire soon. Analyses here can
consider different age groups, as the concerns of the parents of young children will potentially be different
from the views of young adults and older adults who will have had a lifetime of CF care.
Aims from this project
Despite the unanswered questions and limitations encountered, we have developed part of the framework we
intended to, which will support future centre comparison analysis of UK CF Registry data, thereby benefiting
the CF community – both patients and clinicians. The framework, as currently developed, relates to having
established models and processes for making centre-level comparisons on key clinical outcomes and routinely
collected measures of care (such as i.v. antibiotic usage), although these are subject to a number of limitations,
as described above. Our workshops and focus groups have elicited important information on what patients
and clinicians feel is important in delivering good CF care and achieving good outcomes. These events have
helped us to devise questionnaires to be distributed more widely to the clinical and patient community.
This forms the basis of future work linking care and clinical outcomes, which could complete our intended
aims. To resolve the outstanding elements of our proposed work, the following is required:
1. Disseminate the patient questionnaire that was developed in this project.
2. Collect information on the SPPs at centres. We accept that our survey design was inadequate and are
exploring other possibilities, including an ethnographic approach using observation.
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3. Use the information gathered in the first two steps to inform conversations with sites identified in our
centre comparison work to explore whether or not the differences observed relate to care.
Conclusions
This study has demonstrated that we can identify variation between centres and has raised some
hypotheses regarding reasons for these differences. The hypotheses raised in this work – including the
potential role of i.v. antibiotics – require further study and could provide valuable insights for the CF
clinical community.
In fact, the CF Registry is already moving towards the use of funnel plots in making centre comparisons.31
The learning from this work regarding the importance of case-mix adjustment, the limitations of such plots
of detecting special-cause variation in small centres, the usefulness of making comparisons across years
rather than using single-year analyses and the potential usefulness of incorporating available process
measures can all be incorporated into future practice at the CF Registry. We also gleaned valuable
information from select groups of clinicians and patients on what is important in delivering good CF care.
Although we were unable to successfully investigate these issues at the national level, we have gained
insight into how this might be done successfully in the future.
Our approach provides a framework for future centre comparisons in CF or other disease areas for which
routine clinical data are available on well-defined patient populations. This can usefully form the basis of
discussions with sites about outcomes – subject to the limitations described in this chapter – when
following the pyramid of investigation approach.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Expert patient focus group
topic guide
National Institute for Health Research Health Services and Delivery
Research cystic fibrosis study: focus group schedule for expert patients
Preamble
Hello everyone, and thank you for joining this telephone-based focus group. During the next couple of
hours, we are going to discuss some issues that we think help a CF unit to perform well. There are no
right or wrong answers to the questions I am going to ask, so please feel free to agree or disagree with
each other as we go along. Because this focus group is being tape recorded for later analysis, can I please
ask you not to talk over each other? Please try to wait for whoever is speaking to finish before starting to
speak yourself. Whilst we are keen to hear about your own personal experiences, you are welcome to also
mention the experiences of other CF patients who you know about.
Schedule
l Can we start by considering the level of information that CF units should provide to patients and carers?
¢ Is it important in your view that CF units educate their patients about the condition? What benefits
would this have?
¢ What specific aspects of CF is it important for units to educate patients and carers about? And how
is this achieved in your experience?
¢ To your knowledge, what educational materials are routinely given to patients? Are there any gaps
in your view?
¢ Do you think units should have explicit policies and procedures in place around education of
patients? Would this be valuable?
¢ Would you find it helpful if members of the MDT asked questions to confirm your understanding
of aspects of your treatment? What benefits would this have?
¢ What helps or hinders CF units in educating their patients and carers in your view?
¢ In an ideal world, what would a well-performing CF unit look like, with respect to patient education?
l Can we turn next to consider the extent to which units encourage CF patients to have influence and
control over their treatment and care?
¢ So first of all, do you personally feel that you are encouraged to take control over your care and
treatment? How/in what ways?
¢ In your experience, do patients and carers want greater control and influence over their treatment
and care? If so, what aspects of their treatment and care do they want more control over?
¢ Is it important that CF units encourage patients to take greater control of the management of the
their condition? What benefits would this have?
¢ What helps or hinders CF units in encouraging their patients to have more influence and control
over their treatment and care in your view?
¢ In an ideal world, what would a well-performing CF unit look like, with respect to the degree of
control and influence a CF patient has over their treatment and care?
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l The next issue for discussion is how CF units develop a constructive dialogue and relationship with
patients. So, first of all, do you generally feel listened to when receiving care at your CF unit?
¢ Does the MDT try to understand your lifestyle, and fit your treatment around your lifestyle?
Could you provide an example of this?
¢ How do you feel that CF professionals go about developing a constructive dialogue and relationship
with yourself and other CF patients?
¢ Do you think that CF patients are interested in developing a constructive dialogue with specific
members of a unit?
¢ What helps or hinders a CF unit from developing a constructive dialogue with patients in your view?
¢ In an ideal world, what would a well-performing CF unit look like, with regards to how it develops
a constructive dialogue with patients?
l For the next part of the focus group, I’d like us to consider how units measure and manage CF within
the MDT. So first of all, what in your view should units be measuring to know that they are treating
patients effectively?
¢ Do you feel that you understand your target lung function and weight and what these mean? Are
there other aspects of your health that you feel it is important that CF units monitor and manage?
¢ Are you given information about your own condition to help you evaluate how your treatment and
care is progressing?
¢ Have you experienced variation in the standard and quality of your care in visits to your unit?
¢ Do you feel that the MDT in your unit communicates well and delivers a consistent message?
¢ Do you feel that the MDT has a shared understanding of your treatment and care?
¢ Are you confident that the MDT shares information well, so that they all know about your
treatment and care?
¢ Do you think it is important for patients and carers to be involved in monitoring and managing the
performance of CF units? What benefits would this have?
¢ Should CF patients know how their unit performs in relation to other units in the country?
What benefits would this have?
¢ In your view, what factors help or hinder CF units measuring and managing CF effectively?
¢ In an ideal world, what would a well-performing CF unit look like, with respect to the
measurement and management of CF?
l The next part of the focus group relates to resources and multidisciplinary staffing in CF units. First of
all, have you, or patients who you know, ever experienced difficulties in seeing certain members of the
MDT as often as you would like?
¢ Have you, or patients who you know, ever experienced difficulties in obtaining relevant treatments
such as nebulisers?
¢ Are you confident that all members of the MDT in your unit are equipped and trained to manage
your CF effectively?
¢ What, in your view, helps or hinders CF units to obtain the resources and staffing to ensure a good
level of performance?
¢ In an ideal world, what would a well-performing CF unit look like with regard to staffing and
resources?
l I’d like now to broaden the discussion out and for you to describe for me some good and bad
experiences of the care that you have had both as an inpatient and an outpatient. If we could start
with your experiences of being treated as an inpatient:
¢ What is a good experience as an inpatient like?
¢ What is a bad experience as an inpatient like?
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
¢ What is a good experience as an outpatient like?
¢ What is a bad experience as an outpatient like?
¢ What does your CF unit do well?
¢ What could your CF unit improve?
Closing remarks
We have come to the end of the focus group questions. Before we close, does anyone want to add
anything to any of the issues that we have discussed?
Many thanks for your participation. The recording is going to be transcribed verbatim and a copy will be
made available to you for your information.
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Appendix 2 Additional figures
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FIGURE 18 Proportion of 12-year-old patients with data recorded at each of the 31 paediatric centres. (a) FEV1%
predicted; (b) genotype; (c) SES; and (d) pancreatic enzyme use. (continued )
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FIGURE 19 Description of case-mix variables at each of the 31 paediatric centres (for 12-year-old patients).
(a) Sex: female; (b) genotype: homozygous DF508; (c) SES; and (d) pancreatic enzyme use. (continued )
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FIGURE 18 Proportion of 12-year-old patients with data recorded at each of the 31 paediatric centres. (a) FEV1%
predicted; (b) genotype; (c) SES; and (d) pancreatic enzyme use.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
92
0 10 20 30 40 50 60 70 80 90 100 110
Number of 12-year-olds in paediatric centre
43
346 59
0
20
40
60
80
100
SE
S 
q
u
in
ti
le
 5
 p
ro
p
o
rt
io
n
 (
%
)
(c)
54
1
Centres
99.8% limits
95% limits
311
16
23
2527 37 52
31
61
0
20
40
60
80
100
Pa
n
cr
ea
ti
c 
su
p
p
le
m
en
t 
p
ro
p
o
rt
io
n
 (
%
)
0 10 20 30 40 50 60 70 80 90 100 110
Number of 12-year-olds in paediatric centre
(d)
1
Centres
99.8% limits
95% limits
FIGURE 19 Description of case-mix variables at each of the 31 paediatric centres (for 12-year-old patients).
(a) Sex: female; (b) genotype: homozygous DF508; (c) SES; and (d) pancreatic enzyme use.
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FIGURE 20 Proportion of 15-year-old patients with data recorded at each of the 31 paediatric centres. (a) FEV1%
predicted; (b) genotype; (c) SES; and (d) pancreatic enzyme use. (continued )
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FIGURE 20 Proportion of 15-year-old patients with data recorded at each of the 31 paediatric centres. (a) FEV1%
predicted; (b) genotype; (c) SES; and (d) pancreatic enzyme use.
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FIGURE 21 Description of case-mix variables at each of the 31 paediatric centres (for 15-year-old patients). (a) Sex:
female; (b) genotype: homozygous DF508; (c) SES; and (d) pancreatic enzyme use. (continued )
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FIGURE 21 Description of case-mix variables at each of the 31 paediatric centres (for 15-year-old patients). (a) Sex:
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FIGURE 22 Proportion of 15-year-old patients with data recorded for BMI percentile for each of the 31 paediatric centres.
39
(a)
43
20
40
60
80
100
Pr
o
p
o
rt
io
n
 o
f 
p
at
ie
n
ts
 w
it
h
 a
t 
le
as
t
2 
FE
V
1%
 p
re
d
ic
te
d
 r
ec
o
rd
ed
 (
%
)
0 10 20 30 40 50 60 70 80 90 100 110 120 130
Number of 13- to 15-year-old patients
Centres
99.8% limits
95% limits
FIGURE 23 Proportion of patients with non-missing data (at least two annual reviews between the ages of 13 and
15 years: 2007–12). (a) FEV1% predicted; (b) genotype; (c) SES; and (d) pancreatic enzyme use. (continued )
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
54
50
60
70
80
90
100
G
en
o
ty
p
e 
re
co
rd
ed
 (
%
)
0 10 20 30 40 50 60 70 80 90 100 110 120
Number of 13- to 15-year-old patients
(b)
Centres
99.8% limits
95% limits
(c)
1
4
11
20
40
60
80
100
SE
S 
re
co
rd
ed
0 10 20 30 40 50 60 70 80 90 100 110 120 130
Number of 13- to 15-year-old patients
Centres
99.8% limits
95% limits
50
60
70
80
90
100
Pa
n
cr
ea
ti
c 
en
zy
m
e 
u
se
 r
ec
o
rd
ed
 (
%
)
0 10 20 30 40 50 60 70 80 90 100 110 120 130
Number of 13- to 15-year-old patients
(d)
Centres
99.8% limits
95% limits
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FIGURE 25 Comparison of unadjusted FEV1% predicted (Knudson) with case-mix adjusted predicted values
(at 12 years of age using data from 2007–15 and fixed-effect GLM to perform case-mix adjustment).
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from 2007–15 and GLM to perform case-mix adjustment).
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FIGURE 28 Funnel plots of FEV1 adjusted for age using GLMs, by year. (a) 2007; (b) 2008; (c) 2009; (d) 2010; (e) 2011;
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FIGURE 32 Comparison of unadjusted change in FEV1% predicted (Knudson) with case-mix adjusted predicted values
(between ages 18 and 21 years using data from 2007–12 and fixed-effect GLM to perform case-mix adjustment).
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FIGURE 33 Comparison of unadjusted change in BMI with case-mix adjusted predicted values (between ages 18
and 21 years using data from 2007–12 and fixed-effect GLM to perform case-mix adjustment).
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FIGURE 34 Funnel plots of FEV1 adjusted for age using GLMs, by year. (a) 2007; (b) 2008; (c) 2009; (d) 2010; (e) 2011;
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FIGURE 34 Funnel plots of FEV1 adjusted for age using GLMs, by year. (a) 2007; (b) 2008; (c) 2009; (d) 2010; (e) 2011;
(f) 2012; (g) 2013; (h) 2014; and (i) 2015.
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FIGURE 35 Funnel plots of FEV1 adjusted for age using splines, by year. (a) 2007; (b) 2008; (c) 2009; (d) 2010;
(e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015. (continued )
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FIGURE 35 Funnel plots of FEV1 adjusted for age using splines, by year. (a) 2007; (b) 2008; (c) 2009; (d) 2010;
(e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015. (continued )
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FIGURE 35 Funnel plots of FEV1 adjusted for age using splines, by year. (a) 2007; (b) 2008; (c) 2009; (d) 2010;
(e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015.
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FIGURE 36 Funnel plots of FEV1 adjusted for age using splines and other case-mix variables using fixed-effect GLM
models, by year. (a) 2007; (b) 2008; (c) 2009; (d) 2010; (e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015. (continued )
DOI: 10.3310/hsdr07060 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 6
© Queen’s Printer and Controller of HMSO 2019. This work was produced by MacNeill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
60
80
100
120
140
Pe
rc
en
ta
g
e 
p
re
d
ic
te
d
 F
EV
1
0 100 200 300 400 500
Number of patients with data for FEV1
(d)
2
5
6
78
9
10
17
19
20 2930
32
33
34
35
38
40
41
45
47
48
51
55
56
57
58
Centres
99.8% limits
95% limits
60
80
100
120
140
Pe
rc
en
ta
g
e 
p
re
d
ic
te
d
 F
EV
1
0 100 200 300 400 500
Number of patients with data for FEV1
(e)
2
5
6
78
9
10
17
19
20
21
29
3032
33
34
35
38
40
41
4547
48
51
55
56
57
58
Centres
99.8% limits
95% limits
80
90
100
110
120
Pe
rc
en
ta
g
e 
p
re
d
ic
te
d
 F
EV
1
0 200 400 600
Number of patients with data for FEV1
(f)
2
5
6
7
8
9
10
17 19
2021
2930
32
33
34
35
38
40
41
45
47
48
51
55
56
57
58
Centres
99.8% limits
95% limits
FIGURE 36 Funnel plots of FEV1 adjusted for age using splines and other case-mix variables using fixed-effect GLM
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FIGURE 36 Funnel plots of FEV1 adjusted for age using splines and other case-mix variables using fixed-effect GLM
models, by year. (a) 2007; (b) 2008; (c) 2009; (d) 2010; (e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015.
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FIGURE 37 Funnel plots of the proportion of patients receiving i.v. antibiotics, by year. (a) 2007; (b) 2008; (c) 2009;
(d) 2010; (e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015. (continued )
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FIGURE 37 Funnel plots of the proportion of patients receiving i.v. antibiotics, by year. (a) 2007; (b) 2008; (c) 2009;
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FIGURE 37 Funnel plots of the proportion of patients receiving i.v. antibiotics, by year. (a) 2007; (b) 2008; (c) 2009;
(d) 2010; (e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015.
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FIGURE 38 Funnel plots of FEV1 unadjusted for case mix estimated using GLI reference equations, by year. (a) 2007;
(b) 2008; (c) 2009; (d) 2010; (e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015. (continued )
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FIGURE 38 Funnel plots of FEV1 unadjusted for case mix estimated using GLI reference equations, by year. (a) 2007;
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FIGURE 38 Funnel plots of FEV1 unadjusted for case mix estimated using GLI reference equations, by year. (a) 2007;
(b) 2008; (c) 2009; (d) 2010; (e) 2011; (f) 2012; (g) 2013; (h) 2014; and (i) 2015.
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Percentage of respondents who agree
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Our team has a strong (trained, experienced, autonomous) co-ordinator (nurse, physiotherapist, etc.)
We have a CF outpatient facility that allows us to meet the CF Trust standards of care
Our team has adequate consultant time available for patients
Our team has adequate nursing time available for patients
We have a CF ward facility that allows us to meet the CF Trust standards of care
Our team has adequate physiotherapy time available for patients
Our team has adequate dietitian time available for patients
Our team has adequate psychologist time available for patients
Our team has adequate pharmacist time available for patients
Our team has adequate social worker time available for patients
Our team has a dedicated diabetologist who has high-level expertise in the specific problems of CFRD
Our team runs a dedicated CF-related diabetes clinic
Our team has adequate access to a gastroenterologist as required
Our team has adequate administrative staffing
FIGURE 39 Views on facilities, staffing and resources (adult centres). CFRD, cystic fibrosis-related diabetes.
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Percentage of respondents who agree
80 100
We have the flexibility to review
patients of concern within 48 – 72 hours
Our team is able to provide an appropriate
level of support to patients in terms of phone calls
Our patients can always easily access
the medicines they require
Patients can easily access specialist
support 24/7
We are always able to provide the
specialist equipment our patients require
Our team is able to provide popular
food for inpatients
We are able to promptly admit patients
requiring a hospital bed
Our team is able to provide an appropriate
level of support to patients in terms of home visits
FIGURE 40 Views on capacity and demand (adult centres).
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Percentage of respondents who agree
The team feels valued by the hospital management
Our team has skilled and experienced hospital management
Our team has skilled and experienced CF clinical leadership
Our team is well organised
The team feels valued by the CF clinical leadership
FIGURE 41 Views on leadership (adult centres).
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We always promptly identify new isolates of
Pseudomonas
Our team has systems in place to intercept early 
decline in lung function
Our team has systems in place to intercept early
decline in BMI
In routine care, our team uses graphs of lung 
function over time
In routine care, our team uses graphs of BMI 
over time
We have an excellent computerised system which 
specifically supports CF management
FIGURE 42 Views on measurement and monitoring (adult centres).
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Percentage of respondents who agree
80 100
In our team, every voice within the MDT is heard 
and considered
Our annual review process delivers effective
treatment plans for patients that are followed through
It is clear who is responsible for every task in our clinic
Our team has formal structures that ensure key
information is effectively communicated
Our team holds focused post-clinic meetings with the
appropriate people
Our team holds focused pre-clinic meetings with the
appropriate people
Our clinic is known for running efficiently
Patients/carers are provided with written treatment
plans by members of the MDT
We have a foolproof system that means we never
overlook test results
FIGURE 43 Views on MDT processes (adult centres).
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Percentage of respondents who agree
80 100
Our team measures and shares outcome,
satisfaction, clinical process and safety data over
time and the MDT uses these data to make improvements
We have explicit structures that involve patients
in quality improvement
Our team has access to quality improvement 
support (service improvement, transformation,
Lean process improvement team, etc.)
Our team routinely uses quality improvement tools
(such as Lean process improvement, PDSA, process
mapping, etc.) to improve care
FIGURE 44 Views on process improvement (adult centres). PDSA, Plan Do Study Act.
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Percentage of respondents who agree
80 100
Our team understands that nutrition is important 
and anticipates possible interventions
In the event of progressive decline, despite home 
i.v. antibiotics, we usually admit patients for 
hospital assessment
Our team quickly starts i.v. antibiotics when oral 
antibiotics do not produce prompt improvement
Our team believes that we can avoid rescue i.v. antibiotics 
if we support preventative treatment therapies
FIGURE 45 Views on treatment policy (adult centres).
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FIGURE 46 Time lag to starting antibiotics for cough and cold (adult centres). For a CF patient who calls to report
increased cough and cold but no other symptoms, we would consider treatment with antibiotics if symptoms
persisted for _ days.
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Percentage of respondents who agree
80 100
We encourage patients to have high expectations
of our team
Our team always manages to communicate
person-centred non-judgemental positive regard
to all of our patients
We expect, among our patients, women to have a
BMI score of 22 kg/m2 and men of 23 kg/m2
 
Our team has explicit systems in place to support
patients who find it difficult to engage with the
service
We expect no yearly decline in lung function
FIGURE 47 Expectations of care (adult centres).
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Our team has adequate consultant time available 
for patients
We have a CF outpatient facility that allows us to
meet the CF Trust standards of care
Our team has adequate access to a
gastroenterologist as required
Our team has adequate nursing time available 
for patients
Our team has a strong (trained, experienced, 
autonomous) co-ordinator (nurse, physiotherapist, etc.)
We have a CF ward facility that allows us to meet
the CF Trust standards of care
Our team has adequate physiotherapy time available
for patients
Our team has a dedicated diabetologist who has
high-level expertise in the specific problems of CFRD
Our team has adequate dietitian time available 
for patients
Our team has adequate administrative staffing
Our team has adequate pharmacist time available
for patients
Our team runs a dedicated CF-related diabetes clinic
Our team has adequate psychologist time available
for patients
Our team has adequate social worker time available
for patients
Percentage of respondents who agree
FIGURE 48 Views on facilities, staffing and resources (paediatric centres). CFRD, cystic fibrosis-related diabetes.
0 20 40 60 80 100
We have the flexibility to review patients of
concern in our service within 48 – 72 hours
Our team is able to provide an appropriate level of
support to patients in terms of telephone calls
Our patients can always easily access the
medicines they require
Our team is able to provide an appropriate level of
support to patients in terms of home visits
We are always able to provide the specialist
equipment our patients require
Patients can easily access specialist support 24/7
Our team has the resources to perform timely
bronchoscopies when required
We are able to promptly admit patients requiring
a hospital bed
Our team is able to provide popular food for 
inpatients
Percentage of respondents who agree
FIGURE 49 Views on capacity and demand (paediatric centres).
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0 20 40 60 80 100
Our team has skilled and experienced CF clinical leadership
Our team is well organised
The team feel valued by the CF clinical leadership
Our team has skilled and experienced hospital management
The team feel valued by the hospital management
Percentage of respondents who agree
FIGURE 50 Views on leadership (paediatric centres).
0 20 40 60 80 100
Our team has systems in place to intercept early decline
in weight and height percentiles
Our team has systems in place to intercept early decline
in lung function
We always promptly identify new isolates of
Pseudomonas
In routine care, our team uses graphs of lung function
over time
In routine care, our team uses graphs of weight and
height and BMI percentile over time
We have an excellent computerised system that
specifically supports CF management
Percentage of respondents who agree
10 30 50 70 90
FIGURE 51 Views on measurement and monitoring (paediatric centres).
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0 20 40 60 80 100
Our team holds focused post-clinic meetings with
the appropriate people
Our annual review process delivers effective treatment
plans for patients that are followed through
In our team, every voice within the MDT is heard
and considered
It is clear who is responsible for every task in
our clinic
Our team has formal structures that ensure key
information is effectively communicated
Patients/carers are provided with written
treatment plans by members of the MDT
Our team holds focused pre-clinic meetings with
the appropriate people
Our clinic is known for running efficiently
We have a foolproof system that means we never
overlook test results
Percentage of respondents who agree
FIGURE 52 Views on MDT processes (paediatric centres).
0 20 40 60 80 100
Percentage of respondents who agree
10 30 50 70 90
Our team measures and shares outcome, satisfaction,
clinical process and safety data over time and the MDT
uses these data to make improvements
We have explicit structures that involve patients in
quality improvement
Our team has access to quality improvement support
(service improvement, transformation, Lean process
improvement team, etc.)
Our team routinely uses quality improvement tools
(such as Lean process improvement, PDSA, process
 mapping, etc.) to improve care
FIGURE 53 Views on process improvement (paediatric centres). PDSA, Plan Do Study Act.
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0 20 40 60 80 100
Percentage of respondents who agree
10 30 50 70 90
Our team understands that nutrition is important and
they anticipate possible interventions
In the event of progressive decline, despite home 
i.v. antibiotics we usually admit patients for 
hospital assessment
Our team quickly starts i.v. antibiotics when oral
antibiotics do not produce prompt improvement
Our team believes we can avoid rescue i.v. antibiotics if
we support preventative treatment therapies
FIGURE 54 Treatment policy (paediatric centres).
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Appendix 3 Additional tables
TABLE 17 Fixed and random components of the multivariable model analysis for factors associated with FEV1%
predicted in children aged 12 years
Fixed effect Estimate (95% CI) (% predicted) p-value
Constant 87.24 (8.07 to 92.41) < 0.001
Sex (male) 2.98 (0.80 to 5.16) 0.007
Genotype
Homozygous DF508 – 0.111
Heterozygous DF508 1.41 (–0.95 to 3.78)
No DF508 –3.03 (–7.32 to 1.27)
Pancreatic enzyme supplement use –4.23 (–8.38 to –0.07) 0.046
SES quintile
1 (least deprived) – 0.002
2 –1.20 (–4.52 to 2.11)
3 –2.76 (–6.11 to 0.60)
4 –3.91 (–7.24 to –0.57)
5 (most deprived) –5.50 (–9.08 to –1.92)
Random effect
Between-centres SD 4.74 (3.26 to 6.89)
Within-centre SD 17.65 (16.90 to 18.44)
CI, confidence interval.
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TABLE 19 Fixed and random components of the multivariable model analysis for factors associated with BMI
(percentile) at age 15 years
Fixed effect Estimate (95% CI) (% predicted) p-value
Constant 70.29 (62.15 to 78.43) < 0.001
Sex (male) –4.49 (–8.01 to –0.97) 0.012
Genotype
Homozygous DF508 – 0.92
Heterozygous DF508 –0.64 (–4.49 to 3.21)
No DF508 –1.11 (–7.84 to 5.62)
Pancreatic enzyme supplement use –17.15 (–24.00 to –10.29) < 0.001
SES quintile
1 (least deprived) – 0.021
2 –3.51 (–8.98 to 1.97)
3 –1.61 (–7.11 to 3.88)
4 –3.71 (–9.02 to 1.60)
5 (most deprived) –9.58 (–15.40 to –3.77)
Random effect
Between-centres SD 4.15 (2.13 to 8.11)
Within-centre SD 29.07 (27.85 to 30.35)
CI, confidence interval.
TABLE 18 Fixed and random components of the multivariable model analysis for factors associated with FEV1%
predicted at age 15 years
Fixed effect Estimate (95% CI) (% predicted) p-value
Constant 84.50 (78.61 to 90.39) < 0.001
Sex (male) 3.20 (0.73 to 5.68) 0.011
Genotype
Homozygous DF508 – 0.256
Heterozygous DF508 1.58 (–1.11 to 4.28)
No DF508 –1.99 (–6.70 to 2.72)
Pancreatic enzyme supplement use –7.34 (–12.16 to –2.51) 0.003
SES quintile
1 (least deprived) – < 0.001
2 2.81 (–1.04 to 6.66)
3 –0.63 (–4.47 to 3.21)
4 –3.27 (–6.99 to 0.46)
5 (most deprived) –5.61 (–9.76 to –1.46)
Random effect
Between-centres SD 4.83 (3.13 to 7.44)
Within-centre SD 19.89 (19.03 to 20.79)
CI, confidence interval.
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TABLE 20 Fixed and random components of the multivariable model analysis for factors associated with change in
FEV1 between 13 and 15 years
Fixed effect Estimate (95% CI) (% predicted) p-value
Constant 3.61 (–13.28 to 20.50) 0.675
Sex (male) 0.76 (–0.53 to 2.06) 0.248
Genotype
Homozygous DF508 – 0.171
Heterozygous DF508 0.35 (–1.07 to 1.77)
No DF508 –2.02 (–4.46 to 0.41)
Pancreatic enzyme supplement use –1.34 (–4.21 to 1.54) 0.362
SES quintile
1 (least deprived) – 0.665
2 0.45 (–1.56 to 2.46)
3 1.09 (–0.86 to 3.05)
4 –0.37 (–2.32 to 1.59)
5 (most deprived) 0.52 (–1.60 to 2.63)
Age at first visit –0.31 (–1.51 to 0.90) 0.620
Random effect
Between-centres SD 0.57 (0.03 to 9.41)
Within-centre SD 11.03 (10.58 to 11.50)
CI, confidence interval.
TABLE 21 Mean age of patients attending annual reviews by year and paediatric centre
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
12 10.2 9.9 10.5 10.6 10.8 10.6 10.5 10.6 10.4
39 – 9 10.4 10.8 10.8 10.9 10.8 10.7 10.5
52 10.5 10.8 10.8 10.8 10.4 10.4 10.4 10.3 10.2
Across all centres
All 10.5 10.7 10.8 10.8 10.7 10.6 10.5 10.4 10.3
Centres with higher than average FEV1 values
25 10.8 10.8 11 11.1 10.7 10.7 10.5 10.5 10.4
28 10.6 10.5 11.4 10.9 10.1 10.1 9.6 9.8 10
31 10.1 10.8 10.8 10.7 10.7 10.8 10.7 10.2 10
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TABLE 22 Centres showing evidence of special-cause variation and ‘borderline’ centres in analyses adjusted for age
using GLMs, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 12, 52 and 59 11, 16a and 23 14, 31, 36 and 37 25 and 54a
2008 12 and 52 1,a 13, 18, 26 28 and 44 25
2009 12 and 52 11, 16, 23,a 43 and 59 36, 46, 60a and 61 25 and 31
2010 12 and 39 23, 52 and 59 25,a 36, 46 and 61a 31
2011 12, 23 and 39 18 31 and 61 –
2012 39 12, 23,a 26, 52a and 53 14, 25, 28, 31, 43, 54 and 61 –
2013 39 23, 26, 50 and 53 25, 31 and 61 60
2014 50 and 53 25,a 39 and 52 13, 28,a 31, 44, 60 and 61 –
2015 53 25, 26, 50 and 52a 13,a 16, 28,a 31, 43, 60a and 61 –
a Centres approaching the 2-SD control limit without being outside it.
TABLE 23 Centres showing evidence of special-cause variation and ‘borderline’ centres in analyses adjusted for age
using a linear term for age, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 12, 52 and 59 23a 31 and 54 25
2008 52 1a and 12 28 and 44a 25
2009 12 and 52 59 31 and 36a 25
2010 39 and 12 23,a 52a and 59 25a 31
2011 12 and 39 – 61a –
2012 39 12a and 52a 14, 25, 28, 31,a 54a and 61 –
2013 39 50 25, 31a and 61a –
2014 – 25,a 39,a 50 and 52 31,a 44a and 61a –
2015 – 25, 50 and 52a 31, 43a and 61 –
a Centres approaching the 2-SD control limit without being outside it.
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TABLE 25 Distribution of patients who are homozygous DF508 by year and paediatric centre among those who
have been genotyped; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
12 24 (58.5) 28 (57.1) 49 (53.3) 60 (61.2) 52 (55.3) 53 (52.0) 55 (52.9) 52 (50.5) 48 (49.0)
39 – (–) 0 (0.0) 70 (57.4) 93 (56.7) 100 (56.8) 101 (58.0) 92 (55.8) 89 (56.7) 81 (55.1)
52 45 (58.4) 48 (54.5) 69 (51.5) 68 (51.9) 81 (54.4) 91 (58.7) 96 (57.5) 85 (54.5) 91 (55.8)
Across all centres
All 723 (56.4) 955 (56.1) 1144 (55.4) 1201 (55.6) 1238 (54.9) 1236 (55.3) 1243 (53.9) 1233 (54.0) 1247 (53.5)
Centres with higher than average FEV1 values
25 88 (62.4) 100 (61.7) 105 (59.3) 103 (60.6) 105 (60.3) 106 (62.0) 96 (58.5) 87 (57.2) 85 (57.8)
28 19 (46.3) 21 (47.7) 20 (47.6) 23 (46.9) 20 (40.0) 19 (38.0) 30 (44.8) 33 (44.6) 31 (42.5)
31 28 (43.1) 44 (48.4) 41 (48.8) 45 (48.4) 43 (45.3) 39 (46.4) 40 (44.0) 45 (45.5) 48 (46.2)
TABLE 24 Distribution of female patients attending annual review by year and paediatric centre; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
12 19 (46.3) 22 (44.9) 46 (50.0) 49 (50.0) 50 (53.2) 54 (52.9) 55 (52.9) 55 (53.4) 53 (54.1)
39 – (–) 0 (0.0) 69 (54.8) 89 (52.7) 90 (50.3) 86 (48.3) 82 (48.2) 84 (50.0) 77 (49.0)
52 32 (40.5) 40 (44.9) 63 (46.3) 62 (47.3) 70 (47.0) 75 (48.4) 84 (50.0) 78 (49.7) 84 (51.2)
Across all centres
All 640 (48.7) 859 (49.3) 1062 (50.3) 1106 (50.2) 1121 (49.0) 1114 (49.1) 1165 (49.8) 1149 (49.5) 1186 (49.9)
Centres with higher than average FEV1 values
25 59 (41.0) 78 (47.3) 83 (45.9) 79 (45.1) 75 (42.1) 78 (44.6) 71 (42.3) 70 (44.9) 67 (43.2)
28 19 (45.2) 20 (44.4) 19 (44.2) 20 (40.0) 20 (39.2) 18 (35.3) 28 (41.2) 32 (42.1) 33 (44.6)
31 34 (52.3) 43 (46.2) 43 (50.0) 46 (48.4) 44 (45.8) 34 (40.0) 43 (47.3) 48 (48.5) 54 (51.9)
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TABLE 27 Distribution of patients who are pancreatic sufficient by year and paediatric centre; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
12 1 (2.4) 6 (12.2) 12 (13.2) 8 (8.2) 9 (9.6) 12 (11.8) 15 (14.4) 12 (11.7) 11 (11.3)
39 – 0 (0.0) 12 (9.5) 12 (7.1) 15 (8.4) 13 (7.3) 21 (12.4) 23 (13.7) 22 (14.0)
52 6 (7.6) 6 (6.7) 12 (8.8) 14 (10.7) 16 (10.7) 14 (9.0) 20 (11.9) 20 (12.7) 25 (15.2)
Across all centres
All 85 (6.7) 125 (7.3) 176 (8.4) 174 (7.9) 226 (9.9) 229 (10.1) 283 (12.1) 299 (12.9) 315 (13.3)
Centres with higher than average FEV1 values
25 9 (6.3) 8 (4.8) 7 (3.9) 5 (2.9) 4 (2.2) 6 (3.4) 14 (8.3) 17 (10.9) 11 (7.3)
28 5 (11.9) 4 (8.9) 4 (9.3) 4 (8.2) 6 (11.8) 8 (15.7) 13 (19.1) 18 (24.0) 20 (27.4)
31 11 (16.9) 18 (19.4) 16 (18.6) 17 (17.9) 19 (19.8) 15 (17.6) 17 (18.7) 20 (20.2) 21 (20.2)
TABLE 26 Distribution of patients who have at least one G551D mutation by year and paediatric centre among
those who have been genotyped; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
12 2 (4.9) 3 (6.1) 8 (8.7) 9 (9.2) 9 (9.6) 10 (9.8) 9 (8.7) 8 (7.8) 6 (6.1)
39 – (–) 0 (0.0) 7 (5.7) 12 (7.3) 13 (7.4) 12 (6.9) 12 (7.3) 12 (7.6) 12 (8.2)
52 7 (9.1) 7 (8.0) 7 (5.2) 7 (5.3) 5 (3.4) 6 (3.9) 5 (3.0) 7 (4.5) 7 (4.3)
Across all centres
All 92 (7.2) 99 (5.8) 122 (5.9) 135 (6.2) 139 (6.2) 129 (5.8) 131 (5.7) 126 (5.5) 123 (5.3)
Centres with higher than average FEV1 values
25 5 (3.5) 8 (4.9) 8 (4.5) 7 (4.1) 9 (5.2) 6 (3.5) 7 (4.3) 6 (3.9) 5 (3.4)
28 3 (7.3) 3 (6.8) 3 (7.1) 3 (6.1) 5 (10.0) 6 (12.0) 7 (10.4) 8 (10.8) 6 (8.2)
31 5 (7.7) 6 (6.6) 4 (4.8) 6 (6.5) 7 (7.4) 6 (7.1) 9 (9.9) 11 (11.1) 11 (10.6)
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TABLE 29 Comparison of centres showing evidence of special-cause variation and ‘borderline’ centres by method
of case-mix adjustment
Year and
adjustment
method
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007
Unadjusted 12, 52 and 59 11, 16,a 23 and 53a 14, 31, 36, 37 and 54 25
Multilevel model 12, 52 and 59 23 31, 36a and 54a 25
GLM 12, 52 and 59 11 and 18a 31a and 54 25
2008
Unadjusted 12 and 52 1, 13, 18 and 26 36 and 44 25 and 28
Multilevel model 12 and 52 – 28, 44a and 50a 25
GLM 12, 18a and 52 26 44 and 50 25 and 28
2009
Unadjusted 11, 12 and 52 16, 23, 43 and 59 36, 46 and 60 25 and 31
Multilevel model 12 and 52 1 and 59 31 and 36 25
GLM 11,a 12 and 52 1, 16,18,a 23a and 59 27,a 31, 36, 60a and 61 25
2010
Unadjusted 12 and 39 23, 52 and 59 36, 46a and 54a 31
Multilevel model 12 and 39 23, 52 and 59 25, 31, 36a and 44a –
GLM 12, 39 and 59 23 and 52 25, 36 and 50 31a
2011
Unadjusted 12 and 23 18 and 39 31a and 61 –
Multilevel model – 12, 23a and 39 25a –
GLM 12, 23 and 39a 11 and 18 28 and 31 –
continued
TABLE 28 Distribution of the number and proportion of patients in SES quintile 5 (most socioeconomically
deprived) by year and paediatric centre; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
12 7 (17.5) 6 (12.2) 12 (13.0) 12 (12.2) 12 (12.8) 15 (14.7) 9 (8.7) 9 (8.7) 7 (7.1)
39 – (–) 0 (0.0) 23 (18.3) 32 (18.9) 35 (19.6) 38 (21.3) 34 (20.0) 32 (19.0) 32 (20.5)
52 29 (36.7) 33 (37.1) 30 (22.1) 27 (20.6) 28 (18.8) 33 (21.3) 33 (19.9) 27 (17.4) 29 (17.9)
Across all centres
All 239 (18.4) 325 (18.8) 382 (18.2) 376 (17.2) 385 (16.9) 402 (17.8) 417 (17.9) 420 (18.3) 428 (18.2)
Centres with higher than average FEV1 values
25 28 (19.4) 34 (20.6) 47 (26.0) 42 (24.0) 41 (23.0) 43 (24.6) 38 (22.6) 41 (26.5) 40 (26.1)
28 6 (14.3) 9 (20.0) 9 (20.9) 13 (26.0) 13 (25.5) 11 (21.6) 15 (22.1) 18 (23.7) 16 (21.6)
31 10 (15.6) 14 (15.4) 13 (15.5) 15 (16.1) 15 (16.0) 11 (13.3) 11 (12.2) 10 (10.3) 13 (12.7)
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TABLE 30 Intravenous antibiotic use (home and hospital) for all patients and stratified by FEV1, year and
paediatric centre
Centre
Mean
FEV1
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
FEV1 < 70% FEV1 ≥ 70%
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
2007: centres with lower than average FEV1 values
12 72.98 18 (43.9) 27 8 (53.3) 26 9 (36.0) 26
39 – – (–) – – (–) – – (–) –
52 75.63 46 (58.2) 50.5 17 (68.0) 56 29 (54.7) 42
2007: across all centres
All 84.57 561 (42.7) 28 170 (67.2) 42 391 (36.8) 28
2007: centres with higher than average FEV1 values
25 92.2 51 (35.4) 14 8 (53.3) 24 36 (32.4) 14
28 85.85 20 (47.6) 28 6 (75.0) 56 13 (40.6) 28
31 90.61 16 (24.6) 14 3 (33.3) 39 12 (22.2) 13.5
TABLE 29 Comparison of centres showing evidence of special-cause variation and ‘borderline’ centres by method
of case-mix adjustment (continued )
Year and
adjustment
method
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2012
Unadjusted 39 23,a 26, 50a and 52a 25, 31,a 43 and 54 28
Multilevel model 39 12 and 52a 14, 25, 28 and 43a –
GLM 39 12, 18 and 26 14, 31, 43 and 54 25 and 28
2013
Unadjusted 39 23, 26, 50 and 53 25, 28, 31 and 61 60
Multilevel model – 39 and 50 31 25
GLM 39 23,a 26, 50 and 53 31 25 and 60a
2014
Unadjusted 53 25, 39, 50 and 52 13, 28, 31, 44, 60
and 61
–
Multilevel model – 39,a 50 and 52 44a –
GLM 50a and 53 52 13, 43,a 44a and 60 –
2015
Unadjusted 53 25, 26, 39,a 50 and
52a
16, 28, 31, 43, 60a
and 61
–
Multilevel model – 25,a 50a and 52a 31, 43 and 61 –
GLM 53 26 and 52a 16, 31, 43 and 61 –
a Centres approaching the 2-SD control limit without being outside it.
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TABLE 30 Intravenous antibiotic use (home and hospital) for all patients and stratified by FEV1, year and
paediatric centre (continued )
Centre
Mean
FEV1
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
FEV1 < 70% FEV1 ≥ 70%
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
2008: centres with lower than average FEV1 values
12 75.25 17 (37.0) 16 10 (71.4) 22 6 (22.2) 21
39 57.64 1 (100.0) 14 1 (100.0) 14 0 (0.0)
52 76.21 53 (60.2) 54 23 (82.1) 56 29 (50.0) 28
2008: across all centres
All 84.88 738 (45.4) 28 207 (72.6) 50 531 (39.6) 21
2008: centres with higher than average FEV1 values
25 91.14 48 (30.2) 28 11 (64.7) 50 36 (27.7) 14.5
28 93.86 20 (50.0) 28 3 (100.0) 42 16 (44.4) 24.5
31 84.65 21 (22.6) 13 7 (50.0) 36 12 (16.7) 12.5
2009: centres with lower than average FEV1 values
12 77.7 33 (36.7) 21 20 (71.4) 28 9 (16.4) 14
39 82.66 41 (34.5) 56 8 (80.0) 56 13 (43.3) 28
52 78.85 78 (60.0) 41.5 29 (78.4) 56 43 (50.0) 28
2009: across all centres
All 84.17 900 (45.1) 28 257 (73.2) 43 643 (39.1) 27
2009: centres with higher than average FEV1 values
25 89.95 58 (32.2) 17.5 14 (63.6) 31.5 42 (29.2) 14
28 84.22 26 (60.5) 28 5 (100.0) 42 19 (52.8) 28
31 90.66 19 (22.4) 14 5 (62.5) 50 12 (17.1) 12.5
2010: centres with lower than average FEV1 values
12 75.08 46 (46.9) 28 26 (74.3) 34.5 18 (30.0) 14
39 74.05 70 (45.2) 43.5 24 (72.7) 43.5 22 (40.0) 32.5
52 80.32 72 (55.8) 38.5 24 (88.9) 56 41 (44.6) 28
2010: across all centres
All 83.75 979 (47.2) 28 283 (77.3) 49 696 (40.8) 24
2010: centres with higher than average FEV1 values
25 85.77 66 (37.7) 28 20 (69.0) 41.5 41 (30.8) 14
28 83.79 22 (52.4) 47 8 (80.0) 59.5 14 (45.2) 28
31 90.61 28 (31.5) 14 6 (66.7) 84 20 (26.7) 11.5
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TABLE 30 Intravenous antibiotic use (home and hospital) for all patients and stratified by FEV1, year and
paediatric centre (continued )
Centre
Mean
FEV1
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
FEV1 < 70% FEV1 ≥ 70%
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
2011: centres with lower than average FEV1 values
12 78.21 45 (47.9) 28 25 (86.2) 42 18 (30.0) 21.5
39 80.22 103 (59.2) 45 28 (82.4) 56 40 (46.5) 36
52 84.2 73 (49.3) 38 18 (75.0) 54 51 (43.6) 28
2011: across all centres
All 85.16 1049 (46.8) 28 310 (79.5) 42 739 (39.9) 27
2011: centres with higher than average FEV1 values
25 86.32 74 (41.8) 28 24 (77.4) 42 44 (32.4) 15
28 89.34 17 (38.6) 49 4 (100.0) 48 12 (31.6) 45.5
31 88.62 20 (22.2) 14 7 (70.0) 60 12 (16.4) 13.5
2012: centres with lower than average FEV1 values
12 80.62 43 (42.2) 31 24 (75.0) 54 18 (27.3) 25.5
39 76.87 106 (59.6) 42 42 (79.2) 56 45 (50.0) 19
52 82.11 79 (51.3) 28 28 (87.5) 42 48 (41.7) 15.5
2012: across all centres
All 84.69 1065 (47.1) 28 330 (77.6) 45 735 (40.0) 21
2012: centres with higher than average FEV1 values
25 87.8 81 (46.6) 24 22 (88.0) 39 55 (39.3) 14
28 93.01 20 (39.2) 43.5 6 (100.0) 37 14 (33.3) 44
31 88.31 16 (18.8) 13.5 8 (61.5) 27.5 8 (12.3) 9.5
2013: centres with lower than average FEV1 values
12 84.66 39 (37.5) 28 15 (78.9) 56 21 (27.3) 28
39 80.41 99 (58.2) 42 39 (88.6) 56 51 (52.0) 42
52 84.36 71 (42.3) 28 26 (74.3) 28 40 (33.6) 19
2013: across all centres
All 85.78 1021 (43.7) 28 284 (76.5) 42 737 (37.5) 21
2013: centres with higher than average FEV1 values
25 89.44 50 (29.8) 15.5 13 (65) 27 32 (24.2) 14
28 90.17 24 (35.3) 36 5 (71.4) 42 17 (30.4) 27
31 90.37 19 (20.9) 14 5 (55.6) 14 13 (19.1) 10
2014: centres with lower than average FEV1 values
12 86.96 40 (38.8) 24 14 (77.8) 32.5 23 (29.9) 17
39 83.36 81 (48.2) 45 27 (84.4) 56 42 (38.5) 36.5
52 83.64 55 (35.0) 28 21 (61.8) 33 31 (27.2) 14
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TABLE 30 Intravenous antibiotic use (home and hospital) for all patients and stratified by FEV1, year and
paediatric centre (continued )
Centre
Mean
FEV1
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
FEV1 < 70% FEV1 ≥ 70%
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median
number of
days on i.v.
antibiotics
2014: across all centres
All 86.94 958 (41.3) 25.5 262 (78.2) 42 696 (35.0) 15
2014: centres with higher than average FEV1 values
25 83.94 63 (40.4) 17 18 (66.7) 43 37 (32.7) 14
28 91.24 25 (32.9) 42 7 (100.0) 65 16 (26.2) 30
31 91.18 21 (21.2) 21 9 (75.0) 27 10 (14.5) 12.5
2015: centres with lower than average FEV1 values
12 85.9 35 (35.7) 28 9 (52.9) 43 24 (31.6) 16
39 85.42 69 (43.9) 30 18 (85.7) 53.5 43 (36.8) 20
52 85.3 70 (42.7) 14.5 19 (76.0) 28 43 (35.5) 14
2015: across all centres
All 87.9 918 (38.6) 23.5 221 (72.5) 42 697 (33.7) 15
2015: centres with higher than average FEV1 values
25 84.46 62 (40.0) 20.5 20 (83.3) 43.5 37 (32.5) 15
28 91.97 25 (33.8) 28 3 (60.0) 19 22 (32.8) 28
31 92.98 22 (21.2) 14 5 (62.5) 32 15 (17.6) 13
TABLE 31 Centres showing evidence of special-cause variation in FEV1 (GLI reference equations) and ‘borderline’
centres, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 11, 12, 52 and 59 16, 18,a 23 and 53a 14, 31 and 36 25
2008 12 and 52 1,a 13, 18, 26 and 53a 36 and 44 25 and 28
2009 11, 12 and 52 16 and 59 36, 44,a 46 and 60 25 and 31
2010 12 and 39 23, 26,a 52a and 59 36, 43,a 46 and 54 31
2011 12 and 23 18 and 39 31a and 61 –
2012 39 12, 23,a 26, 52a and 53a 25, 31,a 36, 54 and 61 28 and 43
2013 39 23, 26, 50 and 53 25, 28, 31 and 61 60
2014 – 39, 50, 52 and 53 13,a 28, 31, 44, 60 and 61 –
2015 53 25, 26, 39,a 50 and 52 16, 28, 31, 43, 60a and 61 –
a Centres approaching the 2-SD control limit without being outside it.
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TABLE 32 Number of patients providing annual review and FEV1 data and the percentage of these that have FEV1% predicted < 40%, by year and centre
Centre
2007 2008 2009 2010 2011 2012 2013 2014 2015
AR FEV1
< 40
(%) AR FEV1
< 40
(%) AR FEV1
< 40
(%) AR FEV1
< 40
(%) AR FEV1
< 40
(%) AR FEV1
< 40
(%) AR FEV1
< 40
(%) AR FEV1
< 40
(%) AR FEV1
< 40
(%)
Centres with lower than average FEV1 values
9 440 435 26 418 415 26 511 503 25 533 522 23 540 530 22 557 554 16 585 576 23 583 580 21 561 558 20
Centres with higher than average FEV1 values
7 109 106 21 248 238 17 271 267 14 259 247 17 294 289 13 312 296 18 328 315 15 330 320 17 339 319 18
34 178 177 12 206 204 13 225 224 5 241 239 5 237 233 6 239 229 13 251 247 16 268 268 14 262 260 12
40 133 126 95 148 142 96 178 175 98 184 180 98 194 192 99 185 181 98 200 196 98 216 212 98 211 208 99
AR, number of patients providing annual review data.
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TABLE 33 Mean age (years) of patients attending annual reviews by year and adult centre
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
9 29.94 30.36 30.25 30.39 31.00 31.57 32.4 32.9 33.1
Overall mean across all centres
All 27.5 27.8 28.1 28.2 28.7 29.1 30 30.4 30.6
Centres with higher than average FEV1 values
7 29.17 27.96 27.90 28.41 28.77 29.29 30 30.2 30.2
34 25.92 26.44 26.75 27.15 28.22 28.64 29.7 29.8 30.3
40 29.3 29.5 29.2 30.2 31.2 32 33.5 34.2 35.3
TABLE 34 Centres showing evidence of special-cause variation and ‘borderline’ centres in analyses adjusted for age
using GLMs, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 9 2, 17 and 35 47a 7 and 40
2008 – 9 and 56a 5 and 48 7
2009 9 2, 10, 17 and 21 5 and 7 34 and 40
2010 – 2, 9, 10, 17 and 41a 51 34 and 40
2011 9 2, 17,a 21, 35 and 41 40 34
2012 – 9, 10 and 21a 6, 40, 47, 48a and 51a 34
2013 – 9, 10, 20, 21 and 56 34 and 47 40
2014 – 2,a 9, 10, 20 and 21 33,a 34 and 48a 40
2015 – 9,a 10, 20, 21a and 56 34, 47 and 48 40
a Centre approaching the 2-SD control limit without being outside it.
TABLE 35 Centres showing evidence of special-cause variation and ‘borderline’ centres in analyses adjusted for age
using splines, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 9 – 7 40
2008 – 9 – 7
2009 9 10 and 17 7a and 40 34
2010 – 9, 10,a 17 and 41a 40 34
2011 9 41 40 34
2012 – 9 and 10 34 and 40 –
2013 – 9 and 10* 34 and 40 –
2014 – 9 and 10 34 and 40 –
2015 – 9a and 10 34, 40, 47 and 48 –
a Centres approaching the 2SD control limit without being outside it.
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TABLE 36 Distribution of female patients attending annual review by year and adult centre; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
9 182
(41.4)
174
(41.6)
225
(44.0)
236
(44.3)
239
(44.3)
257
(46.1)
268
(45.8)
273
(46.8)
265
(47.2)
Across all centres
All 989
(43.7)
1355
(44.3)
1596
(44.5)
1753
(44.7)
1934
(44.5)
1989
(44.8)
2071
(45.3)
2233
(45.2)
2308
(45.4)
Centres with higher than average FEV1 values
7 54 (49.5) 102
(41.1)
111
(41.0)
108
(41.7)
117
(39.8)
125
(40.1)
137
(41.8)
138
(41.8)
144
(42.5)
34 84 (47.2) 97 (47.1) 102
(45.3)
114
(47.3)
109
(46.0)
110
(46.0)
112
(44.6)
121
(45.1)
116
(44.3)
40 55 (41.4) 70 (47.3) 79 (44.4) 84 (45.7) 86 (44.3) 81 (43.8) 94 (47.0) 107 (49.5) 105 (49.8)
TABLE 37 Distribution of patients who are homozygous DF508 by year and adult centre among those who have
been genotyped; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
9 225
(52.2)
199
(48.1)
250
(49.8)
263
(49.7)
254
(47.7)
261
(47.6)
274
(47.6)
276
(48.1)
264
(47.8)
Across all centres
All 1131
(51.6)
1546
(52.0)
1780
(51.0)
1918
(50.1)
2090
(49.3)
2143
(49.4)
2198
(49.2)
2347
(48.5)
2391
(48.1)
Centres with higher than average FEV1 values
7 56 (51.4) 131
(53.5)
140
(52.2)
137
(53.3)
153
(52.9)
164
(53.2)
165
(51.1)
164
(50.5)
174
(52.1)
34 93 (56.0) 110
(57.6)
118
(55.4)
120
(52.2)
114
(50.2)
114
(50.0)
120
(49.6)
127
(48.7)
128
(50.0)
40 37 (28.2) 56 (38.4) 62 (35.0) 61 (33.5) 66 (34.6) 64 (35.2) 67 (33.8) 72 (33.8) 64 (30.8)
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TABLE 38 Distribution of patients who have at least one G551D mutation by year and adult centre among those
who have been genotyped; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
9 19 (4.4) 13 (3.1) 22 (4.4) 24 (4.5) 24 (4.5) 23 (4.2) 22 (3.8) 23 (4.0) 23 (4.2)
Across all centres
All 136 (6.2) 163 (5.5) 213 (6.1) 237 (6.2) 262 (6.2) 268 (6.2) 281 (6.3) 299 (6.2) 313 (6.3)
Centres with higher than average FEV1 values
7 6 (5.5) 11 (4.5) 12 (4.5) 10 (3.9) 11 (3.8) 12 (3.9) 14 (4.3) 14 (4.3) 16 (4.8)
34 9 (5.4) 11 (5.8) 14 (6.6) 13 (5.7) 16 (7.0) 16 (7.0) 18 (7.4) 19 (7.3) 20 (7.8)
40 15 (11.5) 8 (5.5) 16 (9.0) 16 (8.8) 16 (8.4) 17 (9.3) 19 (9.6) 19 (8.9) 18 (8.7)
TABLE 39 Distribution of patients who are pancreatic sufficient by year and adult centre; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
9 69 (15.7) 80 (19.1) 92 (18.0) 96 (18.0) 95 (17.6) 95 (17.1) 110 (18.8) 109 (18.7) 103 (18.4)
Across all centres
All 281 (12.5) 393 (12.9) 494 (13.8) 564 (14.4) 648 (14.9) 676 (15.2) 737 (16.1) 837 (16.9) 854 (16.8)
Centres with higher than average FEV1 values
7 9 (8.9) 29 (12.2) 28 (10.3) 23 (8.9) 27 (9.2) 35 (11.2) 43 (13.1) 37 (11.2) 41 (12.1)
34 25 (14.0) 27 (13.2) 32 (14.2) 38 (15.8) 38 (16.0) 42 (17.6) 40 (16) 47 (17.6) 42 (16.1)
40 48 (36.1) 43 (29.1) 56 (31.5) 56 (30.4) 63 (32.5) 56 (30.3) 61 (30.5) 71 (32.9) 76 (36.0)
TABLE 40 Distribution of patients in SES quintile 5 (most socioeconomically deprived) by year and adult centre; n (%)
Centre 2007 2008 2009 2010 2011 2012 2013 2014 2015
Centres with lower than average FEV1 values
9 81 (19.0) 76 (18.5) 101 (20.0) 104 (19.8) 116 (21.7) 121 (21.9) 133 (23.0) 125 (21.7) 115 (20.7)
Across all centres
All 392 (17.7) 541 (17.8) 655 (18.4) 752 (19.3) 840 (19.4) 851 (19.3) 863 (19.0) 913 (18.6) 911 (18.1)
Centres with higher than average FEV1 values
7 18 (16.5) 51 (20.6) 45 (16.6) 44 (17.0) 50 (17.0) 48 (15.4) 49 (14.9) 55 (16.7) 59 (17.4)
34 47 (26.9) 61 (30.2) 69 (31.4) 71 (30.0) 71 (30.6) 65 (27.9) 66 (27.0) 69 (26.4) 70 (27.5)
40 27 (20.3) 28 (18.9) 35 (19.7) 33 (17.9) 30 (15.5) 29 (15.7) 28 (14.0) 38 (17.6) 30 (14.3)
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TABLE 41 Centres showing evidence of special-cause variation and ‘borderline’ centres in analyses adjusted for age
(using splines), sex, pancreatic sufficiency, genotype (homozygous DF508, heterozygous DF508 or other) and SES
quintile by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007
Unadjusted 9 2 and 35 47 7 and 40
Multilevel model 9 – 7 and 40 –
GLM 9 2 and 35 40 7
2008
Unadjusted 9 35a 5 and 48a 7
Multilevel model 9 – – 7
GLM 9 56 5 and 48 7
2009
Unadjusted 9 2, 10, 17a and 21 5, 7a and 40 34
Multilevel model 9 10 7a and 29 34
GLM 9 2, 10, 17a and 21 7, 29 and 40a 34
2010
Unadjusted 9 2, 10 and 17 40 and 51 34
Multilevel model – 9 and 10 40a 34
GLM – 2, 9, 10a and 17 40 34
2011
Unadjusted 9 2, 21, 35a and 41 5a and 40 34
Multilevel model 9 41a – 34
GLM 9 2, 21, 35a and 41 7a and 40a 34
2012
Unadjusted 9 8a and 10 6, 40, 47 and 51a 34
Multilevel model – 9 and 10 34 –
GLM – 9 and 10 6a and 47 34
2013
Unadjusted – 9, 10, 20,a 21 and 56 34, 40 and 47 –
Multilevel model – 9 and 10 34 and 40 –
GLM – 9, 10,a 20, 21 and 56 34, 40 and 47a –
2014
Unadjusted 9 and 10 20, 21, and 29a 17, 34, 40, 45 and 47 –
Multilevel model – 9 and 10 34 and 40 –
GLM – 2, 9, 10, 20, 21 and 56 34 and 40 –
2015
Unadjusted – 9, 10, 20, 29 and 56 34, 40, 45 and 48 47
Multilevel model – – 34, 40,a 47a and 48 –
GLM 56 2, 10a and 20 40, 47 and 48 34
a Centres approaching the 2-SD control limit without being outside it.
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TABLE 42 Intravenous antibiotic use (home and hospital) for all patients and stratified by FEV1, by year and adult centre
Centre Mean FEV1
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
FEV1 < 40% 40% ≤ FEV1 ≤ 70% FEV1 > 70%
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
2007: centres with lower than average FEV1 values
9 59.81 176 (40.0) 15.5 80 (71.4) 29.5 69 (40.6) 14 27 (17.6) 14
2007: across all centres
All 64.82 1016 (44.9) 28 278 (69.7) 42 443 (51.9) 28 295 (29.2) 21
2007: centres with higher than average FEV1 values
7 72.62 1 (0.9) 14 0 (0.0) – 1 (2.7) 14 0 (0.0) –
34 66.26 119 (66.9) 24 20 (95.2) 27 59 (76.6) 28 40 (50.6) 14
40 73.42 55 (41.4) 28 11 (91.7) 42 26 (59.1) 21 15 (21.4) 14
2008: centres with lower than average FEV1 values
9 60.09 182 (43.6) 15.5 72 (67.3) 28 74 (46.8) 14 34 (22.8) 14
Across all centres
All 64.48 1656 (59.5) 28 427 (82.9) 48 702 (67.0) 28 527 (43.2) 21
Centres with higher than average FEV1 values
7 71.11 76 (52.4) 28 13 (72.2) 57 30 (78.9) 28 29 (35.8) 24
34 66.39 137 (66.5) 25 26 (96.3) 52.5 70 (74.5) 28 39 (47.0) 14
40 66.73 82 (55.8) 21.5 19 (95.0) 33 35 (64.8) 22 24 (35.8) 13.5
2009: centres with lower than average FEV1 values
9 59.87 252 (49.6) 21 97 (77.6) 32 101 (50.8) 20 49 (27.8) 14
2009: across all centres
All 64.43 2055 (60.4) 28 528 (87.6) 49 851 (67.2) 28 676 (44.1) 23
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TABLE 42 Intravenous antibiotic use (home and hospital) for all patients and stratified by FEV1, by year and adult centre (continued )
Centre Mean FEV1
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
FEV1 < 40% 40% ≤ FEV1 ≤ 70% FEV1 > 70%
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
2009: centres with higher than average FEV1 values
7 67.41 169 (62.6) 38 37 (100.0) 63 75 (72.1) 41 53 (42.4) 24
34 74.08 139 (62.1) 21 9 (81.8) 42 64 (73.6) 28 65 (52.0) 14
40 69.37 85 (48.6) 24 20 (100.0) 39 39 (60.9) 20 24 (27.3) 19.5
2010: centres with lower than average FEV1 values
9 61.26 255 (48.1) 22 88 (73.9) 28.5 110 (53.4) 21 49 (25.3) 14
2010: across all centres
All 64.62 2295 (59.8) 28 600 (87.5) 49 968 (68.6) 28 727 (41.8) 24
2010: centres with higher than average FEV1 values
7 65.78 173 (67.1) 36 41 (95.3) 56 69 (77.5) 42 53 (46.5) 15
34 75.22 137 (56.8) 28 13 (100.0) 29 61 (69.3) 40 61 (44.2) 17
40 69.51 87 (47.5) 21 20 (83.3) 51 35 (59.3) 16 31 (32.0) 15
2011: centres with lower than average FEV1 values
9 60.81 253 (47.1) 24 90 (75.6) 31.5 113 (51.4) 24 45 (23.8) 14
2011: across all centres
All 65.48 2538 (59.2) 28 634 (86.3) 45 1109 (68.5) 31 795 (41.1) 22
2011: centres with higher than average FEV1 values
7 67.57 202 (68.7) 42 37 (100.0) 65 91 (82.0) 42 70 (49.6) 28
34 76.94 147 (62.0) 27 11 (78.6) 34 56 (74.7) 29 77 (53.5) 23
40 69.88 88 (45.4) 16 22 (81.5) 37.5 40 (58.8) 15 24 (24.7) 15
2012: centres with lower than average FEV1 values
9 61.22 241 (43.3) 25 94 (70.7) 31.5 104 (48.1) 26.5 41 (20.0) 14
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Centre Mean FEV1
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
FEV1 < 40% 40% ≤ FEV1 ≤ 70% FEV1 > 70%
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
2012: across all centres
All 64.61 2506 (56.5) 29 683 (83.3) 50 1052 (65.3) 28 771 (38.5) 20
2012: centres with higher than average FEV1 values
7 65.56 205 (65.7) 37 49 (94.2) 56 88 (80.0) 42 58 (43.3) 22
34 69.6 146 (61.3) 21.5 25 (86.2) 76 67 (77.0) 16 49 (43.4) 14
40 68.17 81 (43.8) 29 19 (76.0) 37 40 (56.3) 25 21 (24.7) 16
2013: centres with lower than average FEV1 values
9 62.28 252 (43.1) 26 91 (69.5) 34 113 (50.4) 26 45 (20.4) 14
2013: across all centres
All 65.12 2585 (56.6) 28 688 (83.8) 54 1110 (67.0) 28 787 (37.7) 21
2013: centres with higher than average FEV1 values
7 66.36 211 (64.3) 38 46 (100.0) 64 90 (73.8) 35 62 (42.2) 26
34 68.92 144 (57.6) 26 34 (85.0) 52 60 (66.7) 24 50 (42.7) 15
40 70.33 89 (44.5) 23 18 (78.3) 49.5 37 (52.9) 24 30 (29.1) 14.5
2014: centres with lower than average FEV1 values
9 62.78 267 (45.8) 21 84 (67.7) 28 120 (54.1) 25.5 63 (26.9) 14
2014: across all centres
All 66.07 2738 (55.4) 28 718 (83.6) 49 1158 (66.3) 28 862 (36.9) 20.5
2014: centres with higher than average FEV1 values
7 65.01 202 (61.2) 38.5 51 (92.7) 53 88 (71.0) 28.5 55 (39.0) 25
34 69.65 137 (51.1) 28 32 (84.2) 68 68 (65.4) 28 37 (29.4) 14
40 70.81 83 (38.4) 18 20 (74.1) 29 40 (52.6) 19.5 20 (18.3) 12.5
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TABLE 42 Intravenous antibiotic use (home and hospital) for all patients and stratified by FEV1, by year and adult centre (continued )
Centre Mean FEV1
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
FEV1 < 40% 40% ≤ FEV1 ≤ 70% FEV1 > 70%
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
Any i.v.
antibiotics,
n (%)
Median number
of days on i.v.
antibiotics
2015: centres with lower than average FEV1 values
9 63.49 243 (43.3) 24 70 (63.1) 38.5 121 (51.7) 21 52 (24.4) 14
2015: across all centres
All 66.09 2714 (53.5) 28 721 (82.7) 49 1180 (64.4) 28 813 (34.2) 18
2015: centres with higher than average FEV1 values
7 64.26 217 (64.0) 29 52 (92.9) 59.5 94 (72.3) 29 58 (43.6) 15.5
34 70.35 143 (54.8) 27 25 (80.6) 68 75 (75.0) 28 41 (32.0) 14
40 70.39 73 (34.6) 17 17 (70.8) 29 40 (51.3) 16.5 15 (14.2) 14
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TABLE 43 Centres showing evidence of special-cause variation in FEV1 (GLI reference equations) and ‘borderline’
centres, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 9 2 and 35 47 7 and 40
2008 9 35a 5 and 48a 7
2009 9 2, 10 and 21 5, 7a and 40 34
2010 9 2, 10 and 17 40 and 51 34
2011 9 2, 21 and 41 40 34
2012 9 8a and 10 6, 34, 40,a 47, 51 and 57a –
2013 – 9, 10, 20, 21 and 56 34, 40 and 47 –
2014 9 and 10 20, 21 and 29a 17, 34, 40, 45,a 47 and 48a –
2015 – 9, 10, 20, 29a and 56 34, 40, 45a and 48 47
a Centres approaching the 2-SD control limit without being outside it.
TABLE 44 Centres showing evidence of special-cause variation and ‘borderline’ adult centres in unadjusted
analyses, by year
Year
Centres with lower than average FEV1 values Centres with higher than average FEV1 values
Outside 3-SD limit Outside 2-SD limit Outside 2-SD limit Outside 3-SD limit
2007 9 2 and 35 47 7 and 40
2008 9 35a 5 and 48a 7
2009 9 2, 10, 17a and 21 5, 7a and 40 34
2010 9 2, 10 and 17 40 and 51 34
2011 9 2, 21, 35a and 41 5a and 40 34
2012 9 8a and 10 6, 40, 47 and 51a 34
2013
All patients – 9, 10, 20,a 21 and 56 34, 40 and 47 –
Excluding G551D – 9, 10, 21 and 56 34, 40 and 47 –
2014
All patients 9 and 10 20, 21 and 29a 17, 34, 40, 45 and 47 –
Excluding G551D 10 9, 20,a 21 and 29 17, 34, 40, 45, 47 and 48a
2015
All patients – 9, 10, 20, 29 and 56 34, 40, 45 and 48 47a
Excluding G551D – 9, 10, 20, 29 and 56 34, 40 and 45 47 and 48
a Centres approaching the 2-SD control limit without being outside it.
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TABLE 45 Distribution of responses to adult questionnaire by centre and clinical role of respondent
Centre Response (%) Response count
King’s College Hospital, London 14.0 19
Southampton General Hospital 13.2 18
Northern General Hospital, Sheffield 12.5 17
Royal Papworth Hospital 11.8 16
University Hospital Llandough 11.0 15
Gartnavel General Hospital, Glasgow 5.9 8
Birmingham Heartlands Hospital 4.4 6
Nottingham City Hospital 4.4 6
Royal Brompton Hospital, London 4.4 6
Derriford Hospital, Plymouth 3.7 5
Royal Victoria Infirmary, Newcastle upon Tyne 3.7 5
Aberdeen Royal Infirmary 2.9 4
Royal Devon and Exeter Hospital, Exeter 2.9 4
University Hospital Lewisham, London 2.9 4
Frimley Park Hospital, Camberley 1.5 2
Castle Hill Hospital, Hull 0.7 1
Clinical role of respondents
Doctor – consultant 18.4 25
Nurse 18.4 25
Physiotherapist 17.6 24
Dietitian 12.5 17
Administrative and clerical 8.1 11
Pharmacist 6.6 9
Doctor – other 5.9 8
Psychologist 5.9 8
Social worker 5.1 7
Manager 1.5 2
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